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Abstract 
The reactions of amino- and formylimidazoles, and amino- 
pyrimidinones are described. Conditions were found for the successful 
condensation of 5(4)-aminoimidazole-4(5)-carboxamide with a number of 
substituted benzaldehydes, to provide a series of novel 5(4)-N-benzylidene- 
aminoimidazole-4(5)-carboxamides. Reaction of a subset of the benzylidene 
derivatives with sodium hydride furnished novel imidazo[1,5-a]quinazoline-3- 
carbox-amides in good yields, via an intramolecular cyclisation. Attempted 
mixed acid nitration of imidazo[1,5-a]quinazoline-3-carboxamide led only to 
amide hydrolysis to provide the carboxylic acid. High yielding conditions 
were sought for the synthesis of a formylimidazole by the selective partial 
reduction of commercially available 4,5-disubstituted imidazoles. Lithium 
triethoxy-aluminium hydride reduction of 1-benzyl-4,5-dicyanoimidazole 
gave a mixture of the isomeric monoaldehydes in a yield of 53%. Methyl 5(4)- 
formylimidazole-4(5)-carboxylate was formed by acidic hydrolysis of methyl 
5(4)-diethoxymethylimidazole-4(5)-carboxylate. Unfortunately, Knoevenagel 
condensation of the formyl-imidazoles prepared with ethyl nitroacetate could 
not be achieved. Ethoxycarbonylacetylferrocene and 1,1'-bis(ethoxycarbonyl- 
acetyl)ferrocene, prepared from ferrocene in one and two steps respectively 
via Friedel-Crafts acylations, were heated with guanidine carbonate to provide 
1-(2-amino-3,4-dihydro-4-oxopyrimidin-6-yl)ferrocene and 1,1'-bis(2-amino- 
3,4-dihydro-4-oxopyrimidin-6-yl)ferrocene in low yields, though the latter 
appeared to decompose on storage. In studies aimed at preparing a 
pyrimido[5,4-b]indole, attempted nitrosation of 2-amino-6-phenylpyrimidin- 
4-one with nitrosonium tetrafluoroborate gave the unexpected unsymmetrical 
dimer 2-amino 
-5-(3,4-dihydro-4-oxo-6-phenylpyrimidin-2-yl)-6-phenyl- 
pyrimidin-4-one, in low yield. To overcome the observed poor reactivity of 2- 
amino-5-halopyrimidin-4-ones towards Suzuki coupling with boronic acids, 2- 
iv 
amino-5-halo-4-methoxy-6-phenylpyrimidines were prepared and successfully 
coupled with a range of aryl and heteroaryl boronic acids to provide 5-aryl- 
and 5-heteroarylpyrimidines in good to excellent yields. As expected, the 
iodopyrimidine was more reactive to the palladium catalysed coupling than 
the bromo analogue. Acidic hydrolysis of the 5-arylpyrimidines furnished 2- 
amino-5-aryl-6-phenylpyrimidin-4-ones in excellent yields. Heck reactions of 
2-amino-5-iodo-6-phenylpyrimidin-4-one and 1-hexyne gave only a low yield 
of 6-amino-2-butyl-4-phenylfuro[2,3-d]pyrimidine, involving intramolecular 
cyclisation. Unlike the trend observed for Suzuki reactions, Heck reaction of 
2-amino-5-iodo-4-methoxy-6-phenylpyrimidine with 1-hexyne gave the 
coupled product, 2-amino-5-(1-hexyn-1-yl)-4-methoxy-6-phenylpyrimidine, 
but only in a low yield of 27%. 
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1. Introduction 
1.1 Cancer 
Cancer is possibly the most feared disease of mankind - not without good 
reason, currently accounting for a quarter of all UK deaths. 1 The average age for 
the diagnosis of cancer is 67, and as life spans increase the incidence of cancer is 
expected to rise accordingly. However, even when corrected for this factor, 
mortality rates for a number of common cancers, over several continents, have 
increased significantly (ref. 2 pp 6-7). 
In 1989 (the year for which the most recent complete data are available), 
302220 new cases of cancer were registered in the UK, comprising 137690 male 
and 164530 female cases. The relative incidences of the most common forms for 
both sexes combined are depicted in Figure 1-1 (Data from ref. 3). Lung cancer 
was the commonest cancer in men (21%) and breast cancer the commonest in 
women (19%), with non-melanoma skin cancer the second most common for both 
sexes (although this has a very high cure rate). 
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Figure 1-1 Cancer incidence in the UK, 1989. 
Cancer is not just one disease, the outcome of treatment being as much a 
function of cancer type, as stage at presentation. Figure 1-2 shows the 5 year 
survival rates, for a range of cancers in all stages, registered in England and Wales 
in 1981, survival rates being very similar between sexes (Data from ref. 3). 
Certain cancers now have very high cure rates such as testicular cancer, childhood 
leukaemia, Burkitt's lymphoma and certain ovarian cancers, but these cancers are 
low in incidence. The most common cancers such as breast, lung, colon and 
prostate are far less susceptible to chemotherapy, and even with other treatment 
modalities, such as surgery and radiotherapy, survival rates are still unacceptably 
low. The earlier the diagnosis the better the prognosis, and screening programmes 
have been of great benefit in the treatment of certain cancers, such as breast and 
cervical cancer. 
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Figure 1-2 Five-year survival rates for cancers registered in England 
and Wales in 1981. 
The most recent mortality statistics for the UK, for 1994, are depicted in 
Figure 1-3 in descending order for the ten commonest causes of cancer death, both 
sexes combined (Data from ref. 1). The total figure was 160,680, with 83,342 
male and 77,334 female cancer deaths. Lung cancer was the most common cause 
of male cancer deaths (29%), followed by prostate cancer (12%). For women, 
breast cancer was the biggest cancer killer (19%), followed by lung cancer (17%). 
Interestingly, in Scotland, lung cancer overtook breast cancer to become the most 
common cause of female cancer death, a trend being observed in other 
industrialised counties, showing a strong correlation with increased smoking 
among women (ref. 2, p. 6). 
Total no. of cancer deaths = 160,680 
Lung, 23% 
Other, 31 °h 
Brcast(F), 9/(, 
Ovary, 3% 
Colon, 8%% 
Bladder, 3% 
Rectum, 4% Prostate, 61/( 
Pancreas, Stomach, 
4°/(, Oesophagus, 5% 
4% 
Figure 1-3 Breakdown of cancer mortality, UK, 1994. 
Over the past 50 years significant improvements in anticancer therapy 
have been achieved, with more sophisticated detection, surgery, radiotherapy and 
the arrival of chemotherapy into the mainstream of treatment all making their 
mark. As mentioned above, some cancers are now curable by various 
combinations of these modalities, but the outlook for the most common cancers 
remains rather bleak. The five year relative survival rates for all malignant 
neoplasms considered together is about 40% for both sexes. 4 Major advances are 
still required in the treatment of this life threatening disease. 
4 
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1.2 Should cancer chemotherapy be left to biotechnology? 
1.2.1 Has chemistry failed? 
It is increasingly recognised that traditional approaches to cancer 
chemotherapy are running out of steam. It is true that the established 
antiproliferative cytotoxics, which are now categorised according to mode of 
action, have had an important impact on prolonging survival for many cancer 
patients, and in certain cases cures are now possible by chemotherapy alone. One 
such example is in the treatment of testicular carcinoma with cisplatin, bleomycin 
and etoposide. Indeed, combinations of cytotoxics with differing modes of action 
and non-overlapping toxicities often produce the most successful outcomes, as in 
the MOPP regime (nitrogen mustard, vincristine (oncovin), procarbazine and 
prednisone) introduced in 1963 for the treatment of disseminated Hodgkin's 
Disease. With improved knowledge of drug pharmacology and tumour growth 
kinetics, increasing responses continue to be observed, but our current cytotoxics 
seem fundamentally flawed. 
The current cytotoxics all interfere, rather non-specifically, with the 
biochemistry of cell proliferation, commonly disrupting DNA synthesis. It is 
perhaps not surprising that apart from their severe toxicities towards rapidly 
dividing cells of normal tissue, leading commonly to myelosuppression and 
gastrointestinal (GI) irritation, their main activity is against malignancies of 
haematopoietic origin such as leukaemias and lymphomas, with their high 
proliferation rates. Thankfully, fatalities due to childhood cancers such as acute 
lyphoblastic leukaemia (ALL), Wilm's tumour, Burkitt's lyphoma, other non- 
Hodgkin's lymphomas and retinoblastoma are becoming a thing of the past, but as 
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seen in the previous section, the more common, slower growing solid tumours of 
the breast, lung and GI tract are still not particularly amenable to therapy. 
The effect of such growth kinetics is further compounded by the 
intrinsically higher threshold of certain normal cell types to damage over others 
before the cell decides, through a biochemical cascade of events, to commit 
suicide (a process termed apoptosis). Epithelial cells are just such a type, making 
the more common carcinomas which originate from them inherently more 
resistant to chemo- and radiotherapy than, for example, tumours whose origins are 
the more sensitive haematopoietic cells 
- 
the leukaemias and lymphomas 
.5 In the 
malignant phenotype of an aggressive tumour such apoptotic mechanisms may 
have been subverted by gene mutations or deletions, making them less sensitive 
still to drug induced damage. This, coupled with the ability of initially responsive 
tumours to acquire drug-specific/non-specific resistance has been the failing of 
current chemotherapy. 
Variations of existing cytotoxic agents continue to enter clinical trial, and 
these have been recently reviewed, 6'7 but in order to achieve the objective, which 
must remain to cure cancer, radical new approaches are required. The question is 
- 
can chemistry deliver? 
1.2.2 The problem we face 
It is important to remember that cancer is not some sinister enemy with 
elaborate plans for its every move, rather it is a disease of chance. Consider the 
scenario of the development of a tumour in epithelial tissue. By chance, a normal 
cell sustains a genetic mutation 
- 
maybe due to a DNA transcription error, or some 
7 
mutagenic insult 
- 
which is not corrected and which, by chance, increases its 
propensity to proliferate. It and its descendants still look normal, but they are 
reproducing too much, giving a hyperplasia. After maybe years, one cell in this 
expanded population sustains another mutation which, by chance, further loosens 
the controls on cell growth, or maybe affects the cell's ability to correct future 
transcription errors. The more abnormal cells of this progression lead to the 
designation dysplasia. Again, in time, another mutation in one of the cells alters 
its and its descendants' behaviour further, creating a progressively more 
aggressive cancer, less responsive to proper external influences. If the tumour has 
so far remained contained within its originating tissue it is termed an in-situ 
cancer (in this case a carcinoma). The tumour may remain contained indefinitely, 
but in the heterogeneous mixture of cells in such a population further mutations in 
one cell may engender an ability to recruit nearby endothelial cells to vascularise 
the tumour 
- 
angiogenesis 
- 
the arrival of nutrients allowing the tumour to expand 
rapidly. Some cells in the tumour may have, or gain through further mutations, the 
ability to detatch from the primary tumour and travel to distant sites of the body, 
establishing new tumours (metastasis). The tumour is now malignant, and it is 
usually the establishment of secondary tumours in vital organs that leads to 
fatality in cancer patients. 
Given that there are some 30 trillion cells in the average human body, it is 
perhaps a surprisingly rare event, but that is cold comfort to those afflicted, and 
more effective therapies are eagerly awaited. 
This picture of a tumour's development is not new, but the huge advances 
in the techniques of molecular biology over the last 20 years, including nucleic 
acid and protein sequencing and synthesis, mass cell culture, genetic engineering 
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and recombinant technology have unravelled many of the intricate mechanisms 
governing normal cell growth and proliferation. It has become clear that the 
accumulation of mutations in specific classes of genes are required for the 
malignant transformation of a cell. 
Errors in two types of genes are required for uncontrolled cell proliferation 
- 
oncogenes and tumour suppressor genes. In a normal cell, protein products of 
proto-oncogenes are involved in molecular "bucket-brigades", relaying external 
growth stimulatory signals from neighbouring cells to the nucleus, to initiate the 
proliferative process. Transformation to oncogenes leads to overproduction of, or 
a more active form of, the gene product, telling the cell to multiply when it should 
not. Many defective oncogenes have now been discovered, whose products are 
involved in various parts of the "signal transduction pathway". For example, the 
erb-B2 gene coding for a growth factor receptor is found defective in some breast 
cancers; members of the ras genes coding for cytoplasmic proteins involved in 
relaying the message are defective in a quarter of cancers (e. g. lung and colon 
carcinomas), often through a single point mutation; members of the myc family of 
genes coding for transcription factors that activate growth-promoting genes are 
also defective in a number of tumours. 
More than just the generation of oncogenes is required for malignant 
growth as there are many safeguards wired into all cells, coded by tumour 
suppressor genes. Some of the tumour suppressor gene proteins are involved in 
relaying growth inhibitory signals, preventing cell growth. For example, the NF-1 
gene product, in response to such signals, inhibits the ras protein in the 
cytoplasm, preventing the passage of stimulatory signals, and is defective or 
absent in a number of tumours (e. g. myeloid leukaemia). Similarly, the p15 gene 
9 
protein in the nucleus, in response to transforming growth factor beta (TGF-ß), 
shuts down transcription of growth-promoting genes, and is found discarded in a 
number of cancers. A number of important tumour suppressor genes act on the 
cell cycle clock 
- 
the molecular apparatus controlling the progress of a cell 
through its cycle. At points in the cell cycle certain cyclin-dependent kinases 
(CDKs) require activation by cyclins to allow further progress, their activation 
bringing about the release of transcription factors required in the activation of 
growth-promoting genes. Known tumour suppressor genes code for various 
inhibitory proteins that can restrain forward movement. The p15 protein 
mentioned above inhibits the cyclin D1 CDK4/6 complex at the so called 
restriction-point when the cell decides whether or not to go into S-phase (DNA 
synthesis). If not inhibited, this active complex leads to phosphorylation and 
deactivation of pRB 
-a protein which when active sequesters an important 
transcription factor, acting as a 'master-brake' on the system 
- 
the released 
transcription factor generating proteins required in the cell cycle progression. The 
pRB gene is mutated or absent in 40% of cancers, for example paediatric 
retinoblastoma. Another act of tumour suppressor gene proteins is to ensure that 
progress through the cell cycle is smooth, checking for mistakes made in DNA 
replication for example 
- 
often known as DNA checkpoint proteins. One 
ubiquitous example is the p53 protein which, among its many acts in tumour 
suppression, can halt the cell cycle and induce apoptosis of abnormal cells. As 
well as evading apoptosis, cells without an effective p53 gene can more readily 
accumulate mutations leading to a more malignant phenotype. Unsurprisingly, the 
p53 gene is mutated or absent in over half of all cancers. The errors that can occur 
in the cell cycle clock have been discussed in detail. 8 
10 
Different tumour types commonly have different profiles of oncogenes 
and defective tumour suppressor genes, though no one tumour fingerprint could 
be predicted from its type alone. Most familial cancers arise from the inheritance 
of defective or absent tumour suppressor genes, allowing the time of appearance 
of tumours to leapfrog many years. Notable examples of inherited defective genes 
are pRB predisposing to retinoblastoma in children, and BRCAI and BRCA2 genes 
linked to cetain breast and ovarian tumours. 
Although much less is yet known about the genes involved in later tumour 
development, including angiogenesis and metastasis, what can be done with the 
current knowledge of the very real differences between normal and tumour cells? 
1.2.3 Does biotechnology have the answer? 
Important advances in the techniques of molecular biology are now 
producing some very exciting approaches to the treatment of cancer. 
Perhaps the most exciting come under the gene therapy umbrella, inserting 
a whole gene into a cell, whose product will ultimately eliminate the tumour. One 
approach, virally directed enzyme prodrug therapy (VDEPT) aims to introduce 
selectively into tumour cells genes coding for enzymes able to render cytotoxic an 
administered prodrug. Another approach involves genes coding for 
"immunoattraction" such as tumour necrosis factor (TNF), interleukin-2 (IL-2), 
IL-4, IL-12, interferon-gamma (IFN-y) and foreign peptides 
- 
enhancing immune 
recognition and tumour cell destruction. For example, inoculation of mice with 
mammary tumour cells transfected with the IL-10 gene has led to tumour growth 
inhibition. 9 Gene replacement therapy has been sold as the "magic bullet" for 
11 
cancer 
- 
and reversal of tumour phenotype by the insertion of functional tumour 
suppressor genes has been achieved in vitro. For example, the introduction of 
wild-type p53 into human gingival carcinoma cells induced differentiation., 0 The 
various approaches have been discussed in detail. II At present gene therapy is 
limited by poor incorporation efficiencies in vivo, and despite continued 
improvements in techniques, progress is slow. 
A similar approach is the use of antisense or antigene oligonucleotides, 
targeted to mRNA or DNA respectively that corresponds to an oncogene, a 
sequence of about 15 bases required for selectivity. Despite impressive in vitro 
activities, they have yet to show benefit in vivo. 11 Current problems include 
metabolic stability and cellular uptake. If successful they would be cytostatic 
rather than cytotoxic, requiring continued administration. 
A number of other approaches are more immunologically based, perhaps 
the most advanced of which is the use of monoclonal antibodies (MABs). The 
technique for the production of high affinity antibodies, raised to a specific 
antigen, in virtually indefinite supply has received widespread clinical use, not 
least in experimental cancer therapies, since its inception by Köhler and Milstein 
in 1975. A number of moderately tumour specific antigens (TSAs) are known, 
including carcino-embryonic antigen (CEA) 
- 
present on cells of the foetus but 
not the adult, CEA is common to many carcinomas, especially of the colon. As 
well as being able to bring about an immune response (discussed later), MABs 
have been conjugated to cytotoxic drugs, toxins and radionuclides for tumour 
targeting 
- 
for example, a murine MAB raised against neural cell adhesion 
molecule (NCAM) conjugated to a ricin toxin has shown in vitro activity against a 
12 
small cell lung cancer cell line. 12 A number of such approaches are undergoing 
clinical trial (ref. 2, pp275-276). 
MAB approaches are inherently limited by poor tumour penetration of the 
large macromolecules and the antigenic heterogeneity of cells within a real 
tumour. An approach able to overcome these problems is known as antibody- 
directed enzyme prodrug therapy (ADEPT) where an antibody, raised to a TSA, is 
conjugated to an enzyme that when bound at the tumour site can convert an 
administered non-toxic prodrug to its cytotoxic form. The final cytotoxic 
produced is small and easily diffusible, overcoming the poor penetration of the 
antibody, and the amplification possible from one bound antibody-enzyme 
converting many prodrugs could overcome antigenic heterogeneity providing the 
antigen is expressed on enough of the tumour cells, delivering the cytotoxic 
throughout the tumour. Until recently the major failing of MAB techniques was 
the immune response raised against such rodent antibodies, limiting treatment to a 
single administration. The advent of MAB "humanisation" to avoid immune 
detection, and production of more diffusable antibody fragments is set to 
revitalise this approach and its future has been discussed. 13 
The commonly observed loss of antigenic presentation by tumour cells has 
been regarded as evidence of antitumour activity of the immune system, an 
effective response selective for the emergence of such populations. As a result, 
immunisation with TSAs (or fragments) has received attention as a potential 
vaccine. The intention is to create an expanded population of cytotoxic T 
lymphocytes (CTLs) able to recognise and destroy tumour cells. In vitro studies 
have demonstrated the ability to raise T cells to CEA, 14 and in murine models 
vaccination has protected against subsequent tumour challenge. 15 However, only 
13 
rarely has this approach been effective in the treatment of an established, 
vascularised tumour. The main difficulties in the treatment of human tumours are 
their poor antigen presentation and their antigen heterogeneity. The future of 
vaccine-based immunotherapy has been discussed. 16 
With increasing awareness about the molecular messengers involved in 
regulating the immune response, the administration of such cytokines has received 
continued interest. Initially with the use of crude cell extracts, and subsequently 
with high purity products from recombinant technology, the ability of a single 
agent to trigger a cascade of events ultimately resulting in an effective immune 
response has stimulated great excitement. However, of the many cytokines 
investigated to date, few have shown effective single agent activity. The 
exceptions are IFN-a (approved by the FDA in 1986 for hairy-cell leukaemia and 
AIDS-associated Kaposi's sarcoma), and IL-2 (with marginal activity against 
renal cell carcinoma, melanoma and non-Hodgkin's lymphoma). Toxicities are 
often severe and continue to be a problem, fatalities still being observed with IFN- 
a for example. '7 
In fairness, the full biological effects of many of these cytokines are still 
coming to light and their true benefits may await discovery. For example, many 
are showing potential alongside conventional cytotoxics, combating myelo- 
suppression 
- 
such as granulocyte colony stimulating factor (G-CSF) being used 
in high dose chemotherapy regimes. 18 Another feature of a number of cytokines, 
including the interferons, is the synergistic activity commonly observed in 
combination with cytotoxics 
- 
for example, shown in a recent phase II trial of 
dacarbazine or cisplatin in combination with IFN-a and IL-2 in the treatment of 
metastatic melanoma. 19 
14 
Current therapy in the treatment of aggressive, malignant tumours of 
nearly any sort can be expected to select for the outgrowth of resistant clones that 
can occur spontaneously within the tumour population. While still offering great 
promise, biotechnology has so far failed to live up to expectations. With the 
problems of synthesis, formulation, transport and metabolism of these large 
fragile molecules, what effect can the small molecule have on the new discoveries 
of cancer biology? 
1.2.4 A new age of medicinal chemistry 
As well as directing many of the biotechnology approaches, the 
differences that have been established between normal cells and tumour cells, 
have provided a wealth of new targets for medicinal chemists. For example, many 
of the oncogenes involved in tumour growth code for proteins involved in signal 
transduction pathways where receptors could be antagonised and enzymes 
inhibited. A great deal of such chemistry has already been done. 
The most studied approach at the receptor approach has been with 
hormone-dependant tumours of the breast and prostate. The best known drug, 
tamoxifen (1), is an antioestrogen that competes with oestradiol for the oestrogen 
receptor. Despite minor toxicities, including increased risk of endometrial 
cancer, 20 it has been the endocrine treatment of choice for breast cancer for nearly 
a decade. It suffers from residual agonist activity, 21 and several second generation 
antioestrogens have been prepared such as ICI 182780 (2) 
-a pure antioestrogen 
that has shown in vivo activity 22 that should help determine the full potential of 
such growth factor receptor antagonists. 
15 
ý. N_ 
H OH 
HO (CH2)9SO(CH2)3CF2CFi 
1 Tamoxifen 2 ICI 182780 
Other approaches to oestrogen blockade have also been established. The 
aromatase inhibitors block the conversion of androgens to oestrogen, the only 
source of oestrogen in postmenopausal women. Aminoglutethimide was one of 
the first aromatase inhibitors used in the treatment of advanced breast carcinoma 
in postmenopausal women, but it is not very selective and suffers from side 
effects. Second generation aromatase inhibitors have been discovered such as 
vorozole (3), that are more selective, exhibiting fewer side effects. 23 
NO 
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Other tumour types are amenable to such steroid therapy. These include 
ovarian cancers, prostate cancers (commonly treated with luteinising hormone 
releasing hormone (LHRH) agonists and antiandrogens such as flutamide (4)), 
and cancers of the lymphocytes 
- 
leukaemias and lymphomas 
- 
treated with 
glucocorticoids such as prednisone (5). 
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A growing understanding at the molecular level is allowing a more 
rational approach. However, at present none of these receptor based approaches 
are curative. 
Another group of targets that has already received considerable interest are 
the protein kinases that are involved in relaying messages along the signal 
transduction pathway by phosphorylation of tyrosine or serine/threonine residues 
of the next protein down 
- 
thereby activating it to transmit the message. Protein 
tyrosine kinases (PTKs) are involved in the cytoplasmic region of many receptors 
that are often over-expressed in tumours such as the epidermal growth factor 
receptor (EGF-R) in breast and ovarian tumours. 24 Other receptors for 
transforming growth factor a (TGF-(x), platelet derived growth factor (PDGF), 
fibroblast growth factors (FGFs) and the c-erbB2 receptor whose ligand is 
unknown are also implicated in a number of tumours. There are also non-receptor 
PTKs that are cytoplasmic proteins involved in the transduction pathway, 
including the src family of proteins, implicated in colon and breast cancers, 25 and 
the fes and abl families. 
As such, PTK inhibitors have been the subject of considerable recent 
research. Despite the prediction of up to a thousand different protein kinases 
(PKs), high throughput screening, coupled with the recent X-ray crystal structures 
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of serine/threonine cyclic adenosine monophosphate-dependent kinases, 26.27 and 
cyclin-dependant kinase 2,28 and a knowledge of the amino acid sequence of the 
catalytic domain has produced a number of different structures that show a 
surprising degree of selectivity for individual PKs. 
The natural flavone quercetin (6) and iso-flavone genistein show 
selectivity for PTKs over serine/threonine kinases, 29 despite being competitive 
with adenosine triphosphate (ATP) 
- 
the phosphate source 
- 
rather than the 
substrate. However, their antitumour activity is thought to be due, in part, to a 
cytotoxic effect mediated through interaction with topoisomerases. 13 Other 
derivatives have yet to show promise. 
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The discovery of PTK inhibition and antitumour activity of the styrene 
containing natural product, erbstatin (7), 13 prompted the synthesis of hundreds of 
benzylidene malononitrile analogues now termed tyrphostins. 30 They are 
competitive with substrate, and have shown a great deal of selectivity for the 
EGF-R PTK, even distinguishing it from the closely related c-erbB2/neu PTK. 31 
One such analogue, nitrile 8, has shown potent activity against breast cancer, 32 
and is thought to block the actions of several growth factors. 
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Other tyrosine mimics exhibiting PTK inhibitory activity include 
hydroxycinnamides, 33 thiazolidine-diones, 34 aminoalkylacrylophenones, 35 
quinolines, 36 and dianilinophthalimides that are EGF-R selective and have shown 
in vivo activity. 13 There are also transition state analogues such as the nitrostyryl- 
oxysulphonylbenzoic acid 9, again EGF-R selective 37 Other natural products 
include lavendustin A (10) an EGF-R PTK inhibitor that is competitive with 
ATP, 38 and the benzoquinoid antibiotics herbimycin A and geldanamycin that 
inhibit the non-receptor src PTK and have shown in vivo activity. 39 
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A number of protein kinase inhibitors are in clinical trials and more are 
expected to follow. 
Inhibitors of molecular targets downstream of the receptors carrying out 
the work of the oncogenes are also under investigation. One such target is the 
protein-protein interactions involving the so-called SH2 and SH3 homology 
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domains, important in propagating the 'message'. Phosphorylated peptides have 
been shown to inhibit these interactions 40 That the ras gene is over-expressed or 
mutated in many cancers has made it the target for many approaches. From the 
initial gene protein three steps are required for the maturation of ras to its active 
form 
- 
farnesylation, proteolysis and methylation 
- 
occurring at the 'CAAX' box. 
Farnesyl transferase has been identified and shown to be inhibited by 
benzodiazepine peptide mimetics. 41 Inhibitors of this enzyme are expected to 
enter clinical trials soon. 
The ether lipids are another class of novel anticancer drugs, 42 for example 
miltefosine (hexadecyl phosphocholine) 
- 
approved for the topical treatment of 
skin metastases in breast cancer patients.? They elicit a range of responses 
including an antitumour immune reaction, but also have numerous effects on 
signal transduction at the membrane including antagonism of growth factor 
receptor interactions such as EGF and PDGF, and inhibition of key signalling 
enzymes. 
Suramin is another lead structure that inhibits the binding and mitogenic 
action of a number of polypeptide growth factors including PDGF, FGF, TGF-a, ß 
and EGF. In vivo antitumour activity has been observed in prostate cancer, 
adrenocortical carcinoma and breast and ovarian cancers 43 
There are several potential pitfalls to attacking signal transduction 
pathways. The first problem is one of selectivity. The target, for example a PTK, 
may be involved in many signalling pathways. Even if a target is specific for the 
desired pathway, an inhibitor would inhibit the target in all cells with the risk of 
toxicity to normal tissue. Fortunately the degeneracy of growth factor signalling 
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may allow specific pathway inhibition, thereby eliminating the effects of the 
oncogene, while leaving other paths intact for normal cell function. But, if several 
pathways were under the controls of several oncogenes, inhibition of all these 
may not leave enough signalling integrity for normal cell function. 
Experimentally, the development of regimes based on several drugs, each of 
which is inactive alone, is not an easy task and would also involve patient 
selection based on biopsy results to determine the oncogenic profile. As well as 
these practical problems, the inhibition of signalling pathways is still an 
antiproliferative approach and may fail on slow growing solid tumours expressing 
little of this biochemistry, that so desperately need more effective treatments. The 
results would be cytostatic not cytotoxic, suggesting drugs would be required for 
extended periods, increasing the chances of drug resistance appearing. 
Approaches that address fundamental differences may offer greater 
potential. The most direct approach, similar to antisense oligonucleotide therapy, 
is to target drugs to specific DNA sequences of oncogenes that are different by 
virtue of point mutations or translocations. As stated, this requires the ability to 
recognise about 15 bases in a sequence. At present we are limited to 5 or 6 base 
recognition, for example with distamycins. However, some distamycins coupled 
to nitrogen mustards, have shown the ability to selectively inhibit transcription 
factors and have entered clinical trial. 11 The ability to tailor a molecule for the 
recognition of any sequence seems a long way off, but more sophisticated DNA 
binding experiments and molecular modelling packages are hoped to improve our 
understanding of this challenging area of research. 
The search for telomerase inhibitors has also generated considerable 
excitement. DNA segments at the end of chromosomes called telomeres shorten 
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every time a cell divides, providing a counting mechanism. Once reduced to a 
certain length the cell stops dividing, entering senescence. If a cell manages to 
avoid senescence, further shrinkage of the telomeres will lead to crisis, which 
means cell death. Any cell escaping crisis will become immortal, in the case of a 
tumour enhancing the likelihood of aquiring further mutations. If crisis were not 
avoided, the growth of tumours would be stopped long before they grew large. 
Mortality is commonly avoided by activation of a gene coding for telomerase, 
able to replace telomeric DNA. Telomerase is virtually absent in normal cells, but 
has been found in a large number of tumours. A recent study of head and neck 
squamous cell carcinoma patients detected telomerase activity in 88% of them. ` 
Telomerase is not a universal marker though, absent in cancer cells still having 
long telomeres requiring few mutations, including paediatric retinoblastoma, 45 
and other mechanisms have been postulated for telomerase negative cells 46 
Despite this, a number of groups are seeking telomerase inhibitors. 
Initiation of apoptosis is another potential target. Although the precise 
molecular events are not yet known, a number of genes have been implicated for 
example, p53, bc1-2 andfos. Overexpression of bc1-2 is common in cancers of 
haematologic origin. The bcl-2 protein dimerises with a bax protein, preventing 
the formation of bax: bax homodimers which signals apoptosis, making the bcl-2 
protein a target for inhibition 47 There appear to be a number of origins of 
apoptosis, and signal transduction pathways are thought to be involved in some of 
them, in response to external factors. For example, apoptosis in mammary cells is 
affected by oestrogen levels. Part of the antitumour effect of tamoxifen is due to 
activation of apoptosis; 48 and diethylstilbestrol, leads to apoptosis in hormone- 
insensitive prostate cancer cells, independent of its oestrogenic activity 49 
Similarly, testosterone is related to prostatic apoptosis, in the endometrium and 
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liver TGF-(31 is important, and glucocorticoids and IL's affect the survival of 
haematologic cells. 
The processes of later stage cancerous development 
- 
angiogenesis and 
metastasis 
- 
that ultimately define a cancer's destructive potential, are also the 
target for medicinal chemists. Not a great deal is understood about metastasis, but 
protease and collagenase inhibitors are showing promise in preventing its 
advance. 
More is coming to light about the molecules involved in angiogenesis with 
the discovery of over a dozen promoting factors released by tumour cells (or 
induced from the surrounding stroma), including FGFs and vascular endothelial 
growth factor (VEGF) as well as inhibitory factors, including thrombospondin 
which is usually under the control of the p53 protein. 50 Various approaches 
against angiogenesis have been devised including gene therapies, antibodies to 
growth factors, use of growth factors linked to toxins, but also a number of 
smaller structures have shown anti-angiogenic activity. This broad group 
encompasses cytokines such as IFN-oc, s 1 small peptides such as angiostatin, to 
synthetic molecules such as pentosan polysulphate6 and TNP-470 (the first anti- 
angiogenesis agent to enter clinical trial) 52 
These last two approaches only represent cancer management not 
elimination, but in an animal model the use of angiostatin reduced established 
tumours to microscopic dimensions for as long as treatment continued S2 As the 
effects of anti-angiogenesis agents are generally directed away from tumour cells, 
at slow growing normal cells, the development of resistance is less likely. 
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While far less advanced, these novel approaches directed at more 
fundamental differences between tumour and host, are hoped to revolutionise 
cancer treatment alongside gene therapy and immunotherapy. 
The increasing use of cell free enzyme assays etc., and the switch of 
prescreens from inappropriate animal models that yield active drug candidates, 
only to perform disappointingly in the clinic, to panels of human tumour cell lines 
cultured in vitro is hoped to yield more realistic results. The American National 
Cancer Institute (NCI), for example, dropped the use of its P388 leukaemia in vivo 
prescreen in 1989 in favour of a panel of 60 in vitro human cell lines, making it 
now possible to test large numbers of compounds in a short space of time. While 
in vitro tests suffer from obvious limitations including the lack of cell 
heterogeneity, it is hoped that a more disease orientated approach will be 
established. Initial results from the NCI panel has shown that mechanistically 
similar agents of diverse structures often display a common fingerprint of activity 
across the 60 cell lines. Such fingerprints may also provide clues to the mode of 
action of agents selected through random screening programs of, for example, 
natural products. 
1.2.5 Non-specific immunotherapy 
The immune status of the cancer patient is generally regarded to be very 
important in determining the outcome of therapy. As stated, the loss of antigen 
presentation by cancer cells has been considered evidence of an immune system 
mounting an antitumour response. The fact that tumours are not destroyed before 
getting established may be due to a number of factors. Firstly, the increase in 
cancer incidence in old age is thought to be due to a decline in normal immune 
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function coupled with increasing autoimmunity, allowing aberrant cells to 
survive. 53 Secondly, through the release of as yet unknown factors, the disease 
itself produces an immunological deficiency. This can be further exacerbated by 
the immunosuppressive side-effects of many anticancer drugs. 
A number of anticancer approaches that activate the immune system exist: 
from the vaccine and antibody based therapies discussed above, to adoptive 
immunotherapy, and non-specific immunotherapy. In non-specific immuno- 
therapy the whole immune system is stimulated into activity. A number of anti- 
tumour agents have been shown to have this property, and can generally be 
classified as agents of microbial origin, natural biological substances, or synthetic 
compounds. All these agents are generally pleotropic in their effects on the 
immune system. Although this pleotropism has hampered efforts to understand 
the mechanisms of activity, it may be of practical necessity if multiple effector 
cell activities prove to be important for the successful treatment of cancer. 
1.2.5.1 The antitumour immune response 
Before we examine the advances in using this sort of approach, we will 
consider the components of the immune system that are important in the 
destruction of tumour cells. Figure 1-4 illustrates the major mechanisms involved 
(reproduced from reference 2, p. 44). 
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Figure 14 Components of the antitumour immune response. Solid lines 
represent proliferation/conversion of one cell type into another. 
Dotted lines represent cell-cell interactions. 
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Macrophages bind to and internalise tumour antigen. Here they are 
processed by enzymes involving partial degradation. The processed antigenic 
peptides are then presented at the macrophage cell surface in association with a 
MHC (major histocompatibility) antigen. The MHC antigens are required in the 
activation of the T cell response. Helper/inducer-T cells attach to the processed 
tumour antigen in association with MHC class II antigens, and the 
cytotoxic/suppressor-T cells in association with MHC class I antigens. 
Macrophages also secrete IL-1 leading to activation and proliferation of T cells. 
The two T cells mentioned differ in their cell surface antigens. The 
helper/inducer-T cells bear a CD4 antigen, and are also known as T4 cells. The 
cytotoxic/suppressor-T cells bear a CD8 antigen, hence T8 cells. Once activated 
the T4 cells secrete a range of cytokines including IL-2,4,5 and 6 which 
stimulate B cells (which also process and present tumour antigens) into 
proliferation, leading to their differentiation to antibody-producing plasma cells. 
Once bound to tumour cell antigen the antibodies lead to tumour cell death 
in two ways: by antibody-mediated complement-dependent cell lysis; or more 
importantly by antibody-dependent cell-mediated cytotoxicity (ADCC) 
employing cells such as macrophages, cytotoxic-T cells (CTLs) and natural killer 
(NK) cells, which recognise the bound antibodies. 
The interleukins produced by the T4 cells also serve to stimulate 
proliferation and activation of the primed T8 cells. The T8 cells can mature into 
suppressor-T cells, important in moderating the normal immune response, 
suppressing the T cell response to antigens. They can also mature into CTLs, able 
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to kill tumour cells bearing the antigen to which they are activated, in association 
with MHC class I antigen. This is in addition to their ADCC reactivity. 
Another action of primed T4 cells is the production of IFN-y which 
activates macrophages and NK cells to become cytotoxic. Unlike the CTLs, NK 
cells do not require MHC presentation, and although they do attack antibody 
bound tumour cells this is not necessary for their tumour cell killing either. Thus 
NK cells have a very broad activity 
- 
important when one considers the 
heterogeneity of cells within a tumour and the low antigenicity inherent to some. 
Activated NK cells also secrete IFN-, y, producing a positive feedback system. 
This picture is something of a simplification of the true story. There are 
numerous other cytokine messengers involved. As well as those mentioned 
several other interleukins are known with molecular weights in the range 10-25 
kDa, each with a variety of effects on proliferation and activation of effector cells 
of the immune system. 
The interferons are another large group of peptides ranging in size from 16 
to 25 kDa and at least 20 are known. They are classified as IFN-a, IFN-(3 or IFN-'y 
according to their cellular origins. The interferons exert their effects, as 
mentioned, by stimulation of NK cells and macrophages and also through a direct 
antitumour cytotoxic effect. 
TNF is another important mediator, with both direct and indirect 
cytotoxicity. It is postulated that the cell binding of TNF starts a cytolytic cascade, 
and that there are more TNF receptors on/in tumour cells. TNF also activates 
macrophages and CTLs. 
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The colony stimulating growth factors (CSF's) also have a role. Though 
not involved in direct antitumour effects, as their name suggests these 15-25 kDa 
peptides are able to promote the proliferation and differentiation of cells 
- 
namely 
granulocytes, monocytes and macrophages. 
1.2.5.2 Agents of microbial origin 
From the time of "Coley's toxins" in the 1890's, the use of bacterial 
filtrates to treat cancer was experimented upon sporadically until the 1930's, and 
was then abandoned. Nonspecific immunotherapy gained prominence once more 
in the late 1960's when the clinical efficacy of a mycobacterium BCG (Bacillus 
Calmette-Guerin) was reported. A corynbacteria, C. parvum has also shown 
similar results. Their activity is thought to correlate with augmenting the cytotoxic 
activity of T cells, macrophages and NK cells and there is evidence for their 
inducing the production of IL-1 and TNF (ref. 2, p285). As well as whole killed or 
attenuated cells, cell wall constituents have also shown immunomodulation, 
including MDP (muramyl dipeptide) 
- 
identified as the smallest immuno- 
modulating entity of mycobacterial cell wall, and of which numerous analogues 
have been prepared and investigated. Other active agents include 
lipopolysaccharides (LPS), an endotoxin from gram-negative bacteria that induces 
TNF-a, (3, and which despite its toxicity is still under investigation having shown 
moderate activity in colorectal cancer in a recent phase II study; 54 also yeast 
polysaccharides; bestatin; and krestin. 
To date only BCG has gained approval, and has been in use for the 
treatment of superficial bladder cancer and carcinoma-in-situ of the bladder since 
1990.55 
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1.2.5.3 Natural biological substances 
The use of cytokines involved in regulation of the immune system has 
already been discussed. Despite their exquisite molecular specificities, as 
mentioned only poor activities have been observed. The natural heterogeneity of 
each group of cytokines is negated by the use of pure recombinant products, and 
the relative efficacy of mixtures versus the cloned products remains to be 
determined. It is possible that the "dirtier" response to BCG is to our benefit. 
Despite these apparent setbacks a number of recombinant interferons, 
interleukins, colony stimulating factors and tumour necrosis factor have entered 
clinical trials (ref. 2, pp275-282). 
1.2.5.4 Synthetic drugs 
The number of low molecular weight synthetic compounds that have also 
shown immunomodulatory properties, thought to be responsible for their observed 
antitumour activities, covers a heterogeneous group of structures. They range 
from the large double-stranded polyribonucleotides such as poly A: U 
(polyadenosine-polyuridine) and poly(I, C)-LC (polyinosinic acid-polycytidylic 
acid complexed with poly-L-lysine); to the carbamoyl aziridine, azimexone (15) 
(MW=194). 
Some examples of well known and tested small molecule 
immunostimulants are shown in Figure 1-5, and a summary of their main effects 
on the immune system is collated in Table 1-1. Interestingly, some conventional 
cytotoxic drugs have also demonstrated immunoenhancing activity, including the 
alkylating agents uracil mustard (17) and cyclophosphamide (18). 56 
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Figure 1-5 Small molecule immunomodulators. 
Agent Immunomodulation Reference 
LS-2616 NK and T cell activation 57 
Levamisole Lymphokine production 
Antibody formation 
58 
Tilorone hydrochloride IFN induction 59 
Immi uimod IFN induction 60 
Azimexone CSF production 2 
Loxoribine NK and B cell activation 61 
Table 1-1. Major immunomodulatory effects of representative agents. 
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To date, although the major effects of many of these agents on the immune 
system have been described, the mechanisms of action are not understood. Of the 
variety of synthetic structures possessing immunomodulatory activity, only 
levamisole (12), has demonstrated great clinical utility 
- 
as adjuvant to surgical 
resection in patients with stage B2 or C colon carcinoma, in combination with 5- 
fluorouracil. 62 
1.2.5.5 Aminopyrimidinone immunomodulators 
As well as immunomodulatory guanosine derivatives such as loxoribine 
(16), a number of simple 9-alkyl guanines such as 9-hexylguanine have shown 
antiviral activity thought to be due to immune system potentiation, suggesting the 
carbohydrate moiety is not required for activity. 63 Moreover, previously in 1976 a 
simple pyrimidinone, 2-amino-5-bromo-6-methylpyrimidin-4(3H)-one (19, 
ABMP) was reported to have antiviral properties and shown to be an interferon 
inducer in mice. M Unfortunately this compound suffered from unacceptable renal 
toxicity in certain animal models. The second generation of pyrimidinones to 
show equal or improved interferon induction and antiviral activity, without the 
renal toxicity, were the 2-amino-6-phenylpyrimidinones. 65 The most active were 
the 5-bromo (20) and 5-iodo (21) derivatives, ABPP (or bropirimine) and AIPP 
respectively. 
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ABPP (previously synthesised by Brown and Stevens66) was a more 
potent interferon inducer than ABMP in a range of animals tested. Despite being a 
weak interferon inducer, AIPP showed equal or better antiviral activity than 
ABPP, suggesting that the antiviral activity of the 6-phenylpyrimidinones is only 
partly mediated by the endogenous production of interferon 67 
In the initial report, several analogues were also prepared, and it was found 
that the free 2-amino and 4-oxo functions were essential for activity. 64 Since then 
other analogue studies have been undertaken varying substitution in the phenyl 
ring, and replacing the 6-aryl group with heteroaryl groups; other halogens and 
alkyl groups have been tried in the 5-position. 65.68.69 Certain constraints for 
activity have been found such as the 5-substituent must be no smaller than chloro 
nor larger than propyl, and activity is diminished with para-substituted phenyl 
groups in the 6-position. No compound showed significantly greater activity than 
ABPP or AIPP, but some were comparable such as ABmFPP (2-amino-5-bromo- 
6-(3-fluorophenyl)pyrimidinone). Again there was generally no correlation 
between interferon induction and antiviral activity. 
Further studies with animal tumour models have generally been confined 
to ABPP, AIPP and ABmFPP 
- 
most frequently ABPP with its good oral activity. 
Broad ranging activity has been noted in several tumour types. For instance, 
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ABPP as single agent treatment of B16 melanoma in mice; and ABmFPP in 
combination treatment of P388 Leukaemia in mice with cyclophosphamide 70,71 
More recently, ABPP has shown activity against murine renal cell carcinoma and 
rodent prostate cancers. 72'73 ABPP has also shown activity in human tumours: a 
recently completed phase II trial in the treatment of carcinoma in situ of the 
bladder was effective in treating approximately 50% of patients, including those 
who had previously failed BCG therapy, giving ABPP the potential to replace 
BCG as frontline therapy because of its ease of administration and low toxicity 55 
Other indications include upper urinary-tract carcinoma in situ74 
The mechanism of action of bropirimine is not known, and its effects on 
the immune system are wide ranging. Those effects that have been elucidated 
include the stimulation of NK cells; activation of macrophages; polyclonal B-cell 
activation; enhancement of antigen-mediated antibody formation; bone marrow 
proliferation as well as (and possibly involving) the induction of IFN-a, IL-1 (in 
vitro), IL-2 and TNF-a 75'76 
A clue to the possible mode of action of bropirimine is provided by its 
crystal structure, where two molecules are triply hydrogen bonded in the manner 
of a Watson-Crick cytosine: guanine base pair, with one bropirimine as the 3H- 
tautomer (guanine-like) and the other as the 1H-tautomer (cytosine-like) (Fig. 1- 
6). 77 This ability to exist as either tautomer could allow bropirimine to recognise 
guanine or cytosine residues in single-stranded DNA in classical Watson-Crick 
terms, or to recognise these bases in the major groove of double-stranded DNA by 
Hoogsteen encounters. 
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Figure 1-6 "Base-pair" in crystal stucture of bropirimine, with a cytosine- 
guanine Watson-Crick base pair for comparison. 
The stuctural similarity between the bropirimine "base-pair" and the 
interferon inducer poly(I, C) mentioned above is very striking. However, studies of 
the stucturally similar 9-alkylguanines, and guanosine analogues, with their 
comparable biological profiles, have implicated so-called G-proteins (cell 
membrane, guanine-nucleotide binding proteins) as the site of action. 63 
In answer to the question posed at the beginning of this section, it seems 
unlikely that any one approach could tackle the collection of diseases that are 
grouped under the heading "cancer". Far from being dead however, chemistry is 
becoming increasingly important in probing the mechanisms of this disease at the 
molecular level. To tackle this apparently complex disease it seems likely that a 
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combination approach, without prejudice to scientific discipline, will be most 
effective. 
1.3 The role of immunomodulators 
In comparison to the impact of cytotoxic drugs, immunotherapy has yet to 
provide the quantum leap expected in the treatment of cancer, but research in this 
area is continuing. It is clear that immunomodulators are most effective with low 
tumour burdens, and given that the smallest currently clinically detectable 
tumours are of the order of 1 cm3, with about 109 cells, immunomodulators are 
unlikely to be effective in eradicating disease alone. The immune status of the 
host is very important, however, if we are to eliminate every tumour cell to 
prevent relapse. The optimal setting for immunomodulators is likely to be post- 
operative, destroying residual tumour cells and perhaps preventing the 
establishment of metastases, in combination with conventional cytotoxic drugs. At 
this point it is noteworthy to observe the often synergistic effect observed in the 
combination of immunomodulators and cytotoxics. For example, the use of 
levamisole in combination with 5-fluorouracil in the treatment of resected human 
colon cancer gives a greater than additive effect on survival and remission rates 
than either agent alone 62 Several phase III studies are also looking at the use of 5- 
fluorouracil in combination with recombinant interferons. (ref. 2, pp. 277-282) 
One of the difficulties in the development of small molecule 
immunomodulators is the lack of knowledge about the molecular targets, negating 
a rational drug design approach. In vitro tests generally fail to demonstrate 
activity, due to the importance of the host's immune system in bringing about a 
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response. Many of the immunomodulators mentioned show in vivo activity in the 
growth and metastasis models of the B 16 melanoma in mice (see for example 
refs. 57 & 70), making this a potential prescreen for new agents. Despite the 
difficulties, with the potential to harness the power of the body's own defences, 
such non-specific immunomodulation remains an attractive target for the 
medicinal chemist. 
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2. Aims and Objectives 
In this chapter the main aims of the experimental work are presented. 
2.1 Pyrimidines and imidazoles 
The chemistry of pyrimidines and imidazoles is long established and wide 
ranging, having been dealt with in a number of texts. 78 82 In this work, 
investigations were restricted to a small class of each type of compound 
- 
the 
aforementioned 2-amino-4-pyrimidinones 22, and the functionally similar 
imidazole-4-carboxamides 23. The pyrimidinones may be regarded as endocyclic- 
amides, and the imidazolecarboxamides as exocyclic-amides, both with similar 
intermolecular hydrogen-bonding abilities through the amide groups and two 
other nitrogen atoms (though not necessarily with the same ratio of hydrogen- 
bond donors to acceptors). 
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The imidazole and pyrimidine nuclei, as well as being essential building 
, 
blocks of living organisms, are important pharmacophores, present in a wide 
range of biologically active compounds, both natural and synthetic. For example, 
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both imidazole and pyrimidine subunits feature in the current armoury of 
anticancer cytotoxics, including methotrexate (24) and numerous DNA base 
analogues such as 6-thioguanine (25). A number of the small-molecule 
immunomodulators considered in chapter one also contain one or both subunits 
(see Figure 1-5, Chapter 1). The aim of the present work was to investigate new 
chemistry of these systems, with the potential for the synthesis of novel, small 
molecule immunomodulants. 
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2.2 Chemistry of 2-aminopyrimidin-4-ones 
As mentioned in section 1.2.5.5 it has been found that modifications at 
positions 1 to 4 of the pyrimidine ring results in loss of interferon induction and 
antiviral activity, although studies into variants at these positions 
- 
including 
alkylation and oxidation of the ring nitrogens 
- 
have yielded compounds with 
other biological properties including diuretic, hypotensive and anti-inflammatory 
activity. 83,84 
More recently, electrophilic and nucleophilic reactions at the carbon atoms 
of 2-amino-6-arylpyrimidin-4-ones have been described. 85 The sites of 
39 
electrophile and nucleophile attack are depicted in Figure 2-1 upon 2-amino-6- 
phenylpyrimidin-4(3H)-one (26; APP), the inactive precursor of bropirimine (20), 
the lead compound in this class. 
ýý 
H2N 
0 E 
E (under strongly 
acid conditions) 
Figure 2.1 Sites of electrophilic and nucleophilic attack on APP, 26. 
(E=electrophile; N=nucleophile) 
The free pyrimidinones are amphoteric in nature, bropirimine (20) for 
example ionising to a stabilised anion 20a in alkaline solution, and protonating to 
a stabilised pyrimidinium ion 20b in acidic solution. The pKa values for 20b and 
20 are 3.18 and 8.53 respectively (Figure 2-2). 85 
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Figure 2-2 The amphoteric nature of bropirimine, 20. 
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In this work it was decided to retain the basic 2-aminopyrimidin-4-one 
structure 22, instead looking at the chemistry of positions 5 and 6 of the 
pyrimidine ring, to develop novel substitution patterns for R1 and R2, including 
the formation of fused rings with the pyrimidine. An important consideration in 
the development of pyrimidinone derivatives is their inherent poor aqueous 
solubility, the formation of Watson-Crick-like pairs in the solid state exposing 
only hydrophobic groups to an aqueous environment. For example, the aqueous 
solubility of 20 is less than 40 pg/m1.85 The molecular targets of this research will 
be elaborated in chapter 4. 
2.3 Chemistry of imidazole-4"carboxamides 
As with studies of the pyrimidinones, the basic structural motif of 
imidazole 23 was retained, preserving the intermolecular bonding abilities. 
Studies centered upon varying the substituents R' and R", again with the intention 
of developing novel chemistry, including the elaboration to fused ring structures. 
Unlike the "n-deficient" aminopyrimidines, the reactions of "n-excessive" 
imidazoles are characterised by electrophilic attack at carbon and nitrogen 
- 
as 
exemplified by their more basic character, for example the pKa of protonated 
imidazole is 6.95.86 Free imidazoles are also amphoteric in nature, ionised by 
strong bases to form a resonance stabilised anion. The pKa of free imidazole is 
14.52 86 
-a weaker acid than bropirimine. The acidity and basicity of imidazoles 
however, are very sensitive to their ring-substitution pattern. For example, the 
pKa's of 5-formylimidazole are 2.90 and 10.66 for the protonated and neutral 
forms respectively. 86 
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In the next chapter will be described the investigations into reactions of 5- 
aminoimidazole-4-carboxamide (27), studying substitution and condensation 
reactions; and of 5-formylimidazoles such as 28, studying their synthesis and 
condensation reactions. 
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3. Imidazolecarboxamides 
A number of target imidazolecarboxamides were investigated, and each 
will be considered separately. 
3.1 Reactions of 5(4). aminoimidazole-4(5). carboxamide 
5(4)-Aminoimidazole-4(5)-carboxamide (AIC, 27) was first isolated from 
a culture of Escherichia coli (E. coli) during sulfonamide bacteriostasis. 87 It has 
been shown to be the precursor of purines in the de novo synthesis of nucleic 
acids. 88 Now commercially available, AIC has been synthesised by a number of 
routes, most commonly as the hydrochloride salt (AIC. HCI). An example is the 
procedure of Shaw and Woolley, 89 later modified by Montgomery and 
coworkers90 for large scale preparations, starting with ethyl cyanoacetate (Scheme 
3-1). 
N= C-' 
CO2Et H2N 
H2N 
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Scheme 3-1 Synthesis of AIC. HC1,27 (continued overleaf). 
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Conditions: i EtOH, HCI(g), Et2O (79%); ii alcoholic ammonia, rt, 5 d. (76%); iii PhNH2, 
6N HCI, NaNO2, H2O, <5'C, 5 min.; then rt, 20 h. (90%); iv 30% Pd-C, 98% formic 
3-4 h.; v IN HCI, reflux, 15 min. (71% for steps iv &v 
Scheme 3.1 Synthesis of AIC. HCI, 27. 
AIC has been used as the starting material for a number of important 
compounds including purine analogues such as the cytotoxic 2-azahypoxanthine9l 
(29) and the antitumour imidazotetrazinones mitozolomide92 (30) and temo- 
zolomide93 (31). 
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30 R=CH2CH2C1; Mitozolomide 
31 R=Me; Temozolomide 
In this programme, the first reactions of 27 that were investigated involved 
substitution of the amino group: 
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3.1.1 Rhodium carbenes 
A number of synthetic strategies have employed the internal diazonium 
salt 5-diazoimidazole-4-carboxamide (32) as a common intermediate, by coupling 
to the terminal nitrogen of the diazo group with a nucleophile. For example, 
reaction of 32 with the appropriate isocyanates yields the imidazo-tetrazinones 30 
and 3194 In this programme 32 was synthesised on a moderate scale (35g) 
according to the literature, 95 in good yield (Scheme 3-2). 
H2NOC NH2 
NaN02 
H2NOC N2 H2NOC N2 
N NH HCI dil. HCI, 0-5 C NON NN 
27 32 (86%) 
Scheme 3-2 Synthesis of 5-diazo-(5H)-imidazole-4-carboxamide, 32. 
The transition-metal catalysed carbene reactions of diazo-compounds are 
well established and have been reviewed 96 Employing metals such as rhodium, 
nickel and copper, reactions such as cyclopropanations, additions to aromatic 
rings, formation of ylids, atom abstractions and bond insertions can be performed. 
For example, ethers, thioethers and amines have been formed by reaction of 
diazo-compounds with alcohols, thiols and amines respectively, in the presence of 
rhodium(II) acetate. 97 Procedures are most effective for a-diazocarbonyls, 96 
though sulfonyl and phosphonyl groups are also tolerated a to the diazo group 97 
The generally accepted mechanism is shown in Figure 3-1 (with a rhodium(II) 
catalyst), though whether reaction involves a discrete carbene, or a metal-bound 
carbenoid remains unclear. 
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Figure 3.1 Mechanism of metal catalysed carbene formation from diazo- 
compounds. 
It was of interest to determine whether the diazoimidazole 32 could also 
undergo carbenoid reactions in the presence of a metal catalyst. A number of 
attempts were made to prepare ethers (33) by reaction of diazoimidazole 32 with 2 
mol. % rhodium(II) acetate and two equivalents of an alcohol, according to a 
corresponding literature procedure for transformation of a-diazocarbonyls. 97 In 
these studies, instead of using dichloromethane as solvent (as quoted), to 
counteract the poor solubility of 32, reaction with methanol was performed in 
tetrahydrofuran (THF) at room temperature; and reaction with cyclohexanol was 
performed at room temperature in dimethylsulfoxide (DMSO), and at reflux in 
THF, employing Soxhlet extraction to introduce 32 slowly to the reaction mixture. 
Unfortunately, no ether was formed under any of the conditions used and no 
nitrogen evolution was observed. Instead, the cyclisation product of 32,2- 
azahypoxanthine (29) was produced almost quantitatively under all conditions 
studied, identical with an authentic sample by infrared and1H NMR spectroscopy 
(Scheme 3-3). 
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Scheme 3-3 Attempted Rh(II) catalysed carbene chemistry. 
The transformation of diazoimidazole 32 to azahypoxanthine (29) is well 
known, and the kinetics of the process in aqueous media have been studied 
spectrophotometrically, 95 the mechanism presumed to involve nucleophilic attack 
of the amide nitrogen on the terminal nitrogen of the diazo group. The cyclisation 
is most rapid at alkaline pH, for example 32 cyclises in 0.1N sodium hydroxide 
with a half life of less than two minutes, 95 and it is possible that under the 
anhydrous conditions employed in our reactions, the alcohols are acting as weak 
base catalysts for the cyclisation process. 
Only rhodium(II) acetate was employed in these studies, but different 
metals and different ligands, for example trifluoroacetamide, have also been used 
by researchers in this field 
- 
so suitable conditions may exist for this reaction. 
However, given the intrinsic instability of 32 under likely reaction conditions, this 
question was not investigated further, the reactivity of 32 more closely mirroring 
that of aromatic diazonium salts than a-diazocarbonyls. 
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3.1.2 Suzuki reactions 
Since first reported, the palladium-catalysed coupling of a haloarene and 
an arylboronic acid has become the method of choice for the synthesis of 
unsymmetrical biaryls. 98 Moreover, the Suzuki reaction as it has become known, 
has been extended to a variety of other substrates for C-C bond formation. The 
scope of the Suzuki reaction will be discussed in more detail in the next Chapter, 
in the context of pyrimidine couplings. 
Biaryl units are important pharmacophores, present in a variety of 
biologically active compounds. For example, the angiotensin II receptor 
antagonist losartan (34) contains a substituted biphenyl that has been constructed 
with the Suzuki coupling reaction. 99 The preparations of a number of biologically 
active imidazolecarboxamides with aryl substituents have been patented 
including a range of 5-aryl-2-(trifluoromethyl)imidazole-4-carboxamides (35) as 
pest control drugs, l°° and 2-(4-fluorophenyl)-5-(4-methoxyphenyl)imidazole-4- 
carboxamide (36) as an analgesic antiinflammatory agent. 101 However, these aryl- 
imidazoles were not synthesised using the Suzuki reaction. In fact, there are only 
a few literature examples of haloimidazoles undergoing Suzuki coupling reactions 
(Scheme 3-4). 
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Conditions: i Pd(PPh3)4 (5 mol. %), Na2CO3 (2.1 eq. ), Toluene, reflux; ii Pd(PPh3)4 
(5 mol. %). Na2CO3 (2.1 eq. ), Toluene, EtOH, H2O, reflux. 
Scheme 3-4 Literature examples of Suzuki reactions upon 
bromoimidazoles. 
To prepare a series of 5-arylimidazole-4-carboxamides first required the 
synthesis of a bromo- or iodoimidazole. 
3.1.2.1 Bromoimidazoles 
The synthesis of 5(4)-bromoimidazole-4(5)-carboxamide (41), as its 
hydrobromide salt, has been reported by a number of procedures from mito- 
zolomide, 30, or its diazo precursor, 32.104 From 30, boiling in acetic acid 
containing sodium bromide or hydrobromic acid gave 41 in 17 and 60% yield 
respectively, the reaction presumed to proceed via 32 formed in situ. 
Bromoimidazole 41 was also isolated in 60% yield when 32 was stirred with 
hydrobromic acid in acetic acid at room temperature. 104 
49 
In this programme, though reaction of 32 with sodium bromide in acetic 
acid was unsuccessful, bromoimidazole 41 was prepared in good yield (54 to 
70%) by reaction of diazoimidazole 32 with hydrobromic acid in acetic acid, 
either at room temperature or at reflux, to give a golden crystalline solid with a 
melting point of 245 
- 
251°C (lit., 104 210°C). Despite the discrepancy in melting 
points, which may be due to polymorphism, the product thus prepared displayed 
satisfactory elemental analysis and 1H and 13C NMR spectra consistent with the 
assigned structure (Scheme 3-5). Comparison with literature NMR data is not 
possible because only the 2-H signal was quoted, without the identity of the 
solvent used. 104 
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Scheme 34 Synthesis of 5-bromoimidazole, 41. 
Following a procedure found successful in the Suzuki coupling of an 
unprotected bromopyrrole, 105 bromoimidazole 41 was reacted with phenylboronic 
acid in the presence of tetrakis(triphenylphosphine)palladium(0) catalyst and 
aqueous sodium carbonate as the stoichiometric base (employing more to account 
for the hydrobromide salt of 41) in refluxing N, N-dimethylformamide (DMF). 
However, along with unreacted starting material, only a debrominated by-product 
(42) was isolated (both as their hydrochloride salts) 
- 
identified by mass 
spectrometry and 1H and 13C NMR spectra (Scheme 
50 
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Scheme 3-6 Attempted Suzuki reaction on bromoimidazole, 41. 
Imidazole 42 has been reported previously, 106 but no physical properties 
were reported. Imidazoles 41 and 42 proved to be inseparable by crystallisation or 
chromatography, but in the NMR spectrum, the resonances corresponding to 41 
are easily accounted for. The remaining signals are readily assigned to 42, and in 
the 1H NMR spectrum, weak through bond coupling (-1 Hz) is observed between 
the 2-H and the 5-H protons. 
3.1.2.2 lodoimidazoles 
It is widely accepted that in the Suzuki reaction, iodo substrates are more 
reactive than the corresponding bromo substrates, by virtue of increased reactivity 
with the catalyst (as will be explained in the next Chapter). In the same 
communication cited for the bromoimidazole 41 (ref. 104), 5(4)-iodoimidazole- 
4(5)-carboxamide (43) (as its hydroiodide salt) was prepared by refluxing 
mitozolomide (30) with sodium iodide in acetic acid. However no parallel 
chemistry with diazoimidazole 32 was described. 
Efforts were made to prepare 43 by refluxing 32 with sodium iodide in 
both freshly distilled acetic acid and in dry DMF, but in both cases, as with the 
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bromide reaction, a dark mixture resulted, little or no nitrogen evolution was 
observed, and no products were isolated. Iodide 43 was eventually synthesised in 
low yield by reaction of 32 with potassium iodide in 1M hydrochloric acid 
(Scheme 3-7) 
-a method commonly used for the conversion of aromatic 
diazonium salts to their iodo derivatives. 107 
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Scheme 3.7 Synthesis of iodoimidazole from 32. 
Given the low yield in the synthesis of 43 and the difficulty in obtaining a 
pure sample, Suzuki reactions on this compound were not investigated. Also, 
given the lack of coupling reactivity of bromoimidazole 41, and its propensity for 
dehalogenation to 42, these reactions were not investigated further. 
A feature of the Suzuki reaction is that the halide and boronic acid act as 
the electrophilic and nucleophilic coupling partners respectively. The 5-position 
of an imidazole is not a particularly electrophilic site, and under the basic 
conditions of the Suzuki reaction deprotonation of haloimidazoles 41 or 43 is 
likely to reduce the electrophilicity further still. In the absence of coupling 
reactivity, other more energetically favoured routes are followed, i. e. 
dehalogenation, a phenomenon noted only rarely in the literature, though an 
example is in the couplings of bromoimidazoles. 103 The literature imidazole 
coupling reactions mentioned above (Scheme 3-4) both involved N 
-protected 
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imidazoles, and future studies in this area could look at the coupling reactivity of 
protected derivatives of the bromo- and iodoimidazoles, 41 and 43. 
The second area of interest with AIC 27 concerned the possibilities of 
benzaldehyde condensations at the amino group: 
3.1.3 Benzaldehyde condensations 
The amino group of 27 resides on an electron rich imidazole ring that 
makes few demands on the nitrogen lone pair, making it is a strong nucleophile, 
not only in the diazotisation already mentioned, but in reactions with a range of 
electrophiles. For example, Baig et al discovered that on reacting 5-amino-4- 
carbamoylimidazole-l-carbohydrazide (44) with benzaldehyde in refluxing 
ethanol, instead of the expected semicarbazone 45 (analogous to the product 
formed on reaction with acetone) the product formed was identified as the 
benzylidene derivative (46), 104 involving reaction at the 5-amino group (Scheme 
3-8). Schiffs base 46 was also prepared in 95% yield in the reaction between 27 
(AIC, as the free base) and benzaldehyde in refluxing ethanol. 104 
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Scheme 3-8 Reaction of aminoimidazole with benzaldehyde. 
Instead of a synthesis employing the free base of 27, one using the 
commercially available hydrochloride salt (AIC. HCI) was sought. Previous 
research in this group has shown simple reaction of AIC. HCI with benzaldehydes 
in refluxing ethanol to be unsuccessful; but that use of a catalytic quantity of 
sodium acetate, and reaction in aqueous ethanol furnished a range of Schiff bases 
in good yields. '°8 
In the present work, a reassessment of these conditions (which employed 
two equivalents of the benzaldehyde) has shown the use of equimolar quantities 
of imidazole 27 and benzaldehyde to be equally efficient. As well as the simple 
benzylidene derivative 46, the previously unreported derivatives 47 to 50 were 
prepared in this manner (Scheme 3-9). 
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Scheme 3-9 Modified Schiffs base synthesis. 
Given the ready availability of substituted benzaldehydes a vast range of 
Schiff bases could be synthesised. However novel, from a biological standpoint, 
such compounds would be of little use due to the lability of the imine bond to 
hydrolysis under weakly acidic or basic conditions, and routes to derivatise these 
compounds were sought. 
3.1.3.1 Imidazo[1,5-a]quinazolines 
There is relatively little literature regarding the imidazo[1,5-a]quinazoline 
nucleus, although a number of patents do exist on imidazo[1,5-a]quinazolines of 
general structure 53 as central nervous system (CNS) active agents including 
anticonvulsants, anxiolytics, hypnotics, antipsychotics and antiemetics. 109,110 The 
mode of action is thought to involve antagonism at the benzodiazepine receptor. 
Their synthesis involved reaction of a 4-amino-2-chloroquinazoline (52) with a 
5/4-cyclopropyl-3/5-isocyanomethyl-1,2,4-oxadiazole (51) (Scheme 3-10). 
55 
NR1R2 N4 
NR1R2 
N Yý N5 
N6 
Yý CI--(ý X3 
XN 
+ R3 2N`:: Z: 
/10 R3 
N. G 198 
51 
52 53 X=O, Y=N; X=N, Y=O 
R1, R2=alkyl, alkoxyalkyl, 
aminoalkyl, N-bound 
heterocycle 
R3=halogeno, alkyl 
Scheme 3-10 Patented synthesis of CNS active imidazoquinazolines. 
This procedure involved formation of the imidazole ring as the last stage. 
Any likely route to imidazo[1,5-a]quinazolines from benzylidene derivatives 46 
- 
50 would involve formation of the pyrimidine ring last, and leave C-5 in a 
different oxidation state to compounds of structure 53. Previous studies in this 
group attempted to achieve cyclisations of 2'-chloro or 2'-nitro derivatives, 48 or 
50 respectively, by thermolysis in high-boiling solvents without success. 108 
As a different tack the 2'-halogenobenzylidene derivatives, 47 to 49, were 
treated with sodium hydride in anhydrous DMF, the rationale being that 
deprotonation of the imidazole ring NH would facilitate intramolecular 
nucleophilic substitution in the benzene ring, with halides as the leaving groups. 
In this way the novel imidazoquinazolines 54 and 55 were prepared in good yields 
(Scheme 3-11 and Table 3-1). Interestingly, the parent compound 54 was 
fluorescent upon irradiation at 254 nm, but the nitro-substituted 55 was not. 
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Scheme 3-11 General synthesis of imidazo[1,5-a]quinazolines. 
Benzylidene Conditions Product 
X R Temp. /°C Time/hours Yield/% 
47 F H 25 168 54 0 
47 F H 65 100 61 
47 F H 155 3 86 
48 Cl H 155 30 25 
49 Cl p-NO2 65 264 55 77 
49 Cl p-NO2 100 3 65 
49 Cl p-NO, 155 0.5 15 
Table 3-1 Imidazoquinazoline preparations. 
A number of conclusions can be drawn from these results concerning the 
variables that were changed. Firstly, the effect of temperature: in general 
cyclisation rates dramatically increased with temperature, as can be seen with the 
reactions performed with 47 and 49; also there appeared to be a threshold 
temperature below which no imidazoquinazoline was formed, as with both 47 and 
49 a solution of the anion would persist at temperatures below about 40°C. This 
threshold temperature could be explained by the need for the imine bond to be cis 
for intramolecular attack of the imidazolyl anion, the heat therefore required to 
isomerise from the trans form produced under the thermodynamic control 
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conditions in the Schiffs base synthesis. Secondly, substituent effects: the more 
electronegative the leaving group the better, the transition from fluoro (47) to 
chloro (48) leading to a drastic reduction in the cyclisation rate such that after 30 
hours at reflux, much of the anion of imidazole 48 still persisted, with the 
prolonged reaction time leading to by-product formation; the reaction was also 
very sensitive to the activating ability of R, the introduction of a nitro para to the 
chloro in 49 greatly enhancing reactivity, and not only to reaction along the 
desired path. 
Initially, reaction of 5'-nitro derivative 49 under conditions found optimum 
in the cyclisation of 47 
- 
1.1 equivalents of sodium hydride in refluxing DMF 
- 
was deemed a failure, with all starting material consumed in 30 minutes leaving a 
complex mixture of products, none of which were fluorescent and most of which 
would not elute from the TLC baseline in a solvent system suitable for 
imidazoquinazoline 54. Alternative conditions were sought in a variety of high- 
boiling solvents, but again only a complex mixture resulted. Only on lowering the 
reaction temperature to 65°C was the cyclisation product, 55, slowly formed as a 
non-fluorescent and highly insoluble solid. For 13C NMR of 55 a sample had to be 
prepared in deuterio-trifluoroacetic acid (d-TFA), solubility being too low in d6- 
DMSO. With knowledge of the properties of the nitroimidazoquinazoline 55, 
careful reexamination of products from the initial reflux reaction revealed 55 in 
15% yield, though the other components were not identified. The rate of 
formation of 55 was subsequently greatly improved from the reaction at 65°C, 
with only a minor reduction in yield, by heating the reaction on a steam bath. 
The 1H NMR spectra of the benzylidenes and imidazoquinazolines are 
very similar (Figure 3-2). In transition from 47 to 54, the carbocyclic proton 
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resonances are shifted only slightly downfield, the major shift being that of the 
imine proton (identified in the Schiffs base 47 by its weak coupling to the 
fluorine) moving downfield about 1.5 ppm, on effectively becoming attached to 
an electron deficient pyrimidine ring. 
At the time when cyclisation of imidazole 49 was proving difficult, 
because of the potential of using the nitro group of 55 to introduce other 
functional groups, alternative routes to this molecule were explored. With 
reasonable quantities of the mono-substituted imidazoquinazoline 54 in hand 
direct nitration was an obvious choice. Mixed acid nitration using 70% nitric acid 
(and 98% sulfuric acid) up to room temperature 
- 
sufficient for the nitration of 
many substrates 
- 
left imidazoquinazoline 54 largely intact, only a minute trace of 
another fluorescent component being observed by TLC. Repeat reaction using 
90% nitric acid and heating up to 55°C gave this other fluorescent compound in 
high yield with a number of minor side-products. The 1H NMR spectrum of this 
new compound retained all the CH resonances of 54, precluding nitration, the 
only difference being loss of the amide proton resonances. The mystery 
compound was finally identified as the unknown carboxylic acid of the amide. In 
the course of the work-up it was isolated as the potassium salt 56a, recrystallised 
in 46% yield, and acidification of the filtrate yielded a sample of the free acid 56b 
in a further 16% yield. 
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Figure 3-2 'H NMR spectra of the Schiffs base 47, and its cyclised derivative 54. 
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An interesting feature of the 1H and 13C NMR spectra of the salt 56a, 
which had been prepared in deuterium oxide (D20), was the slow disappearance 
of the higher field (8=8.10 ppm) of the two closely placed singlets in the 1H 
spectrum, the pair originally assigned as the 1-H and 5-H resonances. By the time 
13C NMR was performed one CH resonance was missing, hampering 
identification. Consultation of the literature highlighted the ability of imidazoles 
to undergo deuterium exchange at the 2-position under neutral or basic conditions 
(see for example ref. 78, p. 194), and by analogy the disappearing proton singlet of 
the potassium salt 56a was assigned as H-1. Re-examination of the NMR 
spectrum of a fresh sample in D20 did indeed show the missing CH signal at 
5c=124.8, the intensity of the singlet at SH=8.10 reduced to 13% of original in six 
days. Such exchange reactions are thought to involve transient ylid formation 
(Scheme 3-12). 
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Scheme 3-12 Deuterium exchange at C-1 of imidazoquinazoline 56a. 
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The assignment of H/C-1 and WC-5 given for the carboxylate salt 56a 
cannot be generalised to the other imidazoquinazolines synthesised however, as 
for the free acid 56b, the order of the two singlets in the 1H NMR is reversed such 
that now the 5-H is the the higher field of the two. This was evidenced by a 2- 
dimensional 1H 
- 
13C correlation NMR experiment that linked the lower field 
proton singlet at SH=9.22 to a carbon resonance at 5c=127.5, the likely region 
expected for an imidazole C-2,79 and the other proton singlet at 8H=9.05 to a 
carbon at 5c=154.4, again in the region expected for a quinazoline C-4.79 
Complete assignment of all the members synthesised in this class would require a 
combination of 2-dimensional 1H - 13C correlation and NOE NMR experiments. 
In one final attempt to effect nitration the monosubstituted 
imidazoquinazoline 54 was heated with 90% nitric acid and concentrated sulfuric 
acid at 100°C for 24 hours, accepting that amide hydrolysis would occur and 
hoping that nitration would follow. However, the major product isolated was the 
acid 56b as before, obtained in 70% yield. Two other minor products were also 
isolated in quantities only sufficient for partial identification. Both had 
imidazoquinazoline-like 1H NMR spectra, one with a spin system suggesting 
mono-nitration in the carbocyclic ring; the other, substitution free. Examination of 
their 13C NMR spectra however suggested decomposition of the imidazole ring. 
In both cases, 2-dimensional 1H 
- 
13C correlation NMR linked the two proton 
singlets at around 9 ppm to two CH carbon signals at chemical shifts greater than 
155 ppm, rather than one at around 125 ppm and another at about 155 ppm as 
observed with the other imidazo[1,5-a]quinazolines prepared. 
That mixed acid nitration of these imidazoquinazolines is ineffective is 
perhaps not surprising, as any of the three ring nitrogens could be protonated 
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under the acidic conditions, deactivating the system to attack by an electrophile. 
Alternative nitration procedures do exist including the use of acetyl nitrate, or 
nitronium salts such the tetrafluoroborate salt, but as already mentioned the nitro 
derivative 55 was finally synthesised in good yield using the original procedure. 
An attempt was also made to synthesise the imidazoquinazoline nucleus 
by an alternative route, arylating the imidazole N-1 nitrogen followed by 
condensation at the 5-amino group, circumventing the need for high temperatures 
thought to be required for isomerisation of the imine bond of the benzylidene 
derivatives. Following a reported general method for the regiospecific 1- 
alkylation of AIC. HC1(27) - employing powdered KOH in DMF, followed by the 
alkyl halide at or below room temperatures tt- 2-fluorobenzaldehyde diethyl 
acetal (57), not previously reported, was prepared in 86% yield under standard 
conditions. 112 Attempted arylation of 27 at the imidazole nitrogen with acetal 57, 
under the above conditions, gave no reaction, and heating to reflux gave a 
complex mixture from which no product was isolated - highlighting the difference 
in reactivity to nucleophiles between alkyl and aryl halides (Scheme 3-13). 
Perhaps certain aromatic acetals such as a dinitro derivative would be sufficiently 
activated towards halide displacement, but given the high yield of the established 
route, this route was abandoned. 
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Scheme 3-13 Unsuccessful imidazoquinazoline synthesis. 
Given the lack of generality in the cyclisation of benzylidenes to 
imidazoquinazolines, the preparation of a series of such tricycles for biological 
evaluation could be limited to particular substitution patterns in the carbocyclic 
ring, further dependent upon benzaldehyde availability. However, the preparation 
of derivatives such as 55 opens access to other compounds through functional 
group interconversion, and other chemistry of these imidazoquinazolines awaits 
investigation. 
3.1.3.2 Triazepines and indazoles 
Investigations were also initiated into the possible derivatisations of a 
benzylideneaminoimidazole with a nitrogen containing group in the 2'-position of 
the benzene ring. A number of possibilities, starting from the 2'-nitro derivative 
50 were considered, centering on reactions formally involving nitrene 
intermediates reacting intramolecularly to give the benzoimidazotriazepine 59 or 
the imidazolylindazole 60 (Scheme 3-14). 
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Scheme 3-14 Potential cyclisations of a 2-nitrobenzylidene, 50. 
Lead tetraacetate (LTA) is a multi-faceted oxidising agent, able to react by 
ionic and free radical mechanisms. Of the many and various known reactions of 
LTA, oxidative formation of nitrogen-nitrogen bonds are fairly common (see for 
example reaction 1, Scheme 3-15). 113 Trialkyl phosphites have proved effective in 
the deoxygenative generation of arylnitrenes from aromatic nitro and nitroso 
compounds. 114 The most widely used source of aryl nitrenes however is the 
thermolysis or photolysis of aryl azides 
- 
for example in the synthesis of a 2H- 
indazole (reaction 2, Scheme 3-15). 115 Reaction 2 in Scheme 3-15 might suggest 
for our series (see Scheme 3-14), the indazole 60 to be more likely than the 
triazepine 59, especially starting with a trans imine bond. 
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Scheme 3-15 Intramolecular cyclisations of amino and azido aromatics. 
In this area of work, only attempts to form the 2-aminobenzylidene 58 
were studied. Firstly, reduction of the 2-nitrobenzylidene 50 was attempted by a 
number of literature procedures, without success (Table 3-2). The first conclusion 
to be drawn from these results is that the imine bond is labile under these 
conditions 
- 
either by reduction or simple hydrolysis. Numerous other conditions 
for the reduction of aromatic nitro groups have been described, but the imine bond 
is also reduced by a number of common methods including hydrogenation over 
palladium catalysts, and Raney nickel and zinc metal reductions. Cyclohexene 61 
was only partially characterised by 1H and 13C NMR spectroscopy. Bis(2-amino- 
benzylidene)hydrazine (62) was characterised by its mass spectrum (m/z 239, 
M+1), infrared absorbance and 1H and 13C NMR spectroscopy and had a mp 
249°C (lit. 116 251-252°C). Hydrazine 62 represents the only example where 
reduction of the nitro group was observed to occur, and though not reinvestigated 
at the time, a reaction employing careful addition of hydrazine might lead to 
selective nitro reduction before hydrazine displacement. 
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H2NOC ` 
rN 
Reduction 
NH 
NH 
50 
Run Method (Ref. ) Result 
1 SnC12.2H20/ EtOH/ reflux (117) 27 (AIC) + other 
unidentified components 
2 SnC12.2H20/ EtOAc/ reflux (117) 
3 50 psi H2/ 10% Pd-C/ 1M HCI (118) 
H 
XC 
50 + 27 (AIC) + (Tentative 
O2N 
I 
assignment) 
61 
4 N2H4/ Raney Ni/ EtOH/ (119) 
HOCH2CH2OH/ 50-60°C 
5 Zn dust/ 78% aq. EtOH/ reflux (120) 
HH 
27(AIC)+ C=N-N=C 
NH2 H2N 
I 
62 
27 + complex mixture 
Table 3-2 Attempted nitro reductions of 50. 
Further reductions of 50 were not carried out. A different approach to 
amine 58 was planned involving preparation of a benzaldehyde with a protected 
2-amino group that could be liberated after formation of the imine bond. The 
diethyl acetal of 2-nitrobenzaldehyde (63) was prepared in 76% yield (b. p. 146- 
156°C at 25 mbar, lit. 121 154-156°C at 18 Torr) by the method used previouslyt12 
to prepare the 2-fluoro derivative, 57, and the structure was confirmed by 1H and 
13C NMR. Nitroacetal 63 was then reduced according to the method of Ayyangar 
et al. with hydrazine/Raney nickel in a 1: 1 mixture of ethanol and 1,2- 
dichloroethane at 50 to 60°C. 119 The reaction appeared a success, but on 
attempted recrystallisation of the crude white reaction residue from THE/ethanol, 
a colour change occurred. The orange solid isolated gave a 1H NMR spectrum 
67 
consistent with 2-aminobenzaldehyde (65). Reduction of 63 with stannous 
chloride dihydrate, "7 as per run 2 in table 3-2, gave a mixture of products after 
work-up, none of which were identified. 
If in the hydrazine reduction of acetal 63, aniline 64 was formed, acetal 
hydrolysis in the absence of acid could occur with assistance from the amino 
group (Scheme 3-16). A high activation energy barrier for this process would 
explain the apparent reaction during recrystallisation, to give the benzaldehyde 65 
as the isolated product. Benzaldehyde 65 is unlikely to be synthetically useful due 
to a tendency to polymerise, which may also explain the low yield of solid 
isolated. 
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Scheme 3-16 Possible degradation in the reduction of 63. 
Future studies in this area could employ alternative aldehyde protecting 
groups such 1.3-dithianes (not with Raney nickel reductions), but other 
EtO OEt 
b. 
- 
1 
`ý NH2 
alternatives should also be tried including trialkyl phosphite reaction with the 
68 
nitro derivative 50 as suggested in scheme 3-14. The 2-azidobenzylidene Schiff 
base 67 also presents possibilities, but would require the preparation of 2- 
azidobenzaldehyde (66), 115 adding a further four steps to the procedure (Scheme 
3-17). 
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Scheme 3-17 Alternatives to 2-nitrobenzylidene 50. 
3.2 Syntheses and reactions of 5-formylimidazoles 
3.2.1 Imidazo[1,5-b]pyrazoles 
The Knoevenagel condensation of aromatic aldehydes and azido acetates 
is a well established procedure for the synthesis of aromatic vinyl azides. 122,123 
The main use of such azides formed has been in their thermolyses, generally in 
boiling non-polar aromatic hydrocarbons, to give indoles in good yields. Aromatic 
vinyl azides, with suitable ortho substituents in the benzene ring have also been 
reacted with trialkyl phosphites, the intermediate ylids undergoing aza-Wittig 
reactions to yield isoquinolines (Scheme 3-18). 
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Scheme 3-18 Reactions of azido acetates with benzaldehydes. 
In this programme the intention was to perform an analogous sequence of 
reactions upon a formylimidazole, such as 28, by reaction of azido or nitroacetates 
to form intermediate azido or nitrovinylimidazoles 68, with the hope of 
synthesising novel imidazo[1,5-b]pyrazoles 69 in a reaction paralleling the indole 
formation above. An alternative process, involving an aza-Wittig reaction could 
yield imidazo[4,5-c]pyridines 70 (Scheme 3-19). 
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Scheme 3-19 Proposed imidazo[1,5-b]pyrazole and imidazo[4,5-c]pyridine synthesis. 
The first task was to develop an efficient synthesis of 5(4)-formyl- 
imidazole-4(5)-carboxamide (28) or a synthetic equivalent. 
3.2.2 Reduction of imidazoles 
In an attempt to restrict the synthesis of formylimidazole 28 to as few 
steps as possible, transformations of suitably functionalised, commercially 
available imidazoles were investigated. There is however a relatively small 
number of such compounds, and initial investigations were restricted to 5(4)- 
cyanoimidazole-4(5)-carboxamide (71), 4,5-dicyanoimidazole (72) and 
imidazole-4,5-dicarboxylic acid (73). In all three of these compounds the 4- and 
5- substituents are carboxylic acid derivatives. There are numerous literature 
procedures for the partial reduction of such carboxylic acid derivatives to 
aldehydes, and using one of these procedures it was hoped to achieve selective 
71 
partial reduction of one substituent over the other to give a formylimidazole 74, 
with the unaffected group readily converted to an amide, giving 28 (Scheme 3- 
20). 
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Scheme 3-20 Proposed route to a formylimidazole. 
Though perhaps the most popular reagent for the partial reduction of 
amides, esters and nitriles, diisobutylaluminium hydride (DIBAL)124,125 proved to 
be unsuitable in reductions of imidazoles 71 and 72. Amide 71 suffered from poor 
solubility at the low temperatures generally employed. DIBAL reactions of nitrile 
72 were more complicated. 
It became apparent that rapid deprotonation of 72 occurred in the presence 
of DIBAL. Employing two equivalents of reductant at 0°C and either basic124 or 
acidic126 work-up gave a mixture, from which no products were isolated, though 
by 1H NMR trace aldehyde signals were observed. Reaction at 
-70°C with either 
one or two equivalents of DIBAL resulted in a mixture of starting material 72 and 
72 
the desired monoaldehyde 75 in, at best, a 5: 1 ratio. The novel monoaldehyde 75 
proved to be inseparable from 72 by chromatography, but was identified in the 1H 
NMR spectrum of the mixture, with a characteristic aldehydic signal at 8H =9.86, 
and by its molecular ion in the mass spectrum of the crude mixture (m/z, 121,118; 
M+ (75,72)). 
An explanation for the apparent lack of reactivity of 72 toward DIBAL 
reduction at low temperatures could be that the anion formed from the initial acid- 
base reaction, even if it is able to coordinate a second DIBAL molecule, is 
unreactive to subsequent hydride delivery due to stabilisation of the iminium ion 
from delocalisation of the negative charge. The small amount of aldehyde 
observed after work-up could be due to a competitive process acting upon neutral 
72 (Scheme 3-21). 
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Reduction of dicyanoimidazole 72 was then attempted by the method of 
Fry and Ott, 127 which involves nitrile N-alkylation followed by triethylsilane 
reduction of the resulting activated N-alkylnitrilium ion, and subsequent 
hydrolysis to yield the aldehyde. The procedure has been successfully applied to 
the selective reduction of a dicyano compound, reaction upon 1,4-dicyanobenzene 
giving 4-formylbenzonitrile in good yield. 127 Employing triethyloxonium 
tetrafluoroborate as the alkylating agent, reaction of imidazole 72 in both 
dichloromethane as per the reference, and in THF, more able to dissolve 72, 
appeared to return starting material largely intact in both cases, with none of the 
desired monoaldehyde 75 observed by 1H NMR. 
It would appear that no alkylation of 72 occurred. The procedure could be 
repeated with alternative alkylating agents, for example dimethylsulfate, but such 
alternatives were not investigated. 
So that more rigorous conditions could be employed, an imidazole with 
different 4- and 5- substituents was sought, to use chemoselectivity to generate the 
formyl group, rather than hope for regioselective reduction of identical groups as 
with dicyanoimidazole 72. Following a literature procedure, 128,129 5(4)- 
ethoxycarbonylimidazole-4(5)-carboxylic acid (78) was synthesised in three steps 
from the dicarboxylic acid 73, in 38% overall yield (Scheme 3-22). The low yield 
of the final step is thought to be due to a competing hydrolysis of tricycle 77 to 73 
involving the waters of crystallisation. 129 Monoester 78, recrystallised from 
methanol, had mp 205-207°C (decomp. ) (lit. 130 215-216°C), 1H NMR in 
agreement with the literature, 129 and 13C NMR and mass spectrum analysis 
consistent with the assigned structure. 
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Scheme 3-22 Synthesis of monoester, 78 according to the literature. 
Reduction of monoacid 78 was first attempted with borane-dimethyl 
sulfide complex, a procedure used to selectively reduce carboxylic acids to 
alcohols, or from which the intermediate trialkylborane may be directly oxidised 
to the aldehyde, for example with pyridinium chlorochromate (PCC) (ref. 131, 
p. 596). Two borane-dimethyl sulfide reductions of 78 were attempted, one in 
diethyl ether, and one in THE as solvent, both employing three equivalents of the 
borane complex as suggested in the presence of amines. 132 In both cases 
unreacted acid 78 was returned as the major component, with a mixture of minor 
components not readily identifiable by IH NMR spectroscopy. 
The reasoning for the lack of reactivity of 78 towards this borane reagent 
may mirror the lack of reactivity of the cyano compound 72 to DIBAL reduction, 
where it was postulated that the intermediate adduct, normally able to activate the 
75 
carbon centre to hydride delivery, is counteracted by the electron donating ability 
of the imidazole ring. 
3.2.3 Reduction of N-protected imidazoles 
Despite the allowance for the free imidazole NH in the borane reactions, 
as with the DIBAL reductions of 72, the free imidazoles studied do not seem to be 
sufficiently reactive under the conditions investigated. Attention then shifted to 
the reduction of N-protected imidazoles. The N-benzyl derivative 80 was 
synthesised in 73% yield from 72 according to the literature method and had mp 
128-130°C (lit. 133 124-127°C). The amide 79, previously reported by a two step 
procedure from imidazole 80 without experimental details, 134 was prepared in 
75% yield directly from the free imidazole 71 in an analogous manner to the 
synthesis of 80 (Scheme 3-23). The benzyl group was chosen for its resistance to 
the reductive and hydrolytic conditions likely to be encountered in these studies, 
and such N-benzyl imidazole derivatives have been cleaved in the presence of 
other reducible groups by catalytic transfer hydrogenation with 1,4- 
cyclohexadiene and palladium black catalyst. 135 
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Scheme 3-23 N-Benzylation of imidazoles 71 and 72. 
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With the objective being the selective partial reduction of one of the 4- or 
5-substituents of 79 or 80, amide 79 would be expected to be better with two 
different substituents, but as with the unprotected precursor 71, amide 79 suffered 
from very poor solubility and of the few reductions of 79 attempted this proved to 
be a severe limitation. Reductions of the dicyanoimidazole 80 were studied in 
more depth, which if successful would lead to the production of one or both of the 
possible isomeric monoaldehydes, 81a and 81b. 
HO NC 
CN H 
N. 
CH2Ph CH2Ph 
81a 81b 
The outcome of DIBAL reduction of 80 was found to be highly solvent 
dependent. When performed in THE or in toluene, DIBAL reduction of 80 was 
slow, unreacted reductant leading to hydrogen evolution on acidic work-up. The 
difference was that in THF, even after warming from 
-70 to O C, the result was 
starting imidazole 80 (80%) and one of the monoaldehydes 81a (20%), whereas a 
low temperature reaction in toluene gave 80 (65%), monoaldehyde 81a (4%) and 
the dialdehyde 82 (31 %), as determined by analysis of the 1H NMR spectra. 
Curiously, in the 250 MHz 1H NMR spectrum of the dialdehyde 82, one of 
the aldehyde signals appeared as a singlet and the other as a1 Hz doublet. Long 
range 2-D 1H-1H COSY NMR showed coupling of this aldehydic doublet to the 
imidazole 2-H proton. This phenomenon can be rationalised by considering 
possible canonical forms of dialdehyde 82 (Figure 3-3). In the figure, for the sake 
of illustration both aldehydes in the starting canonical 82a are shown in their 
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ionised forms. Though all the canonicals are inter-convertible, only the positive 
charge of the 5-CHO group can be shared onto C-2 of the imidazole in a single 
electron flow (82a-82b-82c). This direct interaction between C-2 and the 5-CHO 
group leads to enhancement of the through bond coupling between the 2-H and 5- 
CHO to an observable level. The dialdehyde derivative 82 has been reported 
previously, but without NMR data, precluding comparison. 136 
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Figure 3-3 Canonical structures of dialdehyde 82. 
Stannous chloride reduction of imidazole 80 with ethyl acetate as the 
solvent was also attempted under the conditions of the Stephen reaction, a method 
generally reserved for the partial reduction of aromatic nitriles to aldehydes (ref. 
131, p. 595). A mixture of products resulted after the hydrolysis step, but with no 
sign of aldehydes by 1H NMR. Instead, NMR signals characteristic of an 
imidazolecarboxamide were present, possibly formed by nitrile hydrolysis under 
the acidic conditions employed. 
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Reduction of protected imidazole 80 was then performed according to the 
method of Brown and Garg, who employed lithium triethoxyaluminium hydride 
("LiHAI(OEt)3") prepared in situ as an ethereal suspension, for the partial 
reduction of nitriles to aldehydes. 137 Initial LiHAI(OEt)3 reductions of 80 showed 
potential, and reactions in a variety of solvent mixtures were investigated with 
normal or reverse addition of reagents. In all cases studied, mixtures of the two 
isomeric monoaldehydes (81a and 81b), the dialdehyde (82) and starting material 
resulted. The respective proportions of 80,81a, 81b and 82 were estimated by 
analysis of integrations for the benzylic protons in the 1H NMR spectra of the 
crude mixtures (see Table 3-3 for optimised results in reactions at 0°C). 
H -0 NC 0H00 NC 
` 
-CN "LiHAI(OEt)3" CN HH 
NJVýN 0°C, 1 h. 80 -I- NN+ Nom, N+NN N,, 
CH2Ph 
81a 
CH2Ph 
81b 
5 CHZPh 
82 
., 
80 
CH2Ph 
Proportions (%) in crude product: 
80 81a 81b 82 Recovery (%) 
11 33 43 13 70 
Table 3-3 Optimised results for lithium triethoxyaluminium hydride reduction of 79 at 
0°C. 
Brown and Garg reported diethyl ether as the most effective general 
solvent, but in this situation reaction in a mixture of ether (in which the lithium 
aluminium hydride was supplied) and THE gave consistently more reliable 
results. Firstly, imidazole 80 was more soluble in THF, and also the LiHAI(OEt)3 
prepared remained in solution, rendering the addition of reagents an easier 
operation, whichever order of addition was used. 
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The unknown monoaldehydes 81a and 81b were tentatively assigned as 
the 4- and 5-formylimidazoles respectively on the basis of their deuterio- 
chloroform 1H NMR spectra, with reasoning analogous to the assignment of the 
dialdehyde 82 
- 
one of the aldehydic protons of one of the monoaldehydes 
appeared as a singlet and the other appeared as a1 Hz doublet (Figure 3-4). 
Interestingly, as observed in the 1H NMR of the two aldehyde groups of 82, the 
CHO doublet of 81b was at lower field than the CHO singlet of 81a. 
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Figure 3-4 Suggested assignment of the IH NMR spectra of the isomeric 
monoaldehydes 81a and 81b, in deuteriochloroform. 
Although at first glance the yield of monoaldehyde is good, comprising 
75% of the crude product, only partial separation of components was possible by 
silica gel column chromatography such that monoaldehyde 81a co-eluted with the 
dialdehyde 82, and monoaldehyde 81b co-eluted with starting imidazole 80, 
precluding complete characterisation of the formylimidazoles. Debenzylation 
would reduce the number of components to three, with the desired monoaldehyde 
75 comprising 75%, but experience in the DIBAL reductions of the free imidazole 
72 also gave problems in the separation of 72 and aldehyde 75, and debenzylation 
was not attempted. 
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The optimum results in the LiHAI(OEt)3 reduction of 80 at 0°C (Table 3- 
3) suggested the second reduction to be marginally slower than the first. However, 
LiHA1(OEt)3 reduction of 80 at lower temperatures showed only marginal 
improvement in selectivity against dialdehyde formation, and the overall much 
slower reaction created additional problems. For example, slow addition of 
reductant to 80 over 1.5 hours at -70 to -50°C and allowing to warm to -10°C over 
1 hour yielded, after work-up, a crude product consisting of 80 (23%), 81a (37%), 
81b (32%) and 82 (7%). 
It was of interest to determine whether modification of one of the cyano 
groups of 80 would improve selectivity for monoreduction by LiHAI(OEt)3 or 
DIBAL. Bridson and Lambert, 134 reported the synthesis of ethyl 1-benzyl-5- 
cyanoimidazole-4-carboxylate (83) in good yield, by reaction of the dicyano- 
imidazole 80 with sodium ethoxide, but without experimental details. An attempt 
to perform this transformation gave, after column chromatographic purification, a 
solid with mp 110°C and NMR spectra consistent with the structure 83 (or other 
isomer), but in only 12% yield (Scheme 3-24). The remaining products were not 
readily identified, though a number of other ethyl environments were observed by 
1H NMR spectroscopy. Given the poor return of product this approach was not 
investigated further and no reductions of monoester 83 were carried out. 
NC Et02C 
CN CN 
N 
(i), (ii) 
N (12%) ýNf ýNf 
CH2Ph CH2Ph 
80 83 (or isomer) 
Conditions: i NaOEt (1.3 eq. ), EtOH, THF, 0'C, warm to rt, 20 h.; ii IM HCI 
Scheme 3-24 Monoethanolysis of dicyanoimidazole 80. 
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The procedure of Fry and Ott, 127 investigated in the reduction of 
dicyanoimidazole 72, was reinvestigated in the reduction of the N-benzyl 
derivative 80. In two separate reactions, reaction of 80 with triethyloxonium 
tetrafluoroborate gave a white precipitate that was unaffected upon addition of 
triethylsilane according to the literature procedure. The product of these reactions 
was finally identified as the novel imidazolium tetrafluoroborate 84, involving 
reaction at the imidazole nitrogen rather than either of the cyano groups 
- 
demonstrating the greater nucleophilicity of the sp2 hybridised imidazole nitrogen 
over the sp hybridised nitrile nitrogens 
- 
and was isolated in high yield (89 and 
76%) (Scheme 3-25). 
NC NC 
CN CN 
(i) p 
NEt ÖýN BF4 
CH2Ph ,, CH2Ph 
80 84 
Conditions: i Et3O+BF4 (2.1 eq. ), CH2CI2, reflux, 4 d.; then Et3SiH (1.2 eq. ), reflux, 18 
h.; then H2O, reflux, 4 h. 
Scheme 3-25 Accidental synthesis of imidazolium tetrafluoroborate salt 84. 
Interestingly, in the NMR studies of imidazolium salt 84, the imidazole 2- 
H, with a high chemical shift of 9.94 ppm, rapidly exchanged with added 
deuterium oxide due to its acidity, deprotonation leading to ylid formation. This 
feature may be compared to the slow exchange at this position noted with the 
imidazoquinazoline 56a, thought to proceed through an ylid (Scheme 3-12). Also, 
in 13C DEPT NMR experiments, the C-2 signal was barely visible when the other 
signals were very strong, using a 1H-13C coupling constant of 140 Hz in the 
acquisition parameters. When this value was changed to 180 Hz the C-2 signal 
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was more readily visible (though the signals of the ethyl carbons were reduced in 
intensity). 
As an alternative to cyano group derivatisation attempted previously, 
attempts were made to protect the imidazole 72 with more electron-withdrawing 
groups that could alter the relative reactivities of the two cyano groups, promoting 
regioselectivity in the DIBAL and LiHAI(OEt)3 reductions for example. Failing 
that, a mixture of monoaldehydes and dialdehyde might be more readily separated 
than is the case with a benzyl protecting group. By virtue of the stability of the 
imidazolyl anion, protected imidazoles are generally cleaved under far milder 
conditions than required for the cleavage of analogously protected amines. 138 The 
previously unreported N-tosyl derivative 85 of the dicyano-imidazole 72 was 
prepared in good yield (91%) by its reaction with tosyl chloride and triethylamine 
in anhydrous toluene (Scheme 3-26). However, on storage of the solid product, 
decomposition began to occur within a week, presumably by uptake of moisture 
to hydrolyse 85 back to 72 and toluene sulphonic acid, and no reductions of this 
derivative were investigated. An attempt to form the N(1)-tert-butyloxycarbonyl 
(BOC) derivative of 72 with the anhydride (BOC)20 (di-tert-butyl dicarbonate) 
and catalytic 4-dimethylaminopyridine (DMAP), according to the method of 
Grehn and Raynarsson for the preparation of 1-BOC-pyrroles, 139 failed 
completely. This lack of reaction serves to demonstrate the effect of the second 
nitrogen in the heterocyclic ring, the two electron-withdrawing cyano groups 
favouring imidazolyl anion formation further. 
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Scheme 3-26 Synthesis of 1-tosylimidazole, 85. 
In looking for an alternative reduction approach, reviewing the work 
already carried out presented another option. In the synthesis of the ester 78, one 
of the intermediates, the tricycle 76, is effectively a 1-protected-5-carbamoyl- 
imidazole-4-carboxylic acid chloride. A number of different methods exist for the 
conversion of acid chlorides to aldehydes. Room temperature, atmospheric 
pressure hydrogenation with a palladium on carbon catalyst according to a 
modified Rosenmund procedure of Burgstahler et al.; 140 and sodium borohydride 
reduction at 0°C in THF/ DMF, with pyridine as a borane scavenger to prevent 
over-reduction, by the procedure of Babler, 141 were performed upon 76, the hope 
being that hydrolysis of an intermediate dicarbaldehyde 86 would yield 5(4)- 
formylimidazole-4(5)-carboxylic acid (87). Under both sets of conditions a rapid 
reaction was apparent, but after prolonged aqueous hydrolysis of the crude 
products from either method, the major component was imidazole-4,5- 
dicarboxylic acid (73), by comparison with the authentic compound. There are 
two alternative explanations for this observation: either reductions were not as 
successful as thought, and hydrolysis of the crude product of these reactions 
constituted hydrolysis of 76, which would give 73 directly; or the reductions were 
successful, but at some stage of the hydrolysis of the intermediate dialdehyde 86 
aerial oxidation occurred to give the diacid 73 (Scheme 3-27). 
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Scheme 3-27 Attempted reduction of imidazole acid chloride 76. 
3.2.4 Direct imidazole-ring synthesis 
Selective partial reductions of carboxylic acid derivatives linked to 
imidazoles appeared to present a number of difficulties, and other methods for the 
introduction of a formyl group onto an imidazole were sought. Reexamination of 
the literature revealed a one step preparation of methyl 5(4)-diethoxymethyl- 
imidazole-4(5)-carboxylate (90) by reaction of methyl isocyanoacetate (88) and 
diethoxyacetonitrile (89). 142 The diethoxymethyl group is a synthetic equivalent 
of the formyl group, and in this paper anecdotal evidence for the hydrolysis of 90 
to the formyl derivative 91 was reported, though without experimental details. In 
the present work, the imidazole 90 was prepared according to the literature 
method, 142 and conditions were found for its hydrolysis to the formylimidazole 91 
in 92% yield (Scheme 3-28). 
85 
"CN 
'*ýý C02Me 
Me02C CH(OEt)2 Me02C HC=O 
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89 90 91 
Conditions: i KH (1.38 eq. ), diglyme, 0 to 70°C, 5 h., 76%; ii 40% Aq. AcOH, 40'C, 
1 h., 92%. 
Scheme 3-28 Synthesis of 5-formylimidazole 91. 
3.2.5 Knoevenagel condensation reactions of 5-formylimidazoles 
With a formylimidazole 91 in hand, at last, Knoevenagel condensation 
reactions were attempted with ethyl nitroacetate. Reaction in the presence of 
titanium(IV) chloride and pyridine, according to the method used by Vegh and 
coworkers143 in condensations between furancarbaldehydes and nitroacetates, was 
unsuccessful, returning 91 and ethyl nitroacetate essentially intact with only minor 
by-products. 
This lack of reactivity towards a carbon nucleophile parallels the difficulty 
found reducing cyanoimidazoles in the previous sections, by all but the most 
reactive reductants. Electron donation from the heterocyclic ring decreases the 
electrophilic character of the formyl carbon, deactivating it to nucleophilic attack, 
even in the presence of the Lewis acid titanium tetrachloride (Figure 3-5). 
Imidazole deprotonation in the presence of pyridine is likely to further favour the 
deactivation of the formyl group. 
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Scheme 3-28 Potential deactivation of the 5-formyl group of 91 to nucleophilic attack. 
In the hope of establishing the importance of the NH group in precluding 
reaction, it was of interest to attempt Knovenagel condensation upon the N-benzyl 
formylimidazoles prepared in the LiHAI(OEt)3 reductions of 80. As mentioned 
previously, monoaldehydes 81a and 81b were not isolated pure, but a sample of 
81b was isolated by silica gel column chromatography with the dicyanoimidazole 
80 as the only contaminant (35%). Imidazole 80 should not interfere with any 
condensation reaction, which was performed on this mixture and ethyl 
nitroacetate under a number of conditions. 
A repeat of the titanium tetrachloride catalysed reaction of this impure 81b 
returned only starting materials. Reaction in pyridine with a catalytic amount of 
piperidine, used for the condensation of aromatic aldehydes and malonic acid, 144 
again returned the starting materials. Condensation was also tried according to the 
conditions reported satisfactory for the condensation of aromatic aldehydes and 
azido acetates, 122 which involved adding a mixture of alkyl azidoacetate and the 
corresponding alkoxide ion to the aldehyde at about 0°C. Reacting the mixture of 
81b and 80 with ethyl nitroacetate (pretreated with sodium ethoxide) at low 
temperatures did not promote a reaction, and after refluxing in ethanol a mixture 
of products resulted. Silica gel column chromatography of the mixture was unable 
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to completely separate the components, and none could be adequately 
characterised. 
It would appear that the benzyl group, though masking a potentially acidic 
proton, is unable to prevent aldehyde deactivation by the delocalisation route 
suggested above with 91, and derivatives of aldehyde 91 with more deactivating 
imidazole protecting groups were sought. However, mirroring the difficulties 
observed in the preparation of 1-tosyl and 1-BOC derivatives of dicyanoimidazole 
72, all attempts to protect the imidazole NH of 91 failed. Reaction of 91 with tosyl 
chloride (succesful in the protection of imidazole 72) returned only starting 
material; no 1-BOC derivative was formed by reaction of 91 with "BOC-ON" (2- 
tert-butoxycarbonyloxyimino-2-phenylacetonitrile; and attempted protection of 91 
as the 1-formamide by reaction with formic acid according to a number of 
literature procedures, 145-147 also returned only starting material, on all occasions. 
While affording some valuable insights into the chemistry of these 
substituted imidazoles, given the difficulties encountered by all the synthetic 
approaches to formylimidazoles investigated, it was of some disappointment to 
find the formylimidazoles finally prepared unreactive toward Knoevenagel 
condensation with ethyl nitroacetate. 
Future studies in this area might look at more stable imidazole protecting 
groups, that still have sufficient electron-withdrawing ability to reduce the formyl- 
destabilising activity of the N-1 nitrogen lone pair. A 2,4-dinitrophenyl derivative 
for example, though still reactive to nucleophilic attack 
- 
being generally cleaved 
with mercaptoethanol (ref. 138, p. 390) 
- 
is strongly mesomerically electron- 
withdrawing, and expected to be more resistant to hydrolytic cleavage than acyl, 
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carbonate and sulfonate derivatives. Also, the intermediate imidazole 90 might 
prove a better subject for imidazole NH protection, without the influence of a 
formyl group helping to stabilise a deprotonated species and prevent protection. 
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4. Aminopyrimidinones 
4.1 General2-aminopyrimidin-4(3H)-one synthesis 
At the time of the initial pyrimidinone analogue studies mentioned in the 
introduction, aimed at finding a successor to the interferon inducer 19 (ABMP), a 
general synthetic route for pyrimidinone preparation was devised (Scheme 4-1). 68 
Requisite 0-keto esters (III) were prepared from monoethyl malonate (92) and 
appropriate acid chlorides (I), and the intermediate anion formed could be 
alkylated with alkyl halides (II). 148 The ß-keto esters (III) were then refluxed 
with guanidine, or guanidine salts such as the carbonate, to give the 
pyrimidinones (IV) directly. In the case of RI = H, halogenation readily occurred 
at the 5-position to give 5-halogenopyrimidinones (V). 
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Scheme 4-1 2-Aminopyrimidinone synthesis. 
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In this programme, the pyrimidinones 19 to 21,26 and 93 to 97 were 
prepared in good yields, starting from commercially available ß-keto esters (Table 
4-1, yields are from ß-keto esters). The initial 5-H-pyrimidinones 26,93 and 94 
were prepared according to the method of Kulkarni et al., 149 by refluxing the ß- 
keto ester with guanidine carbonate in ethanol. The pyrimidinones thus formed 
were then either brominated according to the method of Stevens et al., 85 heating 
with bromine in acetic acid; or they were iodinated with iodine in a mixture of 
chloroform and aqueous sodium hydroxide, as reported by Skulnick et al. 69 All 
the pyrimidinones formed were characterised by 1H NMR, and melting points 
were in agreement with literature values. 
0 
x HN 
H2N NR 
RX Yield/ %RX Yield/ % 
19 Me Br 55 94 Et H 86 
20 Ph Br 48 95 Et Br 48 
21 Ph I 62 96 Me I 71 
26 Ph H 69 97 Et I 72 
93 Me H 83 
Table 4-1 Synthesised pyrimidinones. 
As previously mentioned, a wide range of substituted 2-aminopyrimidin- 
4(3H)-one derivatives has been prepared according to the procedure of Scheme 4- 
1, and their chemistry has been studied at length. 83-85 In the present work a 
number of discrete novel derivatives were sought as targets, but also the 
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development of new chemistry applicable to the synthesis of a range of new 
derivatives was investigated. The results of these studies are described in the 
following sections. 
4.2 Ferrocenyl derivatives 
Given the previous discovery of the novel crystal structure of bropirimine 
(20) 77 it was of interest to prepare pyrimidinone derivatives with different 
aromatic substituents in the 6-position. It was hoped that studies of crystal 
structures of other derivatives might shed light on the influence of the 6- 
substituent on the structure adopted, as well as investigating IC-stacking 
interactions in the solid state. The cyclopentadienyl rings of ferrocene presented a 
unique opportunity to link the pyrimidine ring to a novel group, and routes were 
sought to prepare two derivatives - with ferrocene singularly attached to the 6- 
position of a pyrimidine ring (100), and with each of the cyclopentadienyl rings 
similarly bonded to pyrimidines (103). 
A further interest in such derivatives, as well as their structural novelty, 
stems from the putative mode of action of the immunomodulatory bropirimine 
(20), thought to involve interaction with guanine or cytosine bases of DNA. If 
derivatives 100 and 103 were able to bind in this fashion, then they may be able to 
deliver iron 
, 
known to cleave DNA (for example the chemistry of the 
involvement of iron in the DNA cleaving action of the antitumour agent 
bleomycin is well known, and has been reviewedtso), thereby bringing about a 
potentially cytotoxic event. 
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The mono-substituted ferrocene derivative 100 was successfully prepared 
in two steps, in low yield (11%) from ferrocene (98) (Scheme 4-2). The known 0- 
keto ester 99 was prepared by Friedel-Crafts acylation of ferrocene (98) with ethyl 
malonyl chloride, according to the procedure of Dormond. 151 Purified by silica- 
gel chromatography, 99 was then reacted with guanidine carbonate under the 
standard conditions to furnish the pyrimidinone 100, which readily crystallised 
from ethanol as purple prisms. The reaction with guanidine carbonate was 
considerably slower than the usual pyrimidinone formation reactions, traces of 99 
persisting after a week at reflux, despite periodic additions of guanidine 
carbonate. 
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98 Ferrocene 99 100 
Conditions: i Ethyl malonyl chloride (0.9 eq. ), AIC13 (1 eq. ), CH2CI2, reflux, 20 h.; 
ii Guanidine carbonate (1.1 eq. ), EtOH, reflux, 7 d. 
Scheme 4-2 Synthesis of ferrocenylpyrimidinone 100. 
An attempt to adapt the above synthesis of 99 to give the bis-(3-keto ester 
102, employing two equivalents of ethyl malonyl chloride, yielded a mixture of 
the orange monoester 99 and the desired red diester 102. The mono and bis 
derivatives 99 and 102 have very similar Rf values, proving to be difficult to 
separate by silica gel column chromatography. Reaction of a fraction partially 
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purified by chromatography, (thought to be richest in ester 102), with guanidine 
carbonate, gave only the pyrimidinone 100, seen previously. The required ß-keto 
ester 102 was finally prepared in two steps from ferrocene (98), according to the 
literature. Firstly, Friedel-Crafts acylation of ferrocene with acetyl chloride gave 
bisacetylferrocene 101,152 which after recrystallisation was reacted with diethyl 
carbonate in the presence of sodium hydride153 to furnish the (3-keto ester 102 in 
moderate overall yield. Reaction of 102 with guanidine carbonate then gave the 
desired pyrimidinone 103 as an almost black solid, in low yield, as its DMF 
solvate (14%), and a significant amount of material that showed no resonances by 
1H NMR (Scheme 4-3). 
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Scheme 4-3 Synthesis of bispyrimidinylferrocene 103. 
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A curious feature of the mass spectrum of 100 was that in two independent 
EI+ (electron impact) experiments, one showed the molecular ion (m/z 295) as the 
parent peak, but under different conditions the highest mass observed 
corresponded to the uptake of water (m/z 313). 
Pyrimidinone 103 had rather unique physical properties: not melting with 
heating to 360°C, producing no EI+ mass spectrum with heating of the sample 
probe to 500°C, and due to its very poor solubility in all solvents encountered was 
only identified by 1H NMR. Such properties are explained by the potential of 103, 
if it forms hydrogen bonds in the solid equivalent to those of bropirimine (20), to 
form an extended hydrogen bonded polymer by self assembly. 
The 111 NMR spectra of both ferrocenylpyrimidinones 100 and 103 are 
shown in Figure 4-1. In both examples, as well as resonances entirely 
characteristic of the NH, NH2 and H-5 protons of pyrimidinones , the resonances 
of the substituted cyclopentadienyl rings appear as two pseudo-triplets (expanded 
regions), and the unsubstituted cyclopentadienyl ring of 100 appears as a singlet, 
indicating unrestricted independent rotation of the ferrocene rings. Unfortunately, 
pyrimidinone 103 seemed to decompose on storage, it proving impossible to 
prepare fresh NMR samples from the original solid, precluding more complete 
analysis. The ß-keto ester 102 also appeared to degrade on storage, and no more 
pyrimidinone 103 could be readily prepared. 
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Figure 4.1 1H NMR spectra of pyrimidinylferrocenes 100 and 103, acquired in 
(CD3)2SO. 
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4.3 Attempted introduction of nitrogen containing groups at the 
pyrimidine 5-position 
In a recent paper already cited, 85 the diaminopyrimidinone 104 was 
prepared in low yield by reduction of the azo compound formed by the reaction of 
26 (APP) and 4-chlorophenyl diazonium chloride (7% from 26). A crude azide 
105 was also reported, formed by diazotisation of 104 and subsequent azide 
displacement, but purification attempts led to decomposition. The same article 
also observed that no 5-nitrosopyrimidinone 106 was formed by reaction of 26 
with inorganic and organic nitrites, or by the reaction of guanidine and the oxime 
107. 
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Under relatively mild conditions, electrophilic substitution occurs at the 5- 
position of these aminopyrimidinones, in preference to many aromatic 
substituents such as the phenyl group of 26, aided by the electron donating 2- 
amino group. The halogenations mentioned previously, and the azo coupling 
reaction above are two relevant examples. However, conventional mixed acid 
nitration of 26 leads to substitution in the phenyl ring to give 108, where 
presumably protonation of the pyrimidine ring nitrogens deactivates the 
pyrimidine 5-position to electrophilic attack. 85 
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It was of interest to study alternative reactions capable of introducing 
nitrogen containing groups at the 5-position. One application of, for example, a 5- 
nitro (109) or 5-nitroso (106) derivative would be in reductive cyclisations with 
trialkylphosphites in an attempt to form the novel pyrimido[5,4-b]indole 110. 
Alternatively, the nitrogen could be initially attached to the phenyl ring, for 
example via the ß-keto ester 111 (Scheme 4-4). 
0 
1 
,., 0 
HN 
NO 
H2N, 
jeN 
. 
oe 
106 x=1 
109 x=2 
HN- 
H2N 4N 
110 
E---" 
O 
Et0 NO2 
O Iý 
111 
Scheme 4-4 Potential routes to pyrimido[5,4-b]indole 110. 
4.3.1 Nitration / nitrosation reactions 
Endeavouring to follow the left-hand route of Scheme 4-4 to the 
pyrimidoindole 110, nitration and nitrosation of 26 (APP) was attempted with the 
nitronium and nitrosonium tetrafluoroborate salts respectively. 
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Nitronium tetrafluoroborate (N02BF4) has previously been used very 
effectively for the nitration of substituted benzenes, including deactivated 
substrates such as nitrobenzene, in nonaqueous, acid-free systems. 154 It was hoped 
that such non-acidic nitration conditions would lead to preferential substitution of 
26 in the pyrimidine ring. However, ambient temperature reactions of 26 with 
N02BF4 in both anhydrous acetic acid and in dry acetonitrile returned only 
starting material, identified by 1H and 13C NMR spectra and mass spectrometry. 
The distinctive sharp singlet from the C-5 proton in the 1H NMR spectrum at 
around 6 ppm readily confirms the lack of substitution at this position. 
In an analogous manner to the use of NO2BF4, it was of interest to 
determine whether nitrosonium tetrafluoroborate (NOBF4) could effect nitrosation 
of 26, the desired site of attack being the 5-position of the pyrimidine ring. 
Reactions were performed with three equivalents of NOBF4 in dry acetonitrile, 
both at ambient temperature and at reflux (82°C). In both cases a mixture of 
several components resulted as monitored by TLC, including unreacted 26. In 
either case, the most abundant component, variously isolated by column 
chromatography or crystallisations, was identified as the novel unsymmetrical 
dimer 112 (for example, 13% from the reaction at reflux), rather than the desired 
5-nitroso derivative 106 (Scheme 4-5). On the small scale of reaction employed it 
proved impractical to isolate 112 as a pure compound, but samples were obtained 
in sufficient purity for analysis by 1H and 13C NMR and high resolution mass 
spectrometry, all in agreement with the structure 112. 
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Scheme 4-5 Production of unsymmetrical dimer 112. 
The formation of 112 could be explained by an ionic mechanism involving 
initial nitrosation of the primary amine of 26, leading to the production of a 
diazonium species 113. Electrophilic substitution at the 5-position of another 
molecule of 26 by 113 would yield the dimer 112 directly (Scheme 4-6). 
Alternatively, a radical mediated pathway operates from the diazonium species 
113 as in the Gomberg reaction, 155 requiring the presence of hydroxide ions, 
potentially generated from the molecule of water produced in diazonium ion 113 
formation. Through either mechanism, the mixture of other products observed in 
the reaction mixtures by TLC could be higher oligomers of this dimeric structure. 
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Scheme 4-6 Mechanistic explanation for formation of dimer 112. 
4.3.2 Synthesis and reaction of a 2-nitrophenyl-(3-keto ester 
Given the difficulties encountered in achieving nitration or nitrosation at 
the 5-position of 26, the alternative route suggested in Scheme 4-4 was 
investigated. The required ethyl 3-(2-nitrophenyl)-3-oxopropanoate (111) has 
been previously prepared by decarboxylation of a malonate 114,156 and by 
deacylation of an acetoacetate 115.157 
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In the present work it was of interest to prepare the ß-keto ester 111 by a 
novel route. Holmquist and Roskamp reported the preparation of ß-keto esters by 
reaction of aldehydes with ethyl diazoacetate, catalysed by tin(II) chloride. tss 
Aromatic and tertiary aldehydes were observed to react the slowest, but under the 
conditions employed 
- 
room temperature in dichloromethane 
- 
nitro groups were 
unaffected, an important consideration in this case. An attempt to react 2- 
nitrobenzaldehyde under these conditions however was unsuccessful, yielding a 
mixture of products that were not readily separable. A number of ethyl ester 
resonances were observed in a1H NMR spectrum of the crude mixture, as well as 
several different aldehyde signals. 
Through a modification of the procedure of Oikawa et A, 159 the P-keto 
ester 111 was finally prepared in low yield (21%). Reaction of 2-nitrobenzoic acid 
(116) with Meldrum's acid, 2,2-dimethyl-1,3-dioxane-4,6-dione (117), in the 
presence of dicyclohexylcarbodiimide (DCCI) as coupling reagent, afforded the 
acyl derivative 118 (Oikawa et a1.159 employed acid chlorides). Ethanolysis of the 
crude 118 then furnished the required ß-keto ester 111, which was purified by 
silica gel chromatography (Scheme 4-5). 1H NMR of the product ester isolated 
was in agreement with literature values, 160 showing evidence of keto-enol 
tautomerism in the chloroform solution. 
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N02 0 N02 OH 0 
C02H 01IffO 
00o0 
116 117 118 
ii 
N02 00 N02 00 
I 
O 
Iý 
0 
111 H OEt 
Conditions: i DCCI (1.15 equiv. ), DMAP (1.5 eq. ), CH2CI2, rt, 20 h.; ii EtOH, reflux, 30 
min. 
Scheme 4-5 Synthesis of ß-keto ester 111, employing Meldrum's acid. 
With ester 111 prepared, formation of pyrimidinone 119 was attempted by 
reaction with guanidine carbonate in refluxing ethanol. Ester 111 appeared to be 
only slowly consumed, and after 48 hours at reflux TLC analysis showed a 
complex mixture including highly coloured blue, orange, purple and brown spots. 
No pyrimidinone was isolated from the reaction. 
Consultation of the literature revealed a propensity of ethyl and methyl o- 
nitrophenyl-ß-keto esters to decompose under basic conditions. 161 Standing in 
aqueous sodium bicarbonate solution, ester 111 has been observed to degrade 
(through several proposed intermediates) to a number of highly coloured products 
including the orange diester 120 and the purple isatogen 121. Given the equivalent 
colours formed in the reaction of 111 with guanidine carbonate, and the basic 
conditions present, similar degradation processes may have occurred. 
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N02 0 
CO2Et CHCO2Et 
HN NO2 ý_ N02 N N02 
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+Ö 
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Though not investigated in this project, reaction of ester 111 with 
guanidine as the free base, or as a less basic salt such as the hydrochloride, is a 
potential alternative route to pyrimidinone 119. The known indoxylic acid 
derivative 122162 might also lead to the pyrimidoindole 110 directly, if it reacted 
as an ordinary ß-keto ester. It was felt however, that this constituted a further step 
away from the original objective of this particular project, which was to attempt to 
broaden the known chemistry of the 5-position of these pyrimidinones. 
0 
H 
HN N 
ý H2N" 'N 
110 
EtO2 
O 
122 
4.4 Palladium catalysed coupling reactions 
As well as the specific targets of sections 4.2 and 4.3, it was of interest to 
develop novel 2-aminopyrimidinone chemistry applicable to the generation of a 
series of new compounds. It was envisaged that palladium-catalysed chemistry of 
the 5-halopyrimidinones, specifically Suzuki and Heck coupling reactions, would 
provide such an opportunity. 
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4.4.1 Suzuki coupling reactions 
The regiospecific palladium-catalysed cross-coupling of phenylboronic 
acid with haloarenes, in the presence of bases, was first reported in 1981,163 and 
has since become known as the Suzuki reaction (Scheme 4-6). The reaction was 
shown to be highly dependent upon the base employed, weak bases such as 
sodium carbonate producing optimum yields, and was only applicable to the 
coupling of bromides and iodides. Tetrakis(triphenylphosphine)palladium(O), 
Pd(PPh3)4 was found to be an effective catalyst, even at just 3 mole %, and the 
reaction was usually conducted in refluxing benzene or toluene with two 
equivalents of the aqueous base. Generally complete in under 6 hours, yields in 
excess of 90% were reported. 163 
B(OH)2 / I' 
+i 
Br 
1.1 equiv. 
Catalyst 
Base 
`/ 
/ýZ 
Scheme 4-6 General Suzuki reaction. 
Biaryl units are important pharmacophores, present in a wide variety of 
biologically active compounds, and the use of boronic acids in Suzuki coupling 
reactions has presented significant advantages over other transition-metal 
catalysed C-C bond forming reactions of organometallics and organic halides in 
use at the time of its publication. For example, the reaction is tolerant of a wide 
variety of functional groups on either reactant, unlike Grignard reagents or 
organolithiums; and boronic acids are easily prepared, generally air and moisture 
stable solids; and they don't suffer from the high toxicities of organotin reagents 
employed in Stille couplings. 164 
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Given the advantages, it is not surprising that the Suzuki reaction has been 
the subject of a great deal of research, and is arguably a favoured method in the 
formation of biaryls. A variety of different conditions have been devised 
involving changing the nature of the palladium catalyst, for example Pd(dppb)C12 
([1,4-bis(diphenylphosphino)butane]palladium(II) dichloride) has broadened the 
process to the coupling of certain heteroaromatic chlorides. 165 Changes of base 
and solvent have also been effective for the optimisations of particular couplings. 
The scope of the reaction has further widened beyond aryl halide and aryl boronic 
acid to include vinyl halides, 166 vinyl boronic acids, 167 alkyl boranes, 168 boronic 
esters, 168 as well as aryl and vinyl triflates. 169,170 
A widely accepted catalytic cycle has been proposed by Martin and 
Yang, 171 for the simple biaryl coupling with sodium hydroxide as base (Figure 4- 
2). Oxidative addition of the aryl halide to a palladium(0) species forms an 
organopalladium halide (Ar-Pd-X) which undergoes metathetical displacement to 
form an organopalladium hydroxide (Ar-Pd-OH). The electrophilicity of the 
palladium is increased in this step by virtue of the increased electronegativity of 
the oxygen atom over bromine or iodine, but at 2.0 the electronegativity of boron 
is very similar to that of carbon at 2.5,171 making the aryl group of the boronic 
acid insufficiently reactive to perform the transmetallation reaction. The boronic 
acid is activated by boronate formation with the second equivalent of base, a 
process shown to produce a 106 fold increase in reactivity with electrophiles. 172 
Boronate and Ar-Pd-OH then transmetallate to form the diorganopalladium (Ar- 
Pd-Ar'), from which the biaryl product readily forms by reductive elimination, 
regenerating the catalytic palladium. In effect, the aryl halide and boronic acid 
behave as electrophilic and nucleophilic coupling partners respectively, and 
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substituents that enhance these characteristics are generally beneficial to the 
process. 
Ar-X 
Ar-Ar' Pd(O) 
oxidative 
reductive addition 
elimination 
Ar-Pd-Ar' Ar-Pd-X 
ý(OH)4 
Transmetallation NaOH 
Ar-Pd-OH 
O NaX 
Ar'-B(OH)3 
NaOH 
Ar'B(OH)2 X=Br, I 
Figure 4-2 Mechanism of the Suzuki coupling reaction. 
With Pd(PPh3)4 as the catalyst, studies have shown Pd(PPh3)2 to be the 
likely catalytic species. 173 Mechanistic studies of the Suzuki reaction in the 
synthesis of the biaryl unit of Losartan 123, an angiotensin II receptor antagonist, 
demonstrated that the rate determining step under conventional Suzuki conditions 
depends upon the nature of the halide. 174 With the bromide, oxidative addition 
was rate determining, requiring heat to proceed; whereas with the iodide, 
oxidative addition was rapid and transmetallation became rate determining, a 
common observation in oxidative additions of organic halides to palladium. 175 
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4.4.1.1 Reaction of 5-halopyrimidinones 
In the present work it was hoped that Suzuki coupling reactions of the 
readily prepared 5-halopyrimidinones (V) with aryl / heteroaryl boronic acids (VI) 
would provide access to a series of novel 5-aryl / heteroaryl pyrimidinones (VII) 
(Scheme 4-7). 
B(OH)2 0 
HN I Suzuki HN I 
H2N NR 
`Y 
H2N NR 
V VI VII 
Scheme 4.7 Proposed route to 5-aryl / heteroaryl pyrimidinones. 
The simple diphenyl derivative 126 has been prepared previously by two 
similar routes, involving dehydrogenation of an intermediate dihydropyrimidine 
125 (Scheme 4-8). The intermediate 125 was prepared either from the 
acrylonitrile 124,176 or the cyclopropenone 127,177 by reaction with guanidine 
carbonate. 
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51% 
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I Ph 
H H2N NH 
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H2N EtOH H 27% 
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Ph 
Ph 
127 124 
Sulfur, 
60-70% 180-200°C 
Ph 
HN I 
H2N" ` Ph 
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Scheme 4-8 Literature preparations of diphenylpyrimidinone 126. 
Suzuki reactions have not been reported with 2-amino-5-halo- 
pyrimidinones, though a limited number of couplings have been successfully 
performed upon 5-halouracils, 5-iodouridine derivatives for example have been 
coupled with aryl boronic acids under standard conditions. 178 As well as further 
probing the chemistry of the immunomodulatory 5-halopyrimidinones, if 
successful, the advantage of this proposed new route to 5-arylpyrimidinones (VII) 
is that novelty is introduced in the final step. Targets VII (Scheme 4-7) would be 
formed in one step by reaction upon a common intermediate (V), rather than 
diverging at the beginning with the synthesis of different acrylonitriles or 
cyclopropenones, as would be the case if one of the previous routes were 
employed. 
An added facet to compounds of structure VII would be the potential to 
form atropisomers, by coupling with suitable ortho-substituted aryl boronic acids, 
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such that rotation about the biaryl bond is prevented by steric clashes with the 
ortho-substituent and the oxygen at the 4-position, or the R group at the 6- 
position. Such atropisomers might be expected to show the same differences in 
biological activities as a pair of enantiomers, and if the barrier to rotation were 
high enough then separation of atropisomers by chiral chromatographic 
techniques might be possible. Alternatively, atropisomer selective Suzuki 
coupling reactions could be investigated. The use of a chromium tricarbonyl 
complexed aryl halide, for example, has been reported in an atropisomer selective 
Suzuki coupling in a stereospecific route to the antileukaemic agent (-)-Steganone 
(128). 179 
O 
O 
IN 
Me0 
ýI O MeO 
OMe 128 (-)-Steganone 
Continuing in our interest of reactions of 6-phenylpyrimidinones, Suzuki 
coupling reactions were first attempted with bropirimine (20) and phenylboronic 
acid. As well as employing fairly standard reaction conditions 
- 
utilising the 
method of Wang and Haseltine, 180 with 3.5 mole % Pd(PPh3)4, in a refluxing 
mixture of toluene, ethanol and aqueous sodium carbonate 
- 
coupling was also 
attempted under the same conditions used for the bromoimidazole 41 in section 
3.1.2.1, at reflux in DMF (Table 4-2). 
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0 
Br 
H2N N Ph 
20 
3.5mot% 
+ PhB(OH)2 Pd(PPh3)4 30 
1.1 N2/ reflux eq, 24hrs 
AorB 
Ph 26 HN I+ 
H2N/`N Ph kBr 
126 20 
Product composition 
Conditions 
126 26 20 
(A) Toluene / ethanol 9% 19% 72% 
2 eq. aqueous Na2CO3 
(B) DMF 17% 83% 0% 
2 eq. aqueous Na2CO3 
Table 4-2 Initial Suzuki reactions of bropirimine 20 and phenylboronic acid. 
A number of conclusions can be drawn from these initial results. The 
major observation was the difficulty with which the components of the product 
mixture (126,26 and 20) were separated -a portion of 126 serendipitously 
crystallising from the ethyl acetate phase during conventional work up of the 
toluene reaction, greatly facilitating its identification, was confirmed by 1H NMR, 
mass spectroscopy and elemental analysis, with mp 312-314°C (lit., 176 319°C). 
The remaining mixtures were not separable by silica gel chromatography, instead 
the values given above were determined by analysis of IH NMR spectra of the 
mixtures. Also, although in refluxing DMF all the bropirimine was consumed, the 
selectivity for coupled product (126) versus debrominated side product (26) was 
considerably poorer than resulted from the toluene reaction. 
On the grounds that successful coupling of the 6-phenyl derivative might 
be disfavoured due to steric clashes, couplings were also attempted with the 6- 
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methylpyrimidinone, ABMP (19), again under the same two sets of conditions 
(Table 4-3). However, in the refluxing toluene / ethanol reaction, pyrimidinone 19 
proved even less reactive than 20, with only traces of coupled product 129 by 1H 
NMR. From the refluxing DMF reaction the selectivity for coupling versus 
debromination was even worse than with 20. However, a sample of the novel 
pyrimidinone 129 was isolated by silica gel chromatography, and its structure 
confirmed by 1H and 13C NMR and its mass spectrum. Unfortunately, elemental 
analysis of a recrystallised sample of 129 was inconclusive, suggesting co- 
crystallisation with an inorganic substance. 
Ii Br 3.5mo1% Ph , IýýH 
HN 
+ PhB(OH)2 Pd(PPh3)4 HN` '+ 93 
H2N" N Me eq. N2/ reflux H2N" N Me 0 24hrs 4< Br 
19 AorB 129 19 
Product composition Conditions 
129 93 19 
(A) Toluene / ethanol Trace Trace >90% 2 eq. aqueous Na2CO3 
(B) DMF 10% 90% 0% 
2 eq. aqueous Na2CO3 
Table 4-3 Initial Suzuki reactions of ABMP (19) and phenylboronic acid. 
The presence of the phenyl group actually appeared to increase both 
reactivity and selectivity for the coupling process, and attentions reverted to 
improving the Suzuki reactions of 20. A repeat reaction in toluene / ethanol as 
before, over 76 hours, with periodic additions of more boronic acid, base and 
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catalysts did consume more starting material, but the ratio of coupled to 
debrominated product remained poor at approximately 1: 2 (the isolated yields 
were 126 (21%), 26 (46%) and 20 (20%)). A series of reactions were then 
performed, varying the nature of the halide, base, solvent and different supplies of 
catalyst, as well as reaction with in situ formation of the presumed catalytic 
species Pd(PPh3)2,174 by reaction of Pd(OAc)2 and PPh3 (Table 4-4). 
pp ýH 
X 3.5mot% Ph 
HN JL.,. + PhB(OH)2 Pd(PPh3)4 HN + 26 )111 1 
N2/ reflux 0 H2N N Ph 1.1 eq. 24hrs H2N N Ph x 
20 X=Br A 0r B 126 
21 X=I A= Toluene, ethanol, water 20 / 21 
B= DMF, water 
Isolated yield * °o 
X Base Catalyst Conditions 126 26 SM Total 
I Na2CO3 Pd(PPh3)4 bathl A/ 24 h. 1 30 38 70 
Br Et3N Pd(PPh3)4 batch 1 B/ 24 h. 0 29 48 77 
Br NaHCO 3 
Pd(PPh3)4 
batch 1 A/ 24 h. 
4 18 56 78 
Br Na2CO3 Pd(PPh3)4 batch 2 A/ 24 h. 15 31 34 80 
Br Na CO 23 
Pd(PPh3)4 
batch 3 A/ 24 h. 
16 25 37 77 
Br Na2CO3 Pd(PPh3)2 A/ 18 h. 10 23 31 64 
* determined by 1H NMR of crude product mixture 
Table 4-4 Further Suzuki coupling reactions of pyrimidinones 20 and 21. 
A number of conclusions can be drawn from these results. Firstly, contrary 
to the literature precedent, the iodopyrimidinone 21 gave a lower yield of coupled 
product 126 than the corresponding bromo analogue 20, but with comparable 
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dehalogenation to 26, under identical conditions-suggesting a difference in 
reactivity between Ar-Pd-Br and Ar-Pd-I (with reference to Fig. 4-2). Preventing 
deprotonation of 20 with weaker bases, namely triethylamine (Et3N) and sodium 
bicarbonate (NaHCO3), also resulted in poorer coupling yields though 
debromination still occurred. It is generally held that Pd(PPh3)4 is best prepared as 
required, and as the age of 'batch 1' was unknown, reaction was repeated with two 
new batches bought-in. However, in all such cases, and with Pd(PPh3)2 prepared 
in situ, reactions were slow and the ratio of coupled product 126 to debrominated 
side product 26 failed to improve above 1: 2. 
Bropirimine 20 was found stable to Na2CO3 at reflux in aqueous acetone, 
and has been reported stable to 0.1 N sodium hydroxide at 37°C for 96 hours, 181 
suggesting involvement of palladium in the debrominations observed, though as 
mentioned in the previous chapter such occurrences are not widely reported in the 
literature. It would appear that oxidative addition of halide to palladium is 
occurring, but that the transmetallation with boronic acid is so slow that an 
alternative reaction pathway competes, leading to dehalogenation. Bromo- 
pyrimidinone 20 is substituted at both positions ortho to the site of reaction, hence 
steric crowding could be a factor affecting rates of reaction. 
A requirement of the Suzuki reaction is that the halide is electrophilic, 
which is entirely opposite to the nature of the C-5 carbon of these 2-amino- 
pyrimidinones, a fact likely to be exaggerated by NH deprotonation under the 
basic conditions of the Suzuki reaction. Though couplings have been achieved in 
these studies, a more reliable high yielding approach was desired, especially given 
the difficulties encountered in the purifications of the mixtures formed. At this 
stage, rather than continue coupling reactions of these pyrimidinones employing 
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alternative reported conditions, approaches that could improve the electrophilicity 
of the C-5 carbon and/or eliminate the acidic proton of the pyrimidinones were 
sought. 
4.4.1.2 Reaction of 5-halopyrimidines 
A stable 4-pyrimidinone derivative from which the pyrimidinone can be 
readily regenerated is a 4-alkoxypyrimidine. Employing such an intermediate, a 
potential alternative route to 5-arylpyrimidinones (VII) involves transformation of 
halopyrimidinones (V), which have already been prepared, to corresponding 4- 
alkoxypyrimidines (IX) via the 4-chloro derivatives (VIII). After successful 
Suzuki coupling, the target pyrimidinones (VII) would be obtained by hydrolysis 
of pyrimidines (X) (Scheme 4-9). 
O CI MeO 
X/X/X 
HN` 
`I _ý \ 
H2NN H2NN H2NN 
V VIII IX 
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ArB(OH)2 VI 
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MeO 
Ar 
` H2N N 
Scheme 4-9 Proposed route to 5-arylpyrimidinones via pyrimidines. 
115 
A limited number of groups have reported successful Suzuki coupling 
reactions with 5-bromopyrimidines. Reactions were confined to 5- 
bromopyrimidine (130), '82,183 or 5-bromo-2,4-dialkoxypyrimidines 131.182,184 
Suzuki reactions have also been reported with 2,4-dichloro and 2,4- 
dibromopyrimidines, undergoing cross-coupling preferentially at the 4- 
position, 182 raising interesting possibilities for reactions upon 4-chloropyrimidines 
(VIII). However, no Suzuki reactions have been reported with a 2-amino-5- 
bromopyrimidine, or a 5-bromopyrimidine with a 6-substituent, either of which 
may have led to the observed reduced Suzuki reactivity of the pyrimidinones. 
OR 
Br Br 
I 
R0 N 
130 131 
Conversion of pyrimidinones and uracils to their 2- or 4-chloro derivatives 
is a well known reaction, performed with a number of reagents, 81'82 for example 
thionyl chloride and DMF, phosphorous oxychioride (POC13), and phosphorus 
pentachloride, the formation of 2,4-dichloropyrimidines from uracils generally 
requiring the presence of an added amine base. The 4-chloro-5-bromopyrimidine 
132 has been previously prepared in low yield (41%) by refluxing bropirimine 
(20) in POC13.185 This reaction was briefly investigated in the conversion of 
bromo and iodopyrimidinones 20 and 21, to their 4-chloro derivatives 132 and 
133 respectively, with and without an added amine base, N, N-dimethylaniline 
(Table 4-4). 
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0 Cl 
HN 
X POCl3, Reflux, 45 min. N/X 
H2N 
ýN 
Ph H2NýN Ph 
20 X=Br 
21 X=I 
132 X=Br 
133 X=I 
X Base (PhNMe2) Yield /% 
Br Yes, 2 equiv. 31 
Br No 54-67 
I No 0 
Table 4-4 Phosphorus oxychloride chlorination of pyrimidinones 20 and 21. 
The reaction of 20 with POC13 was somewhat capricious, though yields of 
132 isolated appeared greater in the absence of base. The identity of pyrimidine 
132 was confirmed by 1H and 13C NMR and mass spectroscopy, and had mp 
135°C (lit. 85 136-138°C) after silica gel column purification. An acetone insoluble 
by-product in the synthesis of 132 could not be identified by IH NMR, but on 
treatment with 1M hydrochloric acid overnight, a sample of reasonably pure 20 
was returned. The insoluble solid may have resulted from intermolecular 
condensation of 132 between 2-amino and 4-chloro groups, with the potential to 
form oligomers. Acid hydrolysis would then cleave the connections and return 
pyrimidinone 20. Unfortunately, heating AIPP (21) with POC13 led to 
decomposition from which no chloropyrimidine 133 was isolated. 
Chloropyrimidine 132 was then converted in excellent yields (82-93%) to 
the novel 4-methoxy derivative 134, according to the method of Prystas and Sorm 
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for the conversion of a 2,4-dichloropyrimidine to its 2,4-dimethoxy derivative, ts6 
by treating 132 with sodium methoxide in refluxing methanol. Suzuki reaction of 
134 and phenylboronic acid, according to the conditions used previously (3.5 
mol% Pd(PPh3)4, toluene, ethanol, aq. Na2CO3), resulted in essentially complete 
conversion to the novel diphenylpyrimidine 135, which was isolated in 75% yield 
after recrystallisation (Scheme 4-10). 
MeO MeO 
Br 3.5 mol% Pd(PPh3)4 N 
Ph 
I+ PhB(OH)2 
1.1 e 
aq. Na2C03 (2.5 eq. ) 
H2N N Ph q Tol. /EtOH/N2 H2N N Ph 
reflux, 18hrs 
134 (75%) 135 
Scheme 4-10 Successful Suzuki reaction of 5-bromopyrimidine 134. 
Unfortunately, these conditions did not appear general. Reaction of 134 
with other boronic acids was slow, a possible result of which was a resurgence of 
competing debromination, though to a lesser extent than observed with 
pyrimidinones (Table 4-5). The novel 2,4-dichlorophenyl-coupled pyrimidine 136 
presents the potential to form separable atropisomers, but, produced in only 24% 
yield, it proved difficult to separate from 134 and 138, and was not isolated pure. 
Readily identifiable by its fluorescence at 254 nm on TLC plates, a sample 89% 
pure in 136 (with 134 the only contaminant by 1H NMR) was obtained by three 
sequential silica gel columns followed by a recrystallisation, and had IH and 13C 
NMR spectra and mass spectrum in agreement with the structure. Reaction of 134 
with 3-thiopheneboronic acid failed, only a trace of the thienylpyrimidine 137 
being observed in the residue by 1H NMR after recovery of 89% of starting 
material 134. 
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MeO 
MeO MeO Br 
Br Ar 
Ni NI 
+I 
134 
Ak 
MeO 
H2N N Ph H2N N Ph 
H 
134 136 
137 138 
Conditions: ArB(OH)2 (1.1 eq. ), 3.5 mol% Pd(PPh3)4, aq. Na2CO3 (2.5 eq. ), 
toluene, ethanol, reflux, N2,18 h. 
Ar Product (Yield) 134 138 
CI 
136 (24%) 58% 11% 
CI 
137 (trace) 89% trace 
Table 4-5 Further Suzuki couplings of 134 with Pd(PPh3)4 as catalyst. 
Scrutiny of the literature suggested a number of alternative conditions. 
Gronowitz et al. 187-189 have shown that the use of 1,2-dimethoxyethane (DME) in 
place of benzene or toluene, reduces the deboronation of boronic acids 
- 
deboronated by-products have been observed in the couplings performed. The use 
of alternative bases, including barium and thallium(I) hydroxides, and potassium 
phosphate (K3PO4), have been reported to produce dramatic rate enhancements in 
Suzuki reactions, especially in the synthesis of hindered biaryls, 190.191 presumably 
through acceleration of transmetallation. Thompson et a1.192 described the use of 
1,1'-bis(diphenylphosphino)ferrocenepalladium(II) acetate (Pd(dppf)(OAc)2), 
prepared in situ, for cross-couplings of moderately hindered halopyrazines where 
Pd(PPh3)4 had failed. It was believed that the longer Pd-P bonds, forced by the 
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rigid ferrocene backbone, decreased steric crowding at the palladium and also 
forced the coupling partners cis for the reductive elimination step. 192 
A combination of these variants, employing K3PO4 as base and 
Pd(dppf)(OAc)2 as catalyst in a mixture of water and DME, were then applied to 
the coupling of 134 and 2,4-dichlorobenzene, 3-thienyl and 4-methoxybenzene 
boronic acids. Reactions were partially successful, though the outcome still 
appeared highly dependent upon boronic acid involved (Scheme 4-11 and Table 
4-6). Coupling was successfully achieved with 3-thiophene and 4- 
methoxybenzeneboronic acids, forming 5-arylpyrimidines 137 and 139 
respectively in moderate yields, though reaction was obviously slow, 
accompanied by increased amounts of debromination. Interestingly, no 136 was 
formed under these conditions. 
MeO 
MeO MeO 
Br 
Br Ar 
I IN, 
Ný 134 N, 
MeO H2N Ph H2N Ph 
134 H 136 
137 138 139 
Conditions: i premix 
- 
Pd(OAc)2 (3 mol%), dppf (4 mol%), DME, 50°C, 15 min., 
then ii 134 (1 eq. ), ArB(OH)2, K3PO4 (2 eq. ), DME, H2O, reflux. 
Scheme 4-11 Scheme for Table 4-6. 
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Product composition 
Reaction Coupled 
Ar time / h. product 134 138 
CI 24 136(0%) 71% 24% 
CI (1.1 equiv. ) 
24 137 (50%) 24% 16% 
C\S 
(1.1 equiv. ) 
ýCý-We 
90 139 (55%) 20% 18% 
(1.7 equiv. ) 
Table 4-6 Suzuki couplings of 134 with Pd(dppf)(OAc)2 as catalyst. 
Suzuki reaction of the 5-bromo-4-chloropyrimidine 132 with phenyl- 
boronic acid, under these modified conditions with Pd(dppf)(OAc)2 as catalyst, 
was also briefly investigated. A mixture of products resulted, the composition of 
which, by TLC, seemed independent of whether one or two equivalents of phenyl- 
boronic acid had been employed. The products were not readily separable by 
silica gel chromatography, but seemed likely to comprise mixtures of mono and 
bis-coupled products, as well as oligomers via intermolecular condensation 
between amino and chloro groups. 
Given the interest in forming the coupled pyrimidine 136, with its 
potential for atropisomerism, alternative high yielding coupling conditions were 
sought for its synthesis. Employing Pd(dppf)(OAc)2 as catalyst, reaction of 134 
was repeated in refluxing DMF in the hope of forcing reaction; reaction was also 
performed in toluene / ethanol which had given a low yield of 136 with Pd(PPh3)4 
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as catalyst, but employing K3P04 as base. Campi et al. 193 reported the use of 
catalytic Pd(OAc)2, in degassed 95% ethanol, with Na2CO3 as the base, for the 
coupling of an ortho-substituted benzeneboronic acid at ambient temperature, and 
these conditions were also applied to the synthesis of 136 (Table 4-7). Once more 
however, only varying amounts of debromination of 134 to 138 were observed. 
CI 
MeO CI Me0 I 
Br 134 c 
c, 
H2NN Ph CI H2N/ýN Ph 138 
134 B(OH)2 136 
1.1 equiv. 
Product composition 
Conditions 136 134 138 
3 mol% Pd(dppf)(OAc)2, 
Na2CO3 (2 eq. ) 0% 28% 4% 
DMF, N2, reflux, 24 h. 
3 mol% Pd(dppf)(OAc)2, 
K3PO4 (2 eq. ) 
Toluene, Ethanol, N2 
0% 67% 29% 
reflux, 6 h. 
5 mol% Pd(OAc)2, 
Na2CO3 (1.5 eq. ) 0% 77% 13% 
95% ethanol, N2, 
reflux, 14 h. 
Table 4-7 Further attempts to form bisarylpyrimidine 136. 
Despite the previous disappointing results on changing from bromo to 
iodopyrimidinones in Suzuki reactions, a route to a 5-iodopyrimidine was sought, 
in the hope that if more reactive than bromide 134, Suzuki reaction could be 
achieved with a wider range of boronic acids, and with improved yields. 
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The novel 5-iodopyrimidine 141 was successfully prepared in three steps 
(Scheme 4-12). The a-ketoketene S, S-diacetal 140 has been previously prepared 
in two steps by the condensation of acetophenone with carbon disulfide to yield a 
dithioacid, 194 which has been alkylated with methyl iodide to provide 140.195 In 
these studies, the dithioacid dianion initially formed was alkylated directly to 
provide a one-pot synthesis of 140 in 62 % yield, which was then reacted with 
guanidine sulfate according to Chauhan and Junjappa, 196 to furnish the 4- 
methoxypyrimidine 138 in 51 % yield. Pyrimidine 138 thus prepared had mp 151- 
152°C (lit., 196 152°C), and was identical by 111 NMR to the by-product observed 
in previous couplings, assigned as 138. Iodination with N-iodosuccinimide, based 
upon the method of Nishiwaki, 197 provided clean conversion to iodopyrimidine 
141 in almost quantitative yield. 
0 
i ? Me 
Ph Ph SMe 
140 
ii 
MeO MeO 
N iii NH I ýN H2N Ph H2N N Ph 
141 138 
Conditions: i CS2 (1 eq. ), KOtBu (2 eq. ), Et20,25*C, 45 min.; then, Mel (2 eq. ), MeOH, 
25'C, 30 min. then, reflux; ii premix-Na (2.1 eq. ), MeOH, then 140, guanidine sulfate 
(1.05 eq. ), reflux, 24 h.; iii N-Iodosuccinimide (1.3 eq. ), CHCI1, reflux, 2 h. 
Scheme 4-12 Synthesis of a 5-iodopyrimidine, 141. 
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Suzuki reaction of iodopyrimidine 141 was then attempted with a series of 
four boronic acids, employing Pd(dppf)(OAc)2 prepared in situ, in refluxing 
aqueous DME, with K3PO4 as base (Scheme 4-13 and Table 4-8). Reaction with 
all but 2,4-dichlorobenzeneboronic acid completely consumed starting material 
within 24 hours, with almost complete conversion to Suzuki coupled products 
139,142 and 143, and only traces of deiodinated 138. The yields in Table 4-8 of 
coupled products are after recrystallisation, but for 138 figures refer to proportions 
in the original crude products by 1H NMR. Interestingly, not only was reaction of 
141 and 4-methoxybenzeneboronic acid more rapid than that of the bromo 
analogue 134 (see Table 4-6), but also the selectivity for coupled 139 versus 
dehalogenated 138 product was considerably greater. With reference to the 
catalytic cycle (Figure 4-2), this would suggest a difference in reactivity between 
not only Ar-Br and Ar-I (as is generally accepted), but also between Ar-Pd-Br and 
Ar-Pd-I, if dehalogenation does indeed involve palladium. 
e 
MeO MeO 
Ar N N` 
+ 
141 
MeO H2N N Ph H2NýN Ph 
141 136 11 
139 
138 142 
143 
Conditions: i premix 
- 
Pd(OAc)2 (3 mol%), dppf (4 mol%), DME, 50'C, N2,15 min, 
then, ii 141, ArB(OH)2 (1.1 eq. ), KIP04 (2 eq. ), DME, 1120, rctlux. 
Scheme 4-13 Scheme for Table 4-8. 
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Yield 
Reaction Coupled 
Ar time / h. product 141 138 
CI 5 136(0%) 67% 22% 
CI 
O24 139 (72%) 0% 6% 
CI 16 142(78%) 0% 4% 
N02 
O 16 143 (75%) 0% 3% 
Table 4-8 Suzuki reactions of iodopyrimidine, 141, with Pd(dppf)(OAc)2 catalyst. 
With a protocol for the Suzuki coupling of 5-halopyrimidines with a range 
of substituted arylboronic acids succesfully developed, except in the reaction with 
more hindered boronic acids, the next stage in this project was to hydrolyse the 4- 
methoxypyrimidines (X) to the target 5-arylpyrimidin-4-ones (VII). To determine 
suitable conditions for this transformation, the hydrolyses of the 
bisphenylpyrimidine 135 and the 5-(4-methoxybenzene) derivative 139 were 
investigated. 
Gronowitz et al. 182 reported the use of a 1: 1 mixture of methanol and 5M 
hydrochloric acid for the room temperature hydrolysis of 2,4"dialkoxypyrimidines 
to the corresponding uracils. However pyrimidine 135 was unaffected under these 
conditions. Pyrimidine 135 also proved to be stable to warming with 1M sodium 
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hydroxide, and to warm 5M hydrochloric acid. Pyrimidines 135 and 139 were 
finally hydrolysed to their pyrimidinone derivatives 126 and 144 respectively, by 
heating to reflux in a 1: 1 mixture of methanol and 12 M hydrochloric acid 
(Scheme 4-14). Pyrimidinone 126 thus prepared had mp 314-316°C, in close 
aggreement to that previously isolated in minor quantities from the Suzuki 
reactions upon bropirimine 20 (312-314°C), and had identical 1H NMR spectra. 
McOH/c. HC1 
reflux, 1-2 h. 
135 R=H 
139 R=OMe 
126 R=H (96%) 
144 R=OMe (97%) 
Scheme 4-14 Acid hydrolysis of pyrimidines to pyrimidinones. 
A possible future alternative route to 5-arylpyrimidines/pyrimidinones, 
that could facilitate the coupling of more hindered groups such as the 2,4- 
dichlorophenyl, stems from the work of Gronowitz et al. who successfully 
prepared and cross-coupled 5-pyrimidine boronic acids and heteroaromatic 
halides. 182 Though adaptation of this route to the aminopyrimidinone substrates 
would require NH protection during boronic acid formation, the general 
nucleophilicity at pyrimidine C-5 positions might prove more in keeping with the 
boronic acid partner in Suzuki reactions, and overcome the difficulties 
encountered in coupling 5-halopyrimidines/pyrimidinones. 
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4.4.2 Heck coupling reactions 
The pioneering work of Heck in 1968 originally involved stereospecific 
arylation of olefins. 198 The procedure involved reaction of organometallics such 
as arylmercuric chlorides (ArHgCI) with olefins in the presence of palladium(II) 
salts, for example Li2PdC14, and an amine base such as triethylamine. In the initial 
reactions, a stoichiometric quantity of palladium was required, as reaction 
produced Pd(O). However, a reaction catalytic in Pd was soon realised, employing 
cupric chloride (CuC12) to reoxidise the palladium. 
It was only later discovered that aryl halides could be used in the presence 
of Pd metal, 199,200 or Pd-triarylphosphine complexes, 201 removing the need for 
stoichiometric quantities of mercury, lead or tin salts, and making the reaction of 
more general utility. The olefination of benzylic and vinylic halides, and 
heterocyclic bromides has also been described 202 
The Heck reaction however, is perhaps more commonly thought of as the 
coupling of aromatic / heteroaromatic halides and terminal alkynes (Scheme 4- 
15). This process was first reported independently by Cassar203 and Heck204 in 
1975, though the high yielding conditions in general use today, involving a bis- 
(triphenylphosphine)palladium(II) dichloride 
- 
cuprous iodide mixed catalyst 
system, were first reported by Sonogashira et al. 205 for the formation of 
symmetrical disubstituted acetylenes from acetylene gas and aryl / vinyl bromides 
/ iodides. A more recent report by Heck and coworkers206 on the alkenylation and 
alkynylation of polyhaloarenes, conveniently describes general conditions (see 
Scheme 4-15). Alkynylation of vinyl chlorides, 207 vinyl triflates208 and 
imidoylchlorides209 have also been described, and, as with the Suzuki reaction, a 
127 
wide range of functionality is tolerated in either coupling partner in Heck 
reactions. 
i 
R' R R' 
R 
-X 
R 
Conditions: i Alkyne (1.1-2.3 eq. ), Pd(PPh3)2C12 (2 mot%), Cu! (0.25 eq. ), Et3N, 
25-50'C; ii Alkene (1.1-2.5 eq. ), Pd(OAc)2 (5 mol%), PPh3 (10 mol%), Et3N, 100'C. 
Scheme 4-15 General Heck reactions of (hetero)aryl I vinyl halides. 
Sonogashira et a1205 also proposed a mechanism for their reaction (Figure 
4-3). The first steps involve generation of the catalytic palladium species, 
Pd(PPh3)2, by reduction with some of the acetylene in the presence of Cul. The 
catalytic cycle then follows the general pattern of oxidative addition of Pd(O) to 
the halide, followed by copper catalysed alkynylation of the Palladium. Reductive 
elimination of coupled product then regenerates the catalytic Pd(O) species. 
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HC=CR' / Cul / Et3N 
+- 
Et3NH Cl 
(Ph3P)2Pd4 CE= CR') 2 
R'C=Cý-CýCR' ýC'R' R-C 
Red 
elfin 
R-X 
Oxidative 
addition 
R 
(Ph3P)2Pd( 
HC= CR' 
CuI /B 
'\\C 
R' 
T 
BH X 
Figure 4-3 Proposed mechanism of Heck alkynylation of organic halides. 
4.4.2.1 Reaction of 5-iodopyrimidinones 
Alkynylations are generally performed under milder conditions than 
alkenylations and, as with Suzuki reactions, iodides have in general proved more 
reactive than corresponding bromides. By application of the Heck reaction 
conditions to 5-iodopyrimidinones (V) in the presence of terminal alkynes (XI), it 
was hoped to synthesise a range of novel 5-alkynylpyrimidinones (XII) (Scheme 
4-16). 
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OX R' 
HN Heck HN 
HN" H2N NRÄ1 2NR XI 
V X=I XII 
Scheme 4-16 Prposed route to 5-alkynylpyrimidinones, XII. 
Literature searches revealed no record of compounds of structure XII, or 
the same without a 6-substituent. However, Heck alkynylations of 
iodopyrimidines have been widely reported (e. g. ref. 210). More closely related, 
the pronounced cytotoxicity and antiviral activity of 5-ethynyl-2'-deoxyuridine 
(145)211,22 has prompted the successful alkynylations of 5-iodouracils, 213-215 5- 
iodouracil nucleosides, 213-215 and related 2,4-dialkoxy-5-iodopyrimidines2ls 
under conventional Heck conditions, in the search for active analogues. Less 
widely reported, high yielding alkynylations have also been performed upon even 
more structurally similar aminopyrimidinones such as the cytosine analogue 
146,216 suggesting the coupling proposed in scheme 4-16 to be feasible. 
R NH2 
Hi 
OON 
HO HO 
HO 
145 146 
In the present work, continuing the interest in 6-phenylpyrimidinones, 
Heck reaction was initially attempted between AIPP (21) and 1-hexyne, according 
to the general procedure. 206 Employing a mixture of triethylamine and DMSO as 
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solvent, with a Pd(PPh3)2C12 - Cu! mixed catalyst system, the components were 
maintained at 50°C overnight. TLC of the mixture appeared to show one major 
component, highly fluorescent at 254 nm irradiation, and considerably less polar 
than 21. During work up, the fluorescent compound was not extracted into 1M 
sodium hydroxide, suggesting it not to be the desired 5-alkynylpyrimidinone 147. 
An impure sample of the fluorescent compound finally obtained was tentatively 
assigned as the novel furo[2,3-d]pyrimidine 148, though despite its suggested 
abundance by TLC only accounting for approximately 15% of starting material 
(Scheme 4-17). 
0 C4H9 
HN 
I= C4H9 HN 
'I --Zý: ý' 
Yý 
N Ph H2N N Ph H2N N Ph H2N 
21 147 (None) 148(-15%) 
Scheme 4-17 Heck reaction of AIPP (20) and 1-hexyne. 
Similar cyclisations have been reported in the literature, for example in 
attempted Heck alkynylations of 5-iodouracils, 213,214 as well as with other 
substrates including 3-iodo-2-pyridones and 4-pyridones 217 In all these cases, 
iodine was only flanked by the oxo function. With iodide 21 a phenyl group is 
also adjacent, and steric effects favouring cyclisation cannot be ruled out. In many 
of the literature examples above, the bicyclic products were just minor ones, but 
in certain cases the major, simple alkynylated product was cyclised under 
coupling conditions but at elevated temperatures. For example, uracil 149 cyclised 
to 150 by treatment with Cul in refluxing triethylamine / methanol, in 92% 
yield. 214 In a repeat attempt to prepare 147, reaction of 21 and hexyne was rerun 
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at room temperature, the only change being that DMSO was replaced with DMF 
to circumvent previous isolation difficulties. After 40 hours, TLC indicated a 
mixture, which included starting material, and possible deiodinated 26 as well as 
148, still forming at the lower temperature. At this stage the desire for 147 was 
abandoned, and the mixture was heated to 50°C for 4 hours to try and produce 
more 148. Despite its apparent intensity by TLC, 148 was isolated in only 4% 
yield, compared with 64% returned 21 and 11% of deiodination by-product 26. 
C4H9 
O/ C4H9 
HN I/NiI 
OýN OJ"17 Ph 
Me Me 
149 150 
Though not obtained sufficiently pure for elemental analysis, the assigned 
structure 148 was supported by 1H and 13C NMR spectra and further corroborated 
by a series of 1H NMR NOe measurements (Figure 4-4). Importantly, they show 
enhancement between the single 'vinylic' proton and the nearest methylene units 
of the butyl chain, as well as one of the phenyl group multiplets 
- 
indicative of 
their spacial proximity. 
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2.7% 
HN" I 
H2N N 
0.6% 
3.3% 
where: 
2.5% 
Hl 
yýH2 
represents the observation 
that irradiation of Ht leads 
to a 2.5% enhancement of 
the H2 signal (by integration) 
Figure 4-4 1H NMR NOe enhancements within furopyrimidine 148. 
As observed in many of the Suzuki reactions of halopyrimidinones and 
halopyrimidines, competitive dehalogenation was a problem in the Heck reaction 
of 21. The milder conditions employed in this Heck reaction further support the 
previous assertion that palladium is involved in this process. Unlike the literature 
of the Suzuki reaction, dehalogenations of substrates in Heck alkenylations and 
alkynylations have been reported on a number of occasions, though without 
rationalisation. 201,206 
4.4.2.2 Reaction of 5"iodopyrimidines 
Though an exact parallel cannot be drawn between the conditions of 
Suzuki and Heck reactions, given the previous experiences in the Suzuki reactions 
of 5-halopyrimidines versus pyrimidinones, and the difficulties encountered in 
Heck reactions upon pyrimidinone substrates, it seemed reasonable to attempt 
Heck reactions upon halopyrimidines. If successful, the 5-alkynylpyrimidines 
could then be converted to the target pyrimidinones XII by hydrolysis. 
H2O- CH3 
CH 
1.1% 0.7% 
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To this end, just one exploratory Heck reaction was performed. 
lodopyrimidine 141, previously synthesised for Suzuki coupling, and 1-hexyne, 
were reacted under identical conditions to those used previously, with the 
exception that triethylamine was the sole solvent (there being no solubility 
problems with 141). After reaction work up and silica gel chromatography, a 
mixture of starting material (141) and novel coupled product 151 was obtained, 
which proved inseparable by a number of techniques (Scheme 4-18). 
OMe OMe C4Hg 
N= C4H9 N/ 
+ 141 
H2N 
CPh 
H2N N Ph 
(55%) 
141 151 (27%) 
Scheme 4-18 Heck reaction of 5-iodopyrimidine 141 and hexyne. 
The likely explanation for the low yield stems from the presence of two 
strongly electron donating substituents on the halide. Other researchers have noted 
lower reactivity towards alkynylation of such electron rich halides. 210 
On the positive side, though the yield of alkynylated product was low, 
clean conversion was observed, without deiodination. With further studies, the 
potential to drive such coupling reactions to completion exists 
- 
for example, by 
attenuating the electron donating ability of the 2-amino group by carbamate 
formation. As with the pyrimidine Suzuki products, the alkynylpyrimidines thus 
generated would be ripe for conversion to the targets, a series of novel 5-alkynyl- 
pyrimidinones (XII), or potentially to related furo[2,3-d]pyrimidines. 
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5. Experimental 
All mps were recorded on a Gallenkamp melting point apparatus, and 
are uncorrected. IR spectra were taken on a Mattson 2020 GALAXY Series 
FT-IR spectrometer as KBr plate or CHC13 films. IH, 13C and 19F NMR 
spectra were recorded on a Bruker ARX250 spectrometer at 250.1 MHz, 62.9 
MHz and 235.3 MHz respectively in solvents as specified, with tetramethyl- 
silane or residual protic solvents as internal standard, or with CFC13 as 
external standard with 19F NMR, J values being in Hz. Low resolution mass 
spectra were recorded on a Micromass Platform (AP+, ES+ and GC-EI), a 
VG70E (EI) or a VG Autospec (FAB+). High resolution mass spectra (HRMS) 
were performed by the EPSRC Mass Spectrometry Service Centre, Swansea. 
Silica gel TLC was performed on 60F-254 pre-coated sheets (E. Merck) and 
column chromatography was done on silica gel C60 (60-120 mesh). Elemental 
analyses were kindly performed by Knoll Pharmaceuticals, Nottingham. 
5.1 Imidazole chemistry 
5-Diazoimidazole-4-carboxamide 3195 5(4)-Aminoimidazole-4(5)- 
carboxamide hydrochloride (27) (48.77 g, 0.30 mmol) was dissolved in cold 
1M hydrochloric acid (400 ml), decolourised with activated carbon, and added 
dropwise to a stirred solution of sodium nitrite (22.11 g, 0.33 mmol) in water 
(600 ml), maintained at 0-5°C, whereupon a precipitate began to form. Before 
the addition of 27 was complete, the mixture began to assume a slight pink 
colour, and the addition was discontinued. The precipitate was isolated by 
filtration, and washed with water (2 x 50 ml). The filtrate was then charged 
with more sodium nitrite (2 g), and the addition of 27 resumed. Once the 
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addition was complete a further crop of solid was isolated by filtration, and 
washed with water. The combined solids were then dried in a vacuum 
desiccator over phosphorus pentoxide to constant weight, to furnish the title 
compound 32 as a yellow solid (35.38 g, 86%). The melting point was not 
determined, as explosions have been reported, 95 but a sample of the product 
gave the following data: vm(KBr)/cm 13282,3151,2193,1710,1449,1369, 
1249 and 1147 (lit., 95 2190 (diazo) and 1380 cnn ); SH([2H6]DMSO) 7.62 
(1H, s, 2-H) and 7.81 and 8.00 (2H, 2x brs, CONH2). 
Attempted carbenoid reaction of 5-diazoimidazole-4-carboxamide 
32: Procedure A. Methanol (0.18 ml, 4.5 mmol) was added to a stirred 
suspension of 5-diazoimidazole-4-carboxamide (32) (0.310 g, 2.26 mmol) in 
anhydrous THE (30 ml), followed by rhodium(II) acetate (0.010 g, 0.023 
mmol). The reaction mixture was then stirred at room temperature, under 
nitrogen, for 76 h. Analysis of an aliquot by IR showed almost complete 
disappearance of the diazo band at 2188 cm-1. A small amount of solid was 
removed by filtration, and the filtrate was concentrated in vacuo to leave a 
pale pink solid (0.49 g). 1H NMR analysis of the pink solid revealed it to be a 
mixture of starting imidazole 32 (10%) and 2-azahypoxanthine (29) (90%). 
By-product 29 gave the following spectroscopic data: Vmax(KBr)/cml 3428, 
3115,2804,1702 (lit., 95 1690), 1093,921,782 and 615; SH([2H6]DMSO) 8.52 
(1H, s, 2-H) and 13-15 and 14.8-15.2 (2H, 2x brs, 2xNH). These 
spectroscopic data were in exact agreement with those of an authentic sample 
of 29 available within the group. 
Procedure B. Rhodium(II) acetate (0.010 g, 0.023 mmol) and 5-diazo- 
imidazole-4-carboxamide (32) (0.310 g, 2.26 mmol) were dissolved in 
anhydrous DMSO (20 ml), under nitrogen. After 10 min at room temperature, 
cyclohexanol (0.47 ml, 4.5 mmol) was added via syringe, and the mixture 
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stirred at room temperature for 20h. The resultant red solution was diluted 
with diethyl ether (100 ml), and a pale pink solid isolated by filtration (0.160 
g). IR analysis of the solid formed was in close agreement with an IR 
spectrum of an authentic sample of 2-azahypoxanthine (29). TLC analysis of 
the filtrate also correlated with an authentic sample of 29. 
Procedure C. A dry flask was charged with rhodium(II) acetate (0.010 g, 
0.023 mmol), anhydrous THE (100 ml) and cyclohexanol (0.47 ml, 4.5 mmol), 
and arranged for Soxhlet extraction with 5-diazoimidazole-4-carboxamide 
(32) (0.3 10 g, 2.26 mmol) in the extractor thimble. Held under nitrogen, the 
contents were heated to reflux for 20 h. After cooling, a small amount of solid 
was removed from the reaction mixture by filtration. TLC and IR analysis of 
the filtrate were consistent with the formation of 2-azahypoxanthine (29) in 
high yield, with reference to an authentic sample. 
5-Bromoimidazole-4-carboxamide hydrobromide 41. A suspension 
of 5-diazoimidazole-4-carboxamide (32) (0.411 g, 3.0 mmol) in glacial acetic 
acid (25 ml) was treated with 30% wt hydrobromic acid in acetic acid (9 ml), 
and the mixture heated to reflux for 2.5 h. After slow cooling, a pale brown 
precipitate was removed by filtration, washed with acetic acid, followed by 
acetone, and dried in a vacuum desiccator to provide the title compound 41 
(0.44 g, 54%) as pale brown crystals, and had mp 245-251°C (lit., 104 210°C) 
(Found: C, 17.8; H, 1.8; N, 15.8; Br, 59.2%. C4H4BrN3O. HBr requires C, 
17.7; H, 1.9; N, 15.5; Br, 59.0%); vm (KBr)/cm-1 2980,2806,1701,1609, 
1473,1395,832 and 623; 6H([2H6]DMSO) 7.21 and 7.71 (2H, 2xbrs, 
CONH2), 8.13 (1H, s, 2-H) and 11.57 (2H, brs, 2xNH); SC([2H6]DMSO) 
111.8,124.9,137.3 (CH) and 159.6. 
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Attempted Suzuki reaction of 5-bromo-lH-imidazole-4- 
carboxamide hydrobromide 41. Phenylboronic acid (0.275 g, 2.25 mmol) 
was added to a mixture of 5-bromo-lH-imidazole-4-carboxamide hydro- 
bromide (41)104 (0.550 g, 2.03 mmol) and tetrakis(triphenylphosphine)- 
palladium(0) (0.080 g, 0.07 mmol) in degassed DMF (15 ml), followed by a 
degassed solution of sodium carbonate (0.765 g, 7.22 mmol) in water (4 ml), 
and the mixture heated to reflux under nitrogen, for 18 h. After cooling, a 
white solid was removed by filtration. The filtrate was evaporated to give a 
gummy purple solid which was extracted with boiling ethyl acetate (200 ml), 
leaving a grey solid. Hydrogen chloride gas was bubbled through the ethyl 
acetate solution, and a pale pink solid collected by filtration (0.239 g). IH 
NMR analysis of the pink solid revealed it to be a mixture of starting 
imidazole 41 (43%) and 1H-imidazole-4-carboxamide (42) (57%), both as 
their hydrochloride salts, accounting for 65% of starting imidazole. 
Crystallisation of the mixture from acetic acid gave a product 71% pure in 
imidazole 42 (with imidazole 41 the contaminant), where the NMR signals 
assigned to 42 were as follows: SH([2H6]DMSO) 7.93 (1H, br s, CONH2), 
8.35 (1H, d, J 1,5-H), 8.56 (1H, br s, CONH2), 8.22 (1H, d, J 1,2-H) and 
14.90 (1-2H, br s, [-NHCHNH-]+); Sc([2H6]DMSO) 120.9 (C-5), 128.0 (C-4), 
135.8 (C-2) and 158.6 (CONH2). 
5-Iodoimidazole-4-carboxamide hydrochloride 43.5-Diazo- 
imidazole-4-carboxamide (32) (0.411 g, 3.0 mmol) was added in one portion 
to an ice-cold solution of potassium iodide (4.98 g, 30 mmol) in 1M 
hydrochloric acid. Protected from light, the flask was connected to a bubbler 
to observe nitrogen evolution, and stirred in the ice-bath. Once effervescence 
had subsided (after about 10 min), the flask was allowed to warm to room 
temperature, whereupon effervescence appeared to resume. After 45 min at 
room temperature, the mixture was then heated to 50°C for 10 min, followed 
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by heating on a steam bath for a further 10 min. After prolonged cooling, a 
metallic looking solid was removed by filtration (iodine), and the solid 
washed with water. The combined dark red filtrate and washings were washed 
with ethyl acetate (4 x 30 ml). The remaining pale yellow aqueous phase was 
then basified with solid sodium hydroxide to pH 9-10 and extracted with ethyl 
acetate (18 x 20 ml). The combined extracts were dried (MgSO4), and 
concentrated in vacuo to 50 ml. Hydrogen chloride gas was passed through the 
remaining solution, and after cooling in ice an impure sample of the title 
compound 43 (0.061 g, 7%) was obtained on filtering the suspension, which 
though initially white, appeared to discolour with the formation of blue and 
orange tinges on drying at the filter. A sample of 43 gave the following data: 
8H([2H6]DMSO) 7.71 (2H, brs, CONH2), 8.72 (1H, s, 2-H) and 9-10 (2H, brs, 
2xNH). Residual resonances attributable to imidazole 42 were also present in 
the IH NMR spectrum of the crude product at SH=8.26 (1H, d, J 1,2 or 5-H) 
and 8H=9.19 (1H, d, J 1,2 or 5-H). 
5(4)-N-(Benzylidene)amino-lH-imidazole-4(5)-carboxamide 46. 
Benzaldehyde (0.51 ml, 5.0 mmol) was added to a stirred solution of 5-amino- 
1H-imidazole-4-carboxamide hydrochloride (27) (0.81 g, 5.0 mmol) and 
sodium acetate trihydrate (0.60 g, 4.4 mmol) in ethanol (10 ml) and water (10 
ml). The mixture was heated to reflux for 1 h. After cooling in ice, the mixture 
was filtered and the precipitate washed with ethanol, then diethyl ether and 
dried in vacuo to furnish the title compound 46 (0.86 g, 80%) as a white solid, 
mp 252°C (decomp. ) (from DMF) (lit., 104 242-245°C for the crude solid); 
Vmax(KBr)/crn 1 3363,3118,1656,1589,1421,1091,828 and 685 (lit., 104 
3400,3160 and 1645); SH([2H6]DMSO) 7.49-7.59 (3H, m, ArH), 7.68 and 
7.84 (2xlH, 2xbrs, CONH2), 7.74 (1H, s, ArCH=N), 7.95-8.02 (2H, m, ArH), 
9.18 (1H, s, 2-H) and 13.06 (1H, brs, NH) (in agreement with the 
literaturel04); Sc([2H6]DMSO) 118.7 (C), 128.8 (CH, 2xArC), 129.0 (CH, 
139 
2xArC), 131.8 (CH, ArC), 135.5 (C, ArC), 136.0 (CH, C-2), 146.8 (C), 158.3 
(CH, ArCH=N) and 160.8 (C, CONH2); m/z (EI), 214, CIIHION40 requires 
M, 214. 
5(4)-N-(2-Fluorobenzylidene)amino-lH-imidazole-4(5)- 
carboxamide 47. Prepared according to the method for the preparation of 46, 
with 5-amino-lH-imidazole-4-carboxamide hydrochloride (27) (1.626 g, 10.0 
mmol), 2-fluorobenzaldehyde (1.407 g, 11.0 mmol) and sodium acetate 
trihydrate (1.2 g, 8.8 mmol), to provide the title compound 47 (2.068 g, 89%) 
as a white solid, mp 278°C (with decomp. ) (from DMF) (Found: C, 56.7; H, 
4.1; N, 24.2%; m/z (FAB+), 233. C11H9FN40 requires C, 56.9; H, 3.9; N, 
24.1%; M+1,233); vma(KBr)/cm-13368,3124,1668,1594,1457,1421,1098 
and 582; SH(PH6]DMSO) 7.34-7.42 (2H, m, 2xArH), 7.58-7.63 (1H, m, ArH) 
7.71 and 7.80 (2x 1H, 2xbr s, CONH2) 7.76 (1 H, d, J 0.7, N=CHAr), 8.15-8.19 
(1H, m, ArH), 9.32 (1H, s, 2-H) and 13.0 (1H, br s, ring NH); SC([2H6]DMSO, 
19F coupled) 116.5 (d, J 21, C-3'), 119.4 (C-5), 123.2 (d, J 9, C-1'), 125.3 (d, J 
3.3, C-6' or 4'), 128.7 (d, J 2.5, C-5'), 133.9 (d, J 9, C-4' or 6'), 136.5 (C-2), 
146.9 (C-4), 151.3 (d, J 4, N=CHAr), 160.8 (CONH2) and 162.3 (d, J 253, C- 
2'); 6F([2H6]DMSO) 
-119.79 to -119.90 (m). 
5(4)-N-(2-Chlorobenzylidene)amino. lH-imidazole-4(5)- 
carboxamide 48. Prepared according to the method for the preparation of 46, 
with 5-amino-1H-imidazole-4-carboxamide hydrochloride (27) (1.626 g, 10.0 
mmol), 2-chlorobenzaldehyde (1.24 ml, 11.0 mmol) and sodium acetate 
trihydrate (1.2 g, 8.8 mmol), to yield the title compound 48 (2.301 g, 93%) as 
a white solid, mp 275°C (decomp. ) (from DMF) (Found: C, 53.1; H, 3.8; N, 
22.6%; nilz (ES+), 249,251. C11H9C1N40 requires C, 53.1; H, 3.6; N, 22.5%; 
M+1,249,251); Vmax(KBr)/cm 1 3389,3150,1655,1584,1422,1157,837 and 
679; SH(PH6]DMSO) 7.48-7.63 (3H, m, 3xArH), 7.73 (2H, br s, CONH2). 
140 
7.76 (1H, s, N=CHAr), 8.25 (1H, dd, J8 and 2, ArH), 9.52 (IH, s, 2-H) and 
13.0 (1H, br s, ring NH); SC([2H6]DMSO) 119.7 (C), 128.0 (CH), 128.6 (CH), 
130.5 (CH), 132.4 (C), 133.3 (CH), 135.3 (C), 136.5 (CH), 146.7 (C), 154.1 
(N=CHAr) and 160.8 (CONH2). 
5(4)-N-(2-Chloro-5-nitrobenzylidene)amino-lH-imidazole-4(5)- 
carboxamide 49. Prepared according to the method for the preparation of 46, 
with 5-amino-IH-imidazole-4-carboxamide hydrochloride (27) (1.626 g, 10.0 
mmol), 2-chloro-5-nitrobenzaldehyde (2.041 g, 11.0 mmol) and sodium 
acetate trihydrate (1.2 g, 8.8 mmol), to provide the title compound 49 (2.767 g, 
94%) as a yellow solid, that would not crystallise from common solvents tried, 
and had mp 298°C (with decomp. ) (Found: C, 45.4; H, 3.1; N, 23.8%; m/z 
(ES+), 294,296. C11H3C1N503 requires C, 44.8; H, 2.7; N, 23.8%; M+1,294, 
296); vmax(KBr)/cm 1 3407,3181,1678,1586,1530,1350,739 and 523; 
SH([2H6]DMSO) 7.67 and 7.84 (2xlH, 2xbr s, CONH2), 7.79 (1H, s, 
N=CHAr), 7.92 (1 H, d, J 9,3'-H), 8.34 (1H, dd, J9 and 3,4'-H), 8.87 (1 H, d, 
J 3,6'-H), 9.50 (1H, s, 2-H) and 12.9 (1H, br s, ring NH); insufficiently 
soluble for 13C NMR; m/z (HRMS-ES+) 294.0394 (M+(35C1)+1. 
C1 1H8C1N503+H requires 294.0394). 
5(4)-N-(2-Nitrobenzylidene)amino. lH-imidazole-4(5)-carboxamide 
50. Prepared according to the method for the preparation of 46, with 5-amino- 
1H-imidazole-4-carboxamide hydrochloride (27) (1.626 g, 10.0 mmol), 2- 
nitrobenzaldehyde (1.696 g, 11.0 mmol) and sodium acetate trihydrate (1.2 g, 
8.8 mmol), to furnish the title compound 50 (2.357 g, 91%) as a yellow solid 
and had mp 256°C (decomp. ) (from DMF) (Found: C, 51.0; H, 3.8; N, 27.1 %; 
m/z (EI), 259. C11H9N503 requires C, 51.0; H, 3.5; N, 27.0%; M, 259); 
umax(KBr)/can 1 3399,3150,1654,1559,1541,1522,1091 and 782; 
8H([2H6]DMSO) 7.53 (1H, br s, CONH2), 7.74-7.81 (3H, m, CONH2, ArH 
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and N=CHAr), 7.87 (1H, t, J 7.5, ArH), 8.09 (1 H, t, J 7.5, ArH), 8.27 (1 H, d, J 
7.5, ArH), 9.40 (1H, s, 2-H) and 13.1 (1H, br s, ring NH); SC([2H6]DMSO) 
120.0 (C-1'), 124.6 (CH), 129.3 (C-2'), 130.2 (CH), 132.2 (CH), 133.6 (CH), 
136.6 (CH), 146.3 (C), 149.4 (C), 154.1 (C-2) and 160.6 (CONH2). 
Imidazo[1,5-a]quinazoline-3-carboxamide 54. Sodium hydride as a 
60% dispersion in mineral oil (0.379 g, 9.5 mmol NaH) was placed in a flask 
and triturated via syringe with freshly distilled petroleum ether (bp 40-60°C) 
(3x10 ml), and then suspended in anhydrous DMF (60 ml). Solid 5(4)-N-(2- 
fluorobenzylidene)amino-lH-imidazole-4(5)-carboxamide (47) (2.00 g, 8.6 
mmol) was added in a single portion to the stirred DMF suspension, sealed 
under a nitrogen atmosphere connected to a bubbler, and stirred at room 
temperature. Once a clear solution was obtained, the mixture was heated to 
reflux for 3 h. The dark mixture was allowed to cool, water (10 ml) was added 
and the pH adjusted to neutral to litmus with 1M hydrochloric acid. After 
further cooling at 4°C, a solid was filtered from solution, washed with water, 
then ethanol, and dried at 60°C/4x10-2 mbar to yield the title compound 54 
(1.444 g, 79%) directly, as a dark yellow crystalline solid. A further crop of 54 
(0.119 g, 6.5%) was obtained by evaporation of the mother liquor, followed 
by crystallisation of the residue from DMF. A sample recrystallised from 
DMF had mp 294-294.5°C (with decomp. ) (Found: C, 61.55; H, 4.1; N, 
26.2%; m/z (EI), 212. C11H8N40.1/6 C3H7NO requires C, 61.6; H, 4.1; N, 
26.0%; M, 212 (for C11H8N40)); Vmax(KBr)/cm t 3436,3154,1665,1612, 
1548,1424,1228 and 695; SH(PH6]DMSO) 7.41 and 7.64 (2xlH, 2xbr s, 
CONH2), 7.71 (1H, t, J 8,7 or 8-H), 8.03 (1H, dt, J8 and 1,8 or 7-H), 8.20 
(1H, dd, J8 and 1,6 or 9-H), 8.48 (1H, d, J 8,9 or 6-H), 8.99 (1H, s, 1 or 5- 
H) and 9.12 (1H, s, 5 or 1-H); Sc([2H6]DMSO) 116.3 (CH), 118.9 (C), 125.7 
(C), 127.6 (CH), 127.7 (CH), 130.4 (CH), 132.9 (C), 135.5 (CH), 136.6 (C), 
142 
153.2 (C-5) and 163.9 (CONH2); m/z (HRMS-EI) 212.0698 (M+. C11H8N40 
requires 212.0698). 
7-Nitroimidazo[1,5-a]quinazoline-3-carboxamide 55. Reactants 
were mixed as in the synthesis of 54, employing sodium hydride (60% 
dispersion in oil) (0.177 g, 4.4 mmol), DMF (60 ml) and 5(4)-N-(2-Chloro-5- 
nitrobenzylidene)-amino-lH-imidazole-4(5)-carboxamide (49) (1.179 g, 4.0 
mmol). Once a clear solution was obtained, the reaction was heated in an oil 
bath maintained at 55-65°C for 11 days, until reaction was determined 
complete by TLC. The mixture was allowed to cool, diluted with water (10 
ml) and neutralised with 1M hydrochloric acid. After cooling in ice, a solid 
was isolated by filtration, washed with water then ethanol, and dried at 
60°C/6.5x10-2 mbar to furnish the title compound 55 (0.797 g, 77%) in 
acceptable purity. Evaporation of the mother liquor and crystallisation from 
aqueous DMF provided a second crop of 55 (0.061 g, 6%). A sample 
crystallised from 50% aqueous DMF had mp >360°C (Found: C, 51.2; H, 3.1; 
N, 27.0%; m/z (ES+), 358. C11H7N503 requires C, 51.4; H, 2.7; N, 27.2%; 
M+1,358); vma, (KBr)/cm-1 3358,3181,1686,1595,1570,1528,1350 and 
698; 6H(CF3CO2D) 9.44 (1H, d, J 10,9-H), 9.70 (1H, dd, J 10 and 3,8-H), 
9.90 (1H, d, J 3,6-H), 10.07 (1H, s, 1/5-H) and 10.83 (1H, s, 5/1-H); 
6c(CF3CO2D) 116.1 (C), 118.1 (CH), 119.8 (C), 126.1 (CH), 126.5 (CH), 
130.6 (CH), 134.0 (C), 135.3 (C), 147.7 (C), 158.0 (CH) and 159.4 (CONH2). 
Hydrolysis of imidazo[1,5-a]quinazoline-3-carboxamide 54 to 
imidazo[1,5-a]quinazoline-3-carboxylic acid, potassium salt 56a, and 
imidazo[1,5-a]quinazoline-3-carboxylic acid 56b. Concentrated (90%) 
nitric acid (0.494 g, 7.1 mmol), concentrated (98%) sulfuric acid (5 ml) and 
amide 54 (1.00 g, 4.7 mmol) were heated on a water bath to 57°C (internal 
temperature) for 45 min. The yellow solution formed was allowed to cool, 
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poured into water (20 ml), further cooled, and a yellow solid isolated by 
filtration which was washed with small portions of water and ethanol. After 
air drying, the solid was dissolved in 1M potassium hydroxide (5 ml), washed 
with chloroform (30 ml), carefully neutralised with dilute sulfuric acid and 
evaporated to give a pale yellow solid. The crude yellow solid was crystallised 
from aqueous ethanol to yield imidazo[1,5-a]quinazoline-3-carboxylic acid, 
potassium salt (56a) (0.605 g, 46%) as its hydrate, and had mp 311-313°C 
(Found: C, 46.7; H, 3.3; N, 14.6. C11H6KN302.1.75H20 requires C, 46.7; H, 
3.4; N, 14.9%); vm (KBr)/cm 1 3432,3108,1609,1551,1427,1370,1231 
and 754; SH(D20) 7.12 (1H, t, J 7,7 or 8-H), 7.28-7.40 (3H, m, 3xArH), 8.10 
(1H, s, slow exchange, 1-H) and 8.21 (1H, s, 5-H); Sc(D20) 113.1 (CH), 
116.6 (C), 124.8 (slow exchange, C-1), 126.4 (CH), 126.8 (C), 128.2 (CH), 
130.2 (C), 133.9 (CH), 134.9 (C), 151.7 (CH) and 169.8 (C02'). The residue 
after evaporation of the aqueous ethanol filtrate was dissolved in the minimum 
volume of water (2 ml) and acidified with concentrated hydrochloric acid. The 
precipitate produced was filtered, washed with a little water and dried in 
vacuo to provide imidazo[1,5-a]quinazoline-3-carboxylic acid (56b) (0.124 g, 
16%) as its hydrate, as a yellow solid, and had mp 194°C (decomp. with 
effervescence) (Found: C, 60.7; H, 3.7; N, 19.3; H2O, 1.3%; mhz (ES+), 214. 
C11H7N302.0.2 H2O requires C, 60.9; H, 3.4; N, 19.4; H20,1.7%; M+1,214); 
vmax(KBr)/cm 13401,3160,1705,1603,1549,1317,1175 and 772; 
SH([2H6]DMSO) 7.73 (1H, t, J 8,7 or 8-H), 8.03 (1H, t, J 8,8 or 7-H), 8.21 
(1H, d, J 8,6 or 9-H), 8.50 (1H, d, J 8,9 or 6-H), 9.05 (1H, s, 5-H) and 9.22 
(1H, s, 1-H); Sc([2H6]DMSO) 115.9 (CH), 118.5 (C), 120.9 (C), 127.5 (CH), 
127.6 (CH), 129.7 (CH), 132.0 (C), 135.0 (C), 137.7 (C), 154.4 (CH) and 
162.6 (CO2H); rn/z (HRMS-CI+) 214.0617 (M+ C11H7N302+H requires 
214.0616). 
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2-Fluorobenzaldehyde diethyl acetal 57.2-Fluorobenzaldehyde 
(3.838 g, 30 mmol) and p-toluenesulfonic acid monohydrate (0.145 g, 0.8 
mmol) were heated to reflux in a mixture of triethyl orthoformate (25 ml) and 
anhydrous ethanol (25 ml) for 2 h, under nitrogen. After cooling, the solution 
was diluted with diethyl ether (250 ml), washed with a 1: 1 mixture of 5% 
sodium hydroxide and saturated brine (40 ml), then water (20 ml) followed by 
saturated brine (20 ml). The ethereal solution was then dried (MgSO4) and 
reduced to 10 ml. Fractional distillation of the residue under reduced pressure 
provided the title compound 57 (5.151 g, 86%) as a colourless oil, and had bp 
99-101°C/22 mbar (Found: C, 66.5; H, 7.5%; m/z (GC-EI), 198. C11H1SF02 
requires C, 66.6; H, 7.6%; M, 198); vmax(CHC13)/cnr' 2978,2882,1489, 
1458,1229,1115,1061 and 760; SH([2H6]DMSO) 1.16 (6H, t, J 7,2xMe), 
3.44-3.65 (4H, m, 2xCH2), 5.67 (1H, s, acetal CH), 7.15-7.24 (2H, m, ArH), 
7.35-7.45 (1H, m, ArH) and 7.47 (1H, m, ArH); Sc([2H6]DMSO, 19F coupled) 
15.3 (2xCH3), 61.7 (2xCH2), 96.5 (d, J 3, acetal C), 115.5 (d, J 21, C-3), 
124.3 (d, J 3, C-5), 126.4 (d, J 13, C-1), 128.0 (d, J 4, C-4 or 6), 130.6 (d, J 8, 
C-6 or 4) and 159.9 (d, J 247, C-2). 
Attempted reduction of 5(4)-N. (2-nitrobenzylidene)amino-lH. 
imidazole-4(5). carboxamide (50), to give 5(4)-N. (2-aminobenzylidene). 
amino-lH-imidazole-4(5)-carboxamide 58: Procedure A. According to the 
literature method, 117 5(4)-N (2-nitrobenzylidene)amino-1H-imidazole-4(5)- 
carboxamide (50) (0.130 g, 0.50 mmol) and stannous chloride dihydrate 
(0.564 g, 2.50 mmol) were heated to reflux in absolute ethanol (20 ml), under 
an argon atmosphere, for 1 h, whereupon TLC analysis indicated complete 
disappearance of imidazole 50. The resultant yellow solution was poured into 
ice-water (50 ml), basified with 5% sodium bicarbonate solution to pH 7-8 to 
decompose tin salts, and extracted with 5% ethanol/ethyl acetate (50 ml). TLC 
analysis of the organic extract showed a complex, mixture of many 
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components, including one with an identical Rf to AIC (27), and the reaction 
was not progressed further. 
Procedure B. According to the literature method, 117 5(4)-N-(2-nitro- 
benzylidene)amino-lH-imidazole-4(5)-carboxamide (50) (0.130 g, 0.50 
mmol) and stannous chloride dihydrate (0.564 g, 2.50 mmol) were heated to 
reflux in ethyl acetate (10 ml), under argon, for 20 h. The solvent was 
evaporated in vacuo, and the residue suspended in water (10 ml), basified with 
5% sodium bicarbonate solution to pH 7-8, and extracted with 5% 
ethanol/ethyl acetate (50 ml). As previously observed, TLC analysis of the 
organic extract showed a mixture of components, including AIC (27). TLC 
analysis of the remaining aqueous phase also demonstrated the presence of 
imidazole 27. The reaction was not progressed further. 
Procedure C. According to the literature method, 118 5(4)-N-(2-nitro- 
benzylidene)amino-lH-imidazole-4(5)-carboxamide (50) (0.644 g, 2.50 
mmol) was suspended in water (5 ml). 12 M Hydrochloric acid (0.5 ml) was 
added, followed by 10% palladium on carbon (approximately 25 mg), and the 
flask connected to a Parr hydrogenation apparatus, which was charged with 
hydrogen (50 psi). After shaking at room temperature for 5 h, the mixture was 
filtered, and the solids washed with water, then acetone. TLC analysis 
identified the pale green crystalline solid filtered off as unreacted 50, 
contaminated with the palladium catalyst, which was later confirmed by Ill 
NMR, on a portion recrystallised from DMF. The combined filtrates above 
were extracted with ethyl acetate (2 x 30 ml). TLC analysis of the aqueous and 
organic phases showed the aqueous phase to contain AIC (27), later confirmed 
by 1H NMR after removal of the water in vacua; and the organic phase to be a 
mixture of three components, with one in far greater abundance than the other 
two. The combined ethyl acetate extracts were combined, and reduced in 
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vacuo to leave a green oil which gave NMR data consistent with the 
cyclohexene structure 61: SH(CDC13) 1.69-1.87 (4H, m, 2xCH2), 2.58 (2H, t, J 
6, CH2), 2.78 (2H, t, J 6, CH2) and 8.09 (1H, s, CHX); DEPT-Sc(CDC13) 18.6 
(CH2), 21.4 (CH2), 22.5 (CH2), 22.6 (CH2), 152.5 (CHX). 
Procedure D. According to the literature method, 119 a suspension of 5(4)-N 
(2-nitrobenzylidene)amino-1H-imidazole-4(5)-carboxamide (50) (0.500 g, 
1.93 mmol) in 1: 1 v/v ethanol/ethylene glycol (10 ml) was treated with 
hydrazine hydrate (0.87 ml, 15 mmol). After stirring for 10 min at room 
temperature, a 50% slurry of Raney nickel in water (2 drops) was added and 
the mixture stirred for a further 30 min. The mixture was then heated in an oil 
bath at 50-60°C for 2 h, cooled, and the catalyst filtered from the solution and 
washed with ethanol. The combined filtrates were diluted with water (50 ml) 
and extracted with diethyl ether (2 x 30 ml). TLC analysis of the remaining 
aqueous phase showed one major component, which appeared identical to an 
authentic sample of AIC (27). The organic extracts were concentrated to 
dryness, and the residue purified by silica gel column chromatography, with 
diethyl ether as eluent, to provide a yellow solid that was identified as the 
hydrazine derivative 62 (0.21 g, 91% of theoretical yield) and had mp 249°C 
(lit., 116 251-252°C) (Found m/z (ES+), 239. C14H14N4 requires M+1,239); 
vmax(KBr)/cin 13486 (asym. NH str. ), 3304 (sym. NH str. ), 3011 (ArH), 1711 
(asym. C=N str. ), 1624 (sym. C=N str. ), 1595,1364 and 1159; 31(CDC13) 
6.35 (4H, brs, 2xNH2), 6.71-6.77 (4H, m, ArH), 7.18-7.29 (411, m, Arli) and 
8.74 (2H, s, 2xCH=N). 
Procedure E. Based on the literature method, 120 a suspension of 5(4)-N-(2. 
nitrobenzylidene)amino-lH-imidazole-4(5)-carboxamide (50) (0.500 g, 1.93 
mmol) in 78% ethanol/water (15 ml) was treated with calcium chloride (0.138 
g, 1.24 mmol), as a solution in water (0.3 ml), followed by zinc powder (0.51 
147 
g, 7.7 mmol), and the mixture heated to reflux. After 1 h, TLC analysis 
showed only starting material, but after a further 20 h at reflux, TLC indicated 
complete consumption of starting material 50 to give a multicomponent 
mixture, including one component identical by TLC with an authentic sample 
of AIC (27). No attempt was made to isolate any of the products, and the 
reaction was abandoned. 
2-Nitrobenzaldehyde diethyl acetal 63.2-Nitrobenzaldehyde (4.53 
g, 30.0 mmol) and p-toluenesulfonic acid monohydrate (0.15 g, 0.8 mmol) 
were heated to reflux, under nitrogen, in a mixture of triethyl orthoformate (25 
ml) and ethanol (25 ml). After 2 h, the yellow solution was cooled, diluted 
with diethyl ether (250 ml), and washed with a 1: 1 mixture of 5% NaOH and 
saturated brine (40 ml), water (20 ml), saturated brine (20 ml) and dried 
(MgSO4). After removal of solvents in vacuo, the residue was purified by 
distillation under reduced pressure, collecting the fraction boiling at 146- 
156°C/25 mbar, to provide the title compound 63 (5.17 g, 76%) (lit., 121 bp 
154-156°C/18 Torr); SH(CDC13) 1.24 (6H, t, J 7,2xCH3), 3.54-3.78 (4H, m, 
2xCH2), 6.03 (1H, s, acetal-CH), 7.43-7.50 (1H, m, ArH), 7.57-7.64 (1H, m, 
ArH) and 7.80-7.85 (2H, m, ArH); Sc(CDC13) 15.1 (2xCH3), 63.4 (2xCH2), 
98.3 (acetal-C), 124.1 (CH, ArC), 128.0 (CH, ArC), 129.1 (CH, ArC), 132.5 
(CH, ArC), 133.7 (ArC) and 149.1 (ArC). 
Attempted synthesis of 4(5)-cyano-5(4)-formylimidazole, 75, via 
DIBAL reduction of 4,5-dicyanoimidazole (72). A solution of 4,5- 
dicyanoimidazole (72) (0.591 g, 5.0 mmol) in anhydrous THE (10 ml), cooled 
to 
-78°C and held under a nitrogen atmosphere, was treated with a 1.0 M 
solution of DIBAL in THE (5.0 ml, 5.0 mmol), dropwise over 10 min. After a 
further 20 min at 
-78°C, the yellow solution formed was poured into ice-water 
(50 g). The mixture was then acidified with 1M hydrochloric acid, a white 
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solid removed by filtration and washed with ethanol, followed by diethyl 
ether, and the combined filtrates evaporated under vacuum to leave the crude 
product, an orange solid (0.499 g). The mass spectrum (EI) of the crude 
mixture contained two peaks corresponding to molecular ions of 72 and 75, at 
nilz 118 (100%) and 121 (34) respectively; and in the 1H NMR spectrum of 
the mixture, after consideration of the signals attributable to starting imidazole 
72, the remaining signals readily assign to formylimidazole 75 
8 ([2H6]DMSO) 8.27 (1H, s, 2-H) and 9.86 (1H, s, CHO). 
5(4)-Ethoxycarbonylimidazole-4(5)-carboxylic acid 78. According 
to the literature procedure, 128 thionyl chloride (30 ml, 413 mmol) was added 
to a suspension of 4,5-imidazoledicarboxylic acid (73) (7.80 g, 50 mmol) in 
dry benzene (100 ml) containing DMF (4 nil), and the mixture was heated to 
reflux for 6 h, sealed with a calcium chloride guard tube. The resultant bright 
yellow solution was allowed to cool, and evaporated to dryness. More 
anhydrous benzene (50 ml) was added to the residue, and the mixture 
concentrated to dryness once more. A second portion of dry benzene (50 ml) 
was added, and after stirring for 30 min, the precipitate was isolated to provide 
5,10-dioxo-5H, 10H-diimidazo[1,5-a: 1', 5'-d]pyrazine-1,6-dicarbonyl di- 
chloride (76) (6.56 g, 84%) as a bright yellow solid. The crude acid chloride 
76 (6,56 g, 21.0 mmol) was then suspended in water (80 ml) and heated to 
40°C for 6 h. After allowing to cool, the solids were removed by filtration, 
washed with water (5 x 10 ml), followed by acetone (5 x 10 ml), then dried 
under vacuum to provide 5,10-dioxo-5H, 10H-diimidazo[1,5-a: l', 5'-d]- 
pyrazine-1,6-dicarboxylic acid dihydrate (77) (6.45 g, 99%) as an off-white 
solid, and had mp 275-276°C (decomp. ) (lit., 128 284°C). 
According to the litrature method, 129 the crude diacid 77 (6.4 g, 20.0 
mmol) was then heated to reflux in anhydrous ethanol for 17 h, with the 
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addition of molecular sieves (type 4A), sealed with a calcium chloride guard 
tube. After cooling, the crude product was isolated by filtration, and washed 
with ethanol. Recrystallisation from methanol, employing hot filtering to 
remove molecular sieves and diacid 73, furnished the title compound 78 (3.42 
g, 46%) as a white crystalline solid, and had mp 205-207°C (decomp. ) (lit., 130 
215-216°C) (Found: m/z (EI), 184. C7H8N204 requires M, 184); 
Vmax(KBr)/cnr' 3423,2924,1735,1637,1459,1328,1069 and 955; 
6H(PH6]DMSO) 1.29 (3H, t, J 7, CH3), 4.31 (2H, q, J 7, CH2), 7.90 (1H, s, 2- 
H) and, 13.43 and 13.58 (2H, 2 overlapping brs, CO2H and NH); DEPT- 
6c([2H6]DMSO) 13.9 (CH3), 61.2 (CH2), 138.0 (C-2). 
1-Benzyl-5/4-cyano-lH-imidazole-4/5-carboxamide 79. (The 5- 
cyano-4-carboxamide isomer of this compound was previously reported by a 
different route, without experimental details. 134 5(4)-Cyano-lH-imidazole- 
4(5)-carboxamide (71) (2.31g, 17 mmol. ) was added to a vigorously stirred 
suspension of 95% sodium hydride (0.408g, 17 mmol. ) in anhydrous DMF (30 
ml), and stirred at room temperature for 30 min giving a pale yellow solution. 
Benzyl bromide (2m1,17 mmol. ) was added and the mixture stirred for a 
further 2 h, whereupon a precipitate slowly formed. The mixture was then 
poured into water (200 ml) to ensure all product had precipitated and the solid 
collected by filtration, washed with water, dried and recrystallised from 2- 
ethoxyethanol to give the title compound 79 (2.88 g, 75%) as a flaky white 
crystalline solid, and had mp 259°C (with decomp. ); 811([2H6]DMSO) 5.41 
(2H, s, CH2), 7.27-7.46 (5H, m, Ph), 7.59 and 7.74 (2xlH, 2xbr s, CON112) 
and 8.30 (1H, s, 2-H); Sc([2H6]DMSO) 50.6 (CH2), 106.2 (C), 111.5 (C), 
128.4 (2xCH, ArC), 129.3 (CH, ArC), 129.8 (2xCH, ArC), 136.2 (C), 142.2 
(C-2), 146.1 (C) and 162.3 (C). 
150 
General procedure for lithium triethoxyaluminium hydride 
reduction of 1-benzyl-4,5-dicyano-lH-imidazole 80. Anhydrous ethyl 
acetate (0.73m1,7.5 mmol. ) was added dropwise over a period of 15-30 min to 
a stirred solution of lithium aluminium hydride as a 1.0 M solution in diethyl 
ether (5 ml, 5 mmol. ) diluted with anhydrous tetrahydrofuran (15-20 ml), 
cooled in ice bath, and held under a nitrogen atmosphere. After a further 15 
min stirring at 0°C the substrate (e. g. 80133) was added to this reductant, or the 
solution of the reductant was added to the substrate as desired. The mixture 
was stirred at 0°C for a further 1h followed by the addition of wet diethyl 
ether (10-30 ml) to decompose any unreacted reductant, and 5N sulfuric acid 
(5 ml) followed by a further 10 ml of water to decompose the intermediate 
aluminium adducts. The layers were separated and the aqueous phase 
extracted with diethyl ether (3 x 25 ml). The combined ethereal layers were 
washed with saturated sodium bicarbonate solution (50 ml), water (40 ml), 
dried over magnesium sulphate and solvents removed in vacuo to leave the 
products of the reaction. Silica gel column chromatography of the product 
mixture with ethyl acetate as eluent separated the mixture into two fractions. 
The faster running components, with an Rf of 0.75-0.81, were identified as 
unreacted 80 and 1-benzyl-4-cyano-5-formylimidazole (81b). The slower 
running components, with an Rf of 0.54-0.63, were identified as 1-bcnzyl-5- 
cyano-4-formylimidazole (81a) and 1-benzyl-4,5-diformylimidazole (82). 
1-Benzyl-5-cyano-4-formyl-lH-imidazole 81a. 311(CDC13) 5.30 (211, s, 
CH2), 7.27-7.32 (2H, m, ArH), 7.40-7.46 (3H, m, ArH), 7.71 (111, s, 2-H) and 
9.94 (1H, s, CHO). 
1-Benzyl-4-cyano-5-formyl-lH-lmidazole 81b. 81t(CDC13) 5.33 (211, s, 
CH2), 7.20-7.25 (2H, m, ArH), 7.36-7.42 (3H, m, ArIl), 7.71 (111, s, 2-11) and 
10.01 (1H, d, J 1, CHO). 
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1-Benzyl-4,5. diformyl-lH-imidazole 82.5H(CDC13) 5.56 (2H, s, CH2), 
7.19-7.25 (2H, m, ArH), 7.33-7.38 (3H, m, ArH), 7.71 (1H, s, 2-H), 10.08 
(1H, s, C(4)CHO) and 10.42 (1H, d, J 1, C(5)CHO). 
Attempted Knoevenagel condensation of 1-benzyl-4. cyano-5- 
formylimidazole (81b) and ethyl nitroacetate: Procedure A. According to 
the literature method, 143 titanium tetrachloride (0.44 ml, 4.0 mmol), in carbon 
tetrachloride (2 ml, previously dried over type 4A sieves and distilled from 
phosphorus pentoxide), was added to vigorously stirred anhydrous THE (10 
ml) cooled to 
-5°C, and the resultant yellow precipitate stirred for a further 30 
min under argon. 1-Benzyl-4-cyano-5-formylimidazole (81b) (0.653 g (65% 
pure), equivalent to 2.0 mmol) was then added, as a solution in dry THE (2 
ml), followed by ethyl nitroacetate (0.23 ml, 2.0 mmol). After a further 30 min 
at 
-5°C, pyridine (0.65 ml, 8.1 mmol) was added dropwise via syringe, as a 
solution in dry THE (2 ml), over 30 min. The reaction mixture was then stirred 
at 
-5°C for 24 h, treated with water (2 ml) and extracted with diethyl ether (3 x 
10 ml). TLC analysis of the two resultant phases indicated only starting 
materials, residing in the organic phase, which was confirmed by 1H NMR 
after drying the organic phase (MgSO4) and concentration in vacuo. 
Procedure B. According to the literature method, 144 1-benzyl-4-cyano-5- 
formylimidazole (81b) (0.653 g (65% pure), equivalent to 2.0 mmol) was 
dissolved in pyridine (2 ml) and treated with ethyl nitroacetate (0.215 ml, 1.95 
mmol), followed by piperidine (1 drop), and the mixture stirred at room 
temperature. After a total of 2d at room temperature, TLC analysis showed 
only starting materials. The mixture was then heated to reflux for 1 h, but TLC 
analysis indicated no reaction. Samples of starting imidazole 81b were indeed 
recovered, characterised by iH NMR, after dilution of the reaction mixture 
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with 5% hydrochloric acid and extraction into chloroform, and the reaction 
was abandoned. 
Procedure C. According to the literature method, 122 ethyl nitroacetate (0.74 
ml, 6.5 mmol), as a solution in ethanol (1-2 ml), was added dropwise to a 
solution of sodium (0.15 g, 6.5 mmol) in ethanol (20 ml), cooled in an ice- 
water bath, and held under a nitrogen atmosphere. The resultant fine white 
suspension was then added to a solution of 1-benzyl-4-cyano-5-formyl- 
imidazole (81b) (1.31 g (65% pure), equivalent to 4.0 mmol) cooled in ice. 
After stirring for 2 h, TLC analysis indicated only starting materials 
remaining. The mixture was then heated to reflux under nitrogen for 20 h, 
wherupon TLC analysis showed a mixture of several components, including 
highly polar products that would not elute on the TLC plate. Dilution of the 
reaction mixture with water, and adjustment of the pH to 5-6 with dilute 
hydrochloric acid yielded a viscous red precipitate that by IH NMR and TLC 
analysis consisted of many products. Attepmts to purify the components of the 
crude solid by silica gel column chromatography were not successful, and the 
reaction was abandoned. 
Ethyl 1-benzyl-5/4-cyano-1H-imidazole-4/5-carboxylate 83.134 A 
stirred solution of 1-benzyl-4,5-dicyano-IH-imidazole (80)133(1.04 g, 5.0 
mmol) in a mixture of dry ethanol (20 ml) and dry THE (10 ml), cooled in an 
ice-water bath, was treated with a solution of sodium metal (0.15 g, 6.5 mmol) 
in anhydrous ethanol (5 ml), and the mixture allowed to warm to room 
temperature over 18 h. The reaction was quenched by the addition of IM 
hydrochloric acid (6.5 ml), and the pH of the mixture adjusted to 5 with more 
of the acid. The mixture was reduced in vacuo to leave the aqueous phase, 
which was diluted with more water (30 ml) and extracted with chloroform 
(2x40 ml). The combined extracts were washed with water (30 ml), dried 
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(MgSO4) and reduced in vacuo to leave a pale yellow solid (1.28 g). Silica gel 
chromatography of the yellow solid, with ethyl acetate as eluent, furnished the 
title compound 83 (0.153 g, 12%) as a single regioisomer. A sample 
crystallised from petroleum ether (bp 40-60°C) / acetone had mp 110°C and 
gave the following 1H NMR spectrum: 5H(CDC13) 1.41 (3H, t, J 7, CH2CH3), 
4.43 (2H, q, J 7, CH2CH3), 5.28 (2H, s, CH2Ph), 7.25-7.31 (2H, m, ArH), 
7.36-7.45 (3H, m, ArH) and 7.68 (1H, s, 2-H). 
1-Benzyl-4,5-dicyano-3-ethylimidazolium tetrafuoroborate 84.1- 
Benzyl-4,5-dicyano-lH-imidazole (80)133 (1.25 g, 6.0 mmol) and triethyl- 
oxonium tetrafluoroborate (2.35 g, 12.4 mmol) were heated to gentle reflux in 
anhydrous dichloromethane for 4 days. According to the procedure to achieve 
nitrile reduction, 127 freshly distilled triethylsilane (0.82 g, 7.1 mmol) was then 
added to the mixture, and reflux was continued for 18 h. Water (10 ml) was 
added and the reaction mixture refluxed for a further 4 h. The resultant 
suspension was filtered and the solid washed with water and dried on the 
filter. Crystallisation from ethanol gave the title compound 84 (1.49 g, 76%) 
as white fluffy needles, and had mp 167-168.5°C (Found: C. 51.9; H, 3.95; N, 
17.2%; m/z (ES+), 237. C14H13BF4N4 requires C, 51.9; H, 4.0; N, 17.3%; M- 
BF4,237 ); Vmax(KBr)/cm-13151,1451,1450,1341,1184,1071,762 and 713; 
SH([2H6]acetone) 1.70 (3H, t, J 7, CH3), 4.68 (2H, q, J 7, CH2)9 5.85 (211, s, 
CH2Ph; ), 7.47-7.52 (3H, m, ArH), 7.58-7.62 (2H, m, ArH) and 9.74 (111, s, 
D20 exchange, 2-H); SC([2H6]DMSO) 13.8 (CH3), 46.7 (Cl12), 53.6 (CH2)9 
105.8 (C), 106.0 (C), 114.2 (C), 116.1 (C), 128.9 (2xCH, ArC), 129.1 (2xCIl, 
ArC), 129.5 (CH, ArC), 131.7 (C, ArC) and 141.8 (C-2); 6F([2H6]DMSO) 
152.01 (82%, 11BF4) and 151.96 (18%, 10BF4). 
4,5"Dicyano. l-(p-toluenesulfonyl)imidazole 85. Triethylamine (0.42 
ml, 3.0 mmol) was added slowly via syringe to a stirred suspension of 4,5- 
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dicyanoimidazole (72) (0.354 g, 3.0 mmol) and p-toluenesulfonyl chloride 
(0.572 g, 3.0 mmol) in anhydrous toluene (15 ml) held at room temperature 
under nitrogen, and the mixture stirred at this temperature for 24 h. More 
toluene (10 ml) was added to aid stirring. The resultant suspension was 
filtered and the solid washed with toluene. The remaining solid was 
partitioned between water (50 ml) and diethyl ether (60 ml). The ethereal layer 
was washed with saturated brine, dried (MgSO4) and evaporated to leave a 
white solid. Evaporation of the initial toluene filtrate also yielded a white 
solid. Crystallisation of the combined white solids from toluene gave the title 
compound 85 (0.745 g, 91%) as a crystalline solid 611(CDC13) 2.52 (3H, s, 
Me), 7.48-7.54 (2H, in, ArH), 8.00-8.05 (2H, in, ArH) and 8.25 (111, s, 2-H); 
8C(CDC13) 22.0 (Me), 106.5 (C), 110.2 (C), 110.3 (C), 126.1 (C), 128.9 
(2xCH, ArC), 131.2 (2xCH, ArC), 131.5 (C), 140.4 (C-2) and 149.3 (C); note- 
decomposed before complete characterisation carried out. 
Attempted synthesis of 5(4)-formylimidazole-4(5)-carboxylic acid, 
87, via reduction of 5,10-dioxo-5H, 10H-diimidazo[1,5-a: 1', 5'-d]pyrazine- 
1,6-dicarbonyl dichloride (76): Procedure A. Based upon the literature 
procedure for the sodium borohydride reduction of acid chlorides, 141 the acid 
chloride 76128 (see 78 for synthesis of 76) (0.626 g, 2.0 mmol), as a solution in 
anhydrous DMF (15 ml), was added to a solution of sodium borohydride 
(0.129 g, 3.4 mmol) and pyridine (2.0 ml) in a mixture of dry THE (2 ml) and 
dry DMF (5 ml), under argon, cooled in an ice-bath. After stirring for 1 min, 
water (0.5 ml) was added. After a further 1 min stirring, diethyl ether (50 ml) 
was added, and a brown solid of presumably the dialdehyde 86 was isolated 
by filtration, and washed with further portions of diethyl ether. The crude 
brown solid was then suspended in water (30 ml) and heated to 40'C for 3 d, 
to leave an orange solution over a pale brown solid. TLC and Ill NMR 
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analysis of the crude product suggested it to be the diacid 73, and the reaction 
was not progressed further. 
Procedure B. Based upon the literature procedure for the hydrogenation of 
acid chlorides, 140 a flask was charged with freshly distilled 2,6-lutidine (0.47 
ml, 4.0 mmol), 10% palladium on carbon catalyst (10-15 mg) and anhydrous 
THE (10 ml), and held under an atmosphere of hydrogen. Then, from a 
pressure-equalising addition funnel was added the acid chloride 76 (0.789 g, 
2.52 mmol) as a solution in dry THE (50 ml), over a period of 4 min, forming 
a vivid red suspension. Stirring was continued at room temperature for 20 h, 
after which the red solid, presumed to be the tricyclic dialdehyde 86, was 
filtered from the solution. The crude intermediate was then suspended in water 
(40 ml), and stirred at room temperature for 3 d, to leave a pale orange 
solution over an orange solid. TLC analysis of the solid and supernatant liquid 
indicated the diacid 73 as the major product, and the reaction was not 
progressed further. 
Methyl 5(4)-diethoxymethylimidazole-4(5)-carboxylate 90.142 
According to the literature method, 142 potassium hydride, as a 35% wt. 
dispersion in mineral oil (4.79 g, 41.8 mmol KH), was placed in a flask and, 
under argon, the oil removed by washing with dry hexane (2 x 20 ml). The 
remaining solids were then suspended in freshly distilled diglyme (20 ml), 
cooled in an ice-water bath, and treated with a solution of methyl 
isocyanoacetate (88) (3.00 g, 30.3 mmol) and diethoxyacetonitrile (89) (3.91 
g, 30.3 mmol) in diglyme (20 ml), dropwise over a period of 20 min. Once the 
addition was complete, the mixture was heated to 70-80°C for 5 h. The dark 
reaction mixture was then cooled, quenched by the cautious addition of 
saturated ammonium chloride solution (80 mi), and extracted with chloroform 
(3 x 50 ml) and ethyl acetate (50 ml). The combined organic extracts were 
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then dried (MgSO4) and reduced in vacuo to leave the title compound 90 (5.26 
g, 76%). A sample recrystallised from hexane/ethanol had mp 147°C (decomp. 
with effervescence) (lit., 142 148-150°C); vma(KBr)/crn t 3434,2979,1718, 
1509,1447,1323,1195,1147,1106,1061 and 1006 (lit., 142 3420,2500-3100, 
1715,1510,1440,1320,1190,1145,1100,1060 and 1000); SH(CDC13) 1.23 
(6H, t, J 7,2xOCH2CH3), 3.58-3.81 (4H, m, 2xOCH2CH3), 3.92 (3H, s, 
CO2CH3), 6.12 (1H, s, CH(OEt)2), 7.62 (1H, s, 2-H) and 10.02 (1H, brs, NH), 
in good agreement with the literature. 142 
Methyl 5(4)-formylimidazole-4(5)-carboxylate 91.142 Methyl 5(4)- 
diethoxymethylimidazole-4(5)-carboxylate (90) (0.736 g, 3.22 mmol) was 
suspended in 40% acetic acid/water (25 ml), and heated to 40-50°C for 3 h. 
TLC analysis showed complete consumption of 90, and the mixture was 
evaporated to dryness under vacuum and then triturated with chloroform (10 
ml) to provide the title compound 91 (0.455 g, 92%), as a golden yellow solid, 
and had mp 222.5°C (decomp. ) (Found: m/z (EI), 154. C6H6N2O3 requires M, 
154); Vmax(KBr)/cm-1 3432,2962,1726,1673,1493,1322,1261,1069 and 
962; SH(PH6]DMSO) 3.88 (3H, s, CH3), 8.08 (1H, d, J 0.6,2-H), 10.22 (111, 
d, J 0.6, CHO) and 13.81 (1H, brs, NH); Sc(CF3CO2D) 56.6 (Me), 130.6 (C), 
134.1 (C), 140.0 (CH, C-2), 159.6 (C, CO2CH3) and 182.8 (CH, CHO). 
Attempted Knoevenagel condensation of methyl 5(4). 
formylimidazole-4(5)-carboxylate (91) and ethyl nitroacetate. According 
to the literature method, 143 titanium tetrachloride (0.89 ml, 8.1 mmol), in 
carbon tetrachloride (5 ml, previously dried over type 4A sieves and distilled 
from phosphorus pentoxide), was added to vigorously stirred anhydrous TIIF 
(25 ml) cooled to 
-5°C, and the resultant yellow precipitate stirred for a further 
20 min under argon. Methyl 5(4)-formylimidazole-4(5)-carboxylate (91) 
(0.624 g, 4.05 mmol) was then added, as a solution in dry DMF (10 ml), 
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followed by ethyl nitroacetate (0.45 ml, 4.05 mmol). After stirring at -5°C for 
a further hour, pyridine (1.31 ml, 16.2 mmol), as a solution in dry THE (3 ml), 
was added dropwise to the reaction mixture, over a period of 30 min. The 
reaction was then stirred at -5 to 5°C for 24 h, after which water (3 ml) and 
diethyl ether (5m1) were added, and the mixture allowed to warm to room 
temperature. The resultant layers were separated, and the aqueous phase 
extracted with THE (4 x 25 ml). TLC analysis of the aqueous and organic 
phases suggested only the presence of starting materials. As confirmation, 
after drying the combined organic extracts over MgSO4, followed by 
concentration in vacuo, a pale pink solid crystallised from the residual oil that 
was identical by 1H NMR to an authentic sample of imidazole 91; 
concentration of the remaining mother liquor gave an oil rich in ethyl 
nitroacetate, as determined by 1H NMR. A further crop of starting imidazole 
91 was obtained after neutralisation of the remaining aqueous phase, and 
further analysis was abandoned. 
5.2 Pyrimidinone chemistry 
2-Amino-5-bromo-6-methylpyrimidin-4(3II)-one 19. According to 
the literature method, 85 a solution of bromine (6.71 g, 42 mmol) in glacial 
acetic acid (15 ml) was added dropwise to a solution of 2-amino-6-methyl- 
pyrimidin-4(3H)-one (93) (4.97 g, 40 mmol) in glacial acetic acid (40 ml), 
heated to 70°C. As the product precipitated, more acetic acid (25 ml) was 
added to aid stirring. After all the bromine had been added, the reaction 
mixture was stirred at 70°C for a further hour, then allowed to cool slowly. 
The suspension was then filtered and the solid residue washed with ethanol (3 
x 20 ml), saturated sodium bicarbonate solution (until effervescence in the 
filter subsided), water (3 x 20 ml), acetone (20 ml) then dried in a vacuum 
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desiccator to give a white solid (6.77 g). The crude white solid was 
recrystallised from DMF to provide the title compound 19 (5.42 g, 66%), and 
had mp 234-234.5°C (with decomp. ) (lit., 218 249°C (from water)) (Found: C, 
29.9; H, 3.0; N, 20.4; Br, 39.2%. C6H6BrN3O requires C, 29.4; H, 3.0; N, 
20.6; Br, 39.2%); Vmax(KBr)/cn 1 3314,3160,1644,1604,1560,1392,1220 
and 765; 8H(PH6]DMSO) 2.20 (3H, s, Me), 6.62 (2H, brs, NH2) and 11.18 
(1H, brs, NH). 
2-Amino-5-bromo-6-phenylpyrimidin-4(3H )-one 20. Prepared 
according to the method for the preparation of 19, with 2-amino-6-phenyl- 
pyrimidin-4(3H)-one (26) (28.08 g, 0.15 mol) and bromine (25.25 g, 0.158 
mol), to provide a crude white solid (29.82 g) which was recrystallised from 
2-ethoxyethanol (800 ml), yielding the title compound 20 (27.85 g, 70%) as a 
white solid, and had mp 274-277°C (with decomp. ) (lit., 69 268-270°C (from 
aqueous DMF)) (Found: C, 45.4; H, 3.0; N, 15.6; Br, 30.4%. C10H8BrN3O 
requires C, 45.1; H, 3.0; N, 15.8; Br, 30.0%); vmax(KBr)/cm-t 3431,3312, 
1676,1583,1454,1338,1226 and 1013; 311(OH61DMSO) 6.76 (211, brs, 
NH2), 7.42 (3H, m, ArH), 7.54 (2H, m, ArH) and 11.42 (1H, brs, NH). 
2-Amino-5-iodo-6-phenylpyrimidin-4(3II)-one 21. According to the 
literature method, 69 to a solution of 2-amino-6-phenylpyrimidin-4(311)-one 
(26) (28.08 g, 0.15 mol) in 1M sodium hydroxide (450 ml) was added 
chloroform (500 ml) and iodine (41.88 g, 0.165 mol), and the mixture was 
heated to gentle reflux on a steam bath for 4 h. The biphasic mixture was then 
cooled and filtered, removing a crop of the title compound 21 (8.21 g) as a 
pale yellow solid. After separation of the phases, the aqueous phase was 
layered with ethyl acetate (250 ml), and the pH of the aqueous phase lowered 
to 9-10 with 12 M hydrochloric acid, to provide a second crop of 21 as a pale 
yellow solid, that was isolated by filtration, washed with water, and dried to 
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constant weight in vacuo. The combined solids (42.21 g, 90%) were pure by 
1H NMR. Attempts to recrystallise the crude product from high boiling 
solvents, including DMF, and 2-ethoxyethanol, appeared to lead to 
decomposition to give 26, but a sample recrystallised from ethanol had mp 
270-274°C (Found: C, 38.4; H, 2.5; N, 13.4; I, 40.2%. C10H8IN30 requires C, 
38.4; H, 2.6; N, 13.4; I, 40.5%); 6H([2H6]DMSO) 6.76 (2H, brs, NH2), 7.35- 
7.55 (5H, m, Ph) and 11.32 (1H, brs, NH). 
2-Amino-6-phenylpyrimidin-4(3H)-one 26. According to the 
literature method, 149 ethyl benzoylacetate (95.14 g, 0.495 mol) and guanidine 
carbonate (40.54 g, 0.450 mol) were heated to reflux in absolute ethanol (450 
ml) for 24 h. After cooling, the reaction mixture was cooled and filtered, and 
the residue washed with ethanol (2 x 30 ml), water (2 x 30 ml), acetone (20 
ml), and dried in vacuo to provide the title compound 26 (58.28 g, 69%), as a 
white solid, in acceptable purity, and had mp 304-306'C (with decomp. ) 
(lit., 149 304°C) ; vmax(KBr)/cart 3351,3091,2951,1657,1503,1475,1380 
and 763; 8H(PH6)DMSO) 6.10 (1H, s, 5-H), 6.61 (2H, brs, NH2), 7.44 (311, m, 
ArH), 7.94 (2H, m, ArH) and 10.82 (1H, brs, NH). 
2-Amino-6-methylpyrimidin-4(3II)-one 93. Prepared according to 
the method for the preparation of 26, with ethyl acetoacetate (13.4 ml, 0.105 
mol) and guanidine carbonate (9.01 g, 0.100 mol), to provide a crude solid 
(11.97 g), which was recrystallised from DMF (250 ml) to yield the title 
compound 93 (10.35 g, 83%) as a pale brown crystalline solid, and had mp 
311-314°C (with decomp. ) (lit., 219 297-299°C (from water)) (Found: C, 47.7; 
H, 5.7; N, 33.2%. C5H7N30 requires C, 48.0; H, 5.6; N, 33.6%); 
umax(KBr)/cm t 3335,3082,2945,1662,1499,1390,1184 and 832; 
611([2H6]DMSO) 1.98 (3H, s, Me), 5.39 (1H, s, 5-11), 6.47 (211, brs, N112) and 
10.68 (1H, brs, NH). 
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2-Amino-6-ethylpyrimidin-4(3H)-one 94. Prepared according to the 
method for the preparation of 26, with ethyl propionylacetate (15.0 ml, 0.105 
mol) and guanidine carbonate (9.01 g, 0.100 mol), to provide a crude solid 
(12.21 g), which was recrystallised from DMF (40 ml) to yield the title 
compound 94 (11.80 g, 86%) as a white solid, and had mp 262-264°C (with 
decomp. ); vma, (KBr)/cm 1 3338,3077,2949,1663,1501,1385,1320 and 
841; 8H([ZH6]DMSO) 1.08 (3H, t, J 7.5, CH2CH3), 2.26 (2H, q, J 7.5, 
CH2CH3), 5.38 (1H, s, 5-H), 6.46 (2H, brs, NH2) and 10.64 (1H, brs, NH) (94 
has been previously reported, 220 but without supporting physical data). 
2-Amino-5-bromo-6-ethylpyrimidin-4(3H)-one 95. Prepared 
according to the method for the preparation of 20, with 2-amino-6-ethyl- 
pyrimidin-4(3H)-one (94) (3.48 g, 25 mmol) and bromine (4.20 g, 26 mmol), 
to yield a crude product (4.02 g) that was recrystallised from DMF/2- 
ethoxyethanol to provide the title compound 95 (3.03 g, 55%) as a white solid. 
Drying the solid under high vaccuum failed to remove the final traces of 2- 
ethoxyethanol, as determined by 1H NMR, and the solid had mp 232-234°C 
(with decomp. ) (lit., 220 225-225.5°C); vmax(KBr)/curl 3375,3107,1671, 
1591,1464,1350,1219 and 1007; 61(pH6]DMSO) 1.10 (311, t, J 7.5, 
CH2CH3), 2.47-2.56 (multiplet coincident with DMSO signal, C112C113), 6.64 
(2H, brs, NH2) and 11.18 (1H, brs, NH). 
2-Amino-5-iodo-6-methylpyrimidin4(3II)-one 96. Prepared 
according to the method for the preparation of 21, with 2-amino-6-methyl- 
pyrimidin-4(3H)-one (93) (4.97 g, 40 mmol) and iodine (10.66 g, 42 mmol), 
and a reaction time of 28 h, to give the title compound 96 (8.63 g, 86%) 
directly, as a pale yellow solid, in acceptable purity, and had mp 216-217'C 
(with decomp. ) (lit., 221 211.5-212.5'C); 811([2H6]DMSO) 2.28 (311, s, Mc), 
6.64 (2H, brs, NH2) and 11.12 (1H, brs, NH). 
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2-Amino-6-ethyl-5-iodopyrimidin-4(3H) 
-one 97. Prepared 
according to the method for the preparation of 21, with 2-amino-6-ethyl- 
pyrimidin-4(3H)-one (94) (6.96 g, 50 mmol) and iodine (13.33 g, 52.5 mmol), 
to provide the title compound 97 (11.11 g, 84%) directly, as a pale yellow 
solid, in reasonable purity. A sample was purified by dissolving in 2M 
sodium hydroxide, decolourising the solution with charcoal, before acidifying 
with acetic acid to precipitate 97. After filtering off the solid, washing with 
water and drying in vacuo, the resultant white solid had mp 203-206°C (with 
decomp. ) (lit., 221 199-200°C (from ethanol)); SH([2H6]DMSO) 1.08 (3H, t, J 
7.5, CH2CH3), 2.56 (2H, t, J 7.5, CH2CH3), 6.64 (2H, brs, NH2) and 11.08 
(1H, brs, NH). 
1-(2-Amino-3,4-dihydro-4-oxopyrimidin-6-y1)ferrocene 100. 
Guanidine carbonate (0.45 g, 2.5 mmol) and ethoxycarbonylacetylferrocene 
(99)90 (1.54 g, 5.0 mmol) were heated to reflux in absolute ethanol (20 ml), 
and the reaction periodically monitored by TLC. After 4 days another portion 
of guanidine carbonate (0.045 g, 0.5 mmol) was added and the reaction 
returned to reflux. When ester 99 was judged to have been consumed by TLC 
(7 days) the mixture was cooled, reduced in vacuo to ca. 2 ml and filtered to 
give a brown solid (0.62 g). Crystallisation of the crude brown solid from 
ethanol furnished the title compound 100 (first crop-0.212 g, 14%; second 
crop-0.176 g, 12%) as the hemihydrate, a purple crystalline solid, and had mp 
220-230°C (onset of decomp. ) (Found: C, 55.0; H, 4.5; N, 13.7%; m/z (EI), 
295. C14H13FeN3O. 0.5H20 requires C, 55.3; H, 4.6; N, 13.7%; 14,295); 
vmax(KBr)/cm-1 3397,3088,1655,1640,1603,1460,1254 and 814; 
SH([2H6]DMSO) 4.08 (5H, s, C5H5), 4.38 (214, t, J 2, C5H4), 4.83 (21-1, t, J 2, 
C5H4), 5.79 (1H, s, pyrimidine 5-H), 6.58 (2H, br s, NH2) and 11.01 (111, br s, 
NH); 6C([2H6]DMSO) 67.8 (2xCH, C5H4), 69.7 (5xCH, C5H5), 70.1 (2xCII, 
C5H4), 81.9 (C, C5H4), 96.4 (CH, pyrimidine C-5), 155.7,163.5 and 166.1 
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(3xC, pyrimidine C-2,4 and 6); m/z (HRMS-EI) 295.0408 (M+. C14H13FeN30 
requires 295.0407). 
1,1'-Bis(2-amino-3,4-dihydro-4-oxopyrimidin-6-yl)ferrocene 103. 
1,1'-Bis(ethoxycarbonylacetyl)ferrocene (102) (2.72 g, 6.57 mmol) (prepared 
according to the literature method, 91,92 and used crude) and guanidine 
carbonate (1.18 g, 6.57 mmol) were heated to 80°C in ethanol (150 ml). After 
76 h the dark red mixture was cooled, concentrated in vacuo to approximately 
50 ml, re-cooled in ice and a solid was filtered from the solution and washed 
with ethanol. The solid was then triturated with boiling DMF (3x 100 ml), 
washed with diethyl ether and dried to provide the title compound 103 (0.43 g, 
14%) as the 1: 2 DMF solvate, an almost black powder, and had mp >360'C 
(no elemental analysis obtained, EI mass spectroscopy failed); Vmax(KBr)/cm-, 
3390,1651,1463,1393,1250,1080,821 and 595; 511([2H6]DMSO) 2.73 (6H, 
s, 2xDMF-Me), 2.90 (6H, s, 2xDMF-Me), 4.25 (4H, m, 2xC5H4), 4.70 (4H, 
m, 2xC5H4), 5.69 (2H, s, 2xpyrimidine-5-H), 6.41 (4H, br s, 2xNH2), 7.95 
(2H, s, 2xDMF-CHO) and 10.50 (2H, br s, 2xNH); note insufficiently soluble 
for 13C NMR. 
Ethyl 2-nitrobenzoylacetate 111. To a stirred suspension of 2- 
nitrobenzoic acid (116) (0.836 g, 5.0 mmol) in dichloromethane (25 ml, 
freshly distilled from calcium hydride) was added dicyclohexylcarbodiimide 
(DCCI) (1.186 g, 5.75 mmol), followed by 2,2-dimethyl-l, 3-dioxane-4,6- 
dione (117) (Meldrum's acid) (0.749 g, 5.2 mmol) and 4-dimethylamino- 
pyridine (DMAP) (0.916 g, 7.5 mmol), and the mixture stirred at room 
temperature for 18 h. A white solid was removed by filtration, which was 
washed with dicloromethane until washings were colourless. The combined 
filtrates were then washed with 1M hydrochloric acid (20 ml), water (20 ml), 
dried (MgSO4) and concentrated in vacuo to leave an orange oil (0.94 g). The 
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crude oil, taken to be 2,2-dimethyl-5-(2-nitrobenzoyl)-1,3-dioxane-4,6-dione 
(118), but used without analysis, was heated to reflux in ethanol (50 ml) for 30 
min, until complete disappearance of intermediate 118 noted by TLC. After 
cooling, the orange solution was concentrated to give an oily orange solid 
which was purified by silica gel column chromatography, with ethyl acetate / 
hexane (3: 7) as eluent, to provide the title compound 111 (0.249 g, 21%) as a 
yellow oil; SH(CDC13) 1.24 (2.57H, t, J 7, CH2CH3 (keto)), 1.34 (0.43H, t, J 
7, CH2CH3 (enol)), 3.88 (1.71H, s, CH2 (keto)), 4.16 (1.71H, q, J 7, CH2CH3 
(keto)), 4.28 (0.29H, q, J 7, CH2CH3 (enol)), 5.42 (0.14H, s, CH (enol)) and 
7.51-8.20 (4H, m, ArH) (in agreement with literature valuest60). 
Reaction of Ethyl 2-nitrobenzoylacetate (111) with guanidine 
carbonate. Guanidine carbonate (0.094 g, 1.05 mmol) and ethyl 2-nitro- 
benzoylacetate (111) (0.249 g, 1.05 mmol) were heated to reflux in ethanol 
(10 ml). After 4 h, though the colour of solution had changed from pale 
yellow to dark red, TLC analysis indicated 111 remaining, with residual, 
highly coloured, polar components not eluting from the baseline of the 
chromatogram. After a further 24 h at reflux, TLC analysis indicated the 
presence of several coloured components with varying Rf values, but also 
remaining 111. More guanidine carbonate (0.047 g, 0.53 mmol) was added, 
and reflux continued until all 111 was consumed (24 h). After cooling, a small 
amount of a brown solid was filtered from the reaction mixture, but 111 NMR 
analysis showed no sign of the intended product, pyrimidinonc 119, only an 
overlapping set of weak signals between 7 and 8 ppm. The filtrate was 
reduced to leave a red oil, but which again, by III NMR, showed a complex 
pattern between 7 and 8 ppm, as well as several ethyl environments, but no 
sign of the pyrimidinone 119 
- 
for which would be expected a sharp singlet at 
about 6 ppm, for the 5-H. 
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2-(2-Amino-3,4-dihydro-4-oxo-6-phenylpyrimidin-5-yl). 6-phenyl- 
pyrimidin-4(3H)-one 112 (example preparation). Nitrosonium tetra- 
fluoroborate (0.175 g, 1.5 mmol) was added, as a solution in acetonitrile (1 
ml, dried by azeotropic distillation with dichloromethane), to a stirred solution 
of 2-amino-6-phenylpyrimidin-4(3H)-one (26)149 (0.094 g, 0.5 mmol) in 
acetonitrile (20 ml), cooled in an ice-water bath. The reaction was allowed to 
warm slowly to room temperature. After stirring at room temperature for 2 
days, the reaction mixture was heated to reflux for a further 2 days. After 
cooling, water (3 ml) was added and the mixture neutralised with 1M sodium 
hydroxide. The mixture was cooled to 4'C and a solid removed by filtration, 
which was discarded. Dilution of the filtrate with more water and evaporation 
of the acetonitrile in vacuo gave a second precipitate which was filtered from 
the solution and washed with small portions of water. This second precipitate 
was then dissolved in 2M sodium hydroxide (1-2 ml) with heating, 
decolourised with activated carbon, and the clear orange solution acidified 
with acetic acid to pH 5 forming a brown precipitate. Direct crystallisation of 
the mixture by the addition of the minimum quantity of DMF yielded the title 
compound 112 (6.5 mg, 7 %) as a brown solid. A further crop of 112 (5.6 mg, 
6%) was obtained on dilution of the crystallisation mother liquor with water, 
and had mp 332°C (with decomp. ); vmax(KBr)/cm t 3424,2920,2851,1655, 
1638,1561,1544 and 698; 6}1(FH6]DMSO) 6.62 (111, s, 5-H), 7.24-7.46 
(12H, m, ArH and NH2), 11.67 (1H, br s, NH) and 12.52 (111, br s, N11); 
5C([2H6]DMSO) 105.8 (pyrimidine C-5'), 106.5 (C-5), 127.0 (2xCII, ArC), 
128.1 (4xCH, ArC), 128.6 (2xCH, ArC), 129.0 (CH, ArC), 130.4 (CII, ArC), 
136.5 (C), 140.1 (C), 155.6 (C), 155.9 (C), 160 7 (C), 162.8 (C) and 163.0 
(broad signal, coincidence of 2xC? ); m/z (HRMS-FAB+) 358.1228 (MW. 
C20H16N502 requires 358.1304). 
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2-Amino-5,6-diphenylpyrimidin-4(3H)-one 126.12 M Hydrochloric 
acid (5 ml) was added to a solution of 2-amino-5,6-diphenyl-4-methoxy- 
pyrimidine (135) (0.044 g, 0.16 mmol) in methanol (5 ml), and the mixture 
was heated to reflux for 1 h. After cooling, the solution was basified with solid 
sodium hydroxide (2.27 g) and then re-acidified with acetic acid to pH 6. 
After cooling in ice, the precipitate was collected by filtration, washed with 
water and dried in vacuo to furnish the title compound 126 (0.040 g, 96%) as a 
fine white solid. A sample crystallised from ethanol had mp 314-316°C 
(lit., 176 319°C). The following data have not been reported previously: 
SH(PH6]DMSO) 6.64 (2H, br s, NH2), 6.86-7.02 (2H, m, ArH), 7.06-7.22 
(8H, m, ArH) and 11.12 (1H, br s, NH); Sc([2H6]DMSO) 113.2 (C-5), 126.1 
(CH, ArC), 127.5 (2xCH, ArC), 127.6 (2xCH, ArC), 128.2 (CH, ArC), 129.4 
(2xCH, ArC), 131.6 (2xCH, ArC), 135.7 (C, ArC), 139.7 (C, ArC), 154.3 (C), 
162.1 (C) and 162.7 (C). Also gave m/z (HRMS-EI), 263.1038. (M+. 
C16H13N30 requires M, 263.1058). 
2-Amino-6-methyl-5-phenylpyrimidin4(3II)-one 129.2-Amino-5- 
bromo-6-methylpyrimidin-4(3H)-one (19)218 (0.414 g, 2.03 mmol) and 
tetrakis(triphenylphosphine)palladium(0) (0.080 g, 0.07 mmol) were stirred 
with DMF (5 ml) for 5 min. Phenylboronic acid (0.275 g, 2.25 mmol) and 
more DMF (10 ml) were added, followed by sodium carbonate (0.550 g, 5.19 
mmol) dissolved in water (2 ml) and the mixture was heated to reflux for 24 h, 
under a gentle flow of nitrogen. After cooling, the reaction was filtered, and 
the filtrate evaporated in vacuo. The residue was purified by silica gel column 
chromatography, with ethyl acetate / methanol / acetic acid (16: 4: 1) as clucnt 
to yield the title compound 129 (0.040 g, 10%) as a white solid with R10.61. 
Crystallisation of 129 from ethanol or from 50% aqueous DMF yielded solids 
that failed to give satisfactory elemental analyses, with broad melting ranges, 
but a sample crystallised from ethanol had vm. (KBr)/cm 1 3368,3134,2925. 
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1655,1613,1508,1048 and 704; SH(PH6]DMSO) 1.98 (3H, s, Me), 6.96 (2H, 
br s, NH2), 7.18-7.40 (5H, m, Ph) and 10.5-12.5 (1H, br s, NH); 
8c([2H6]DMSO) 20.8 (Me), 114.1 (C-5), 126.8 (CH, ArC), 127.8 (2xCH, 
ArC), 130.6 (2xCH, ArC), 134.4 (C, ArC), 153.1 (C), 157.0 (C) and 161.9 
(C); Wz (HRMS-EI), 201.0899. (M+. C11H1 1N30 requires M, 201.0902). 
2-Amino-5-bromo-4-chloro-6-phenylpyrimidine 132.2-Amino-5- 
bromo-6-phenylpyrimidin-4(3H)-one (20) (3.725 g, 14.0 mmol) was heated to 
reflux in phosphorus oxychloride (12 ml) for 45 min, the vessel fitted with a 
calcium chloride guard tube. The solution was concentrated in vacuo to leave 
an orange oil, which was treated with ice-water (50 ml), and the oil broken up 
by the action of a glass rod. The mixture was then neutralised by the dropwise 
addition of aqueous ammonia to pH 7. After then standing overnight at 4°C, 
more ammonia was added to restore the pH to 7. The solid was then removed 
by centrifugation of the suspension formed, at 4000 rpm, washing with water, 
and drying the solid to constant weight. On standing, the supernatant 
precipitated more white solid, which was combined with that isolated by 
centrifugation. The combined crude solids were then warmed with 
dichloromethane, filtered to remove an insoluble by-product (2.09 g, sec text), 
and reduced in vacuo to ca. 40 ml. Precipitation was then induced by the 
addition of petroleum ether (bp 40-60°C), to provide the title compound 132 
(2.681 g, 67%) as a yellow crystalline solid, and had mp 135°C (lit., 85 136- 
138°C); SH([ZH6]DMSO) 7.36 (2H, brs, NH2), 7.45-7.50 (311, m, Arli) and 
7.57-7.61 (2H, m, ArH); Sc([2H6]DMSO) 102.0 (C-5), 128.0 (CII, 2xArC), 
128.8 (CH, 2xArC), 129.7 (CH, ArC), 138.3 (C, ArC), 160.4 (C), 161.4 (C) 
and 168.0 (C); rWz (ES+), 284,286,288; C10H7BrC1N3 requires M+1,284, 
286,288). 
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2-Amino-5-bromo-4-methoxy-6-phenylpyrimidine 134. Sodium 
methoxide, 25%wt solution in methanol (2 ml, -8.8 mmol) was added via 
syringe to a stirred suspension of 2-amino-5-bromo-4-chloro-6-phenyl- 
pyrimidine (132)185 (0.647 g, 2.27 mmol) in anhydrous methanol (25 ml), and 
the mixture heated to reflux for 30 min, under nitrogen. After slowly cooling 
overnight, excess sodium methoxide was decomposed by the addition of solid 
carbon dioxide, followed by water (200 ml). The suspension was extracted 
with chloroform (3x50 ml) and the combined organic extracts were washed 
with water (25 ml), dried (MgSO4) and reduced to give a white solid. The 
solid was crystallised from hexane to furnish the title compound 134 (0.588 g, 
93%) and had mp 174°C (Found: C, 47.1; H, 3.5; N, 14.8%; m/z (ES+), 280, 
282. C11H10BrN3O requires C, 47.2; H, 3.6; N, 15.0%; M+1,280,282); 
vmax(KBr)/cm4 3486,3291,3154,1630,1543,1375,1200 and 698; 
SH(CDC13) 4.01 (3H, s, Me), 5.11 (2H, br s, NH2), 7.40-7.47 (3H, m, ArH) 
and 7.61-7.65 (2H, m, ArH); 6c(CDC13) 54.8 (Me), 92.5 (C-5), 127.9 (2xCH, 
ArC), 128.8 (2xCH, ArC), 129.2 (CH, ArC), 138.1 (C, ArC), 160.9 (C), 166.0 
(C) and 166.8 (C). 
2-Amino-5,6-diphenyl-4-methoxypyrimidine 135. Sodium 
carbonate (0.276 g, 2.61 mmol), as a solution in water (2 ml), was added to a 
mixture of 2-amino-5-bromo-4-methoxy-6-phenylpyrimidine (134) (0.287 g, 
1.02 mmol), phenylboronic acid (0.138 g, 1.13 mmol) and tetrakis(triphenyl- 
phosphine)palladium(0) (0.040 g, 0.035 mmol) in toluene (2 ml) and ethanol 
(2 ml), and the mixture heated to reflux for 18 h, under nitrogen. After 
cooling, the mixture was extracted with chloroform (3x25 ml), and the 
combined extracts washed with water (10 ml), 0.5 M sodium hydroxide 
(2x5m1), water (10 ml) and saturated brine (10 ml). The organic solution was 
then dried (MgSO4) and reduced to give a grey solid which was crystallised 
from 10% ethyl acetate / hexane to provide the title compound 135 (0.212 g, 
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75%), as a crystalline white solid, and had mp 185-185.5°C (Found: C, 73.5; 
H, 5.4; N, 15.0%; m/z (ES+), 278. C17H15N30 requires C, 73.6; H, 5.45; N, 
15.15%; M+1,278); vmax(KBr)/cm-1 3379,3171,1638,1568,1543,1371, 
1198 and 696; SH(CDCb) 3.88 (3H, s, Me), 5.14 (2H, br s, NH2) and 7.08- 
7.28 (10H, m, 2xPh); Sc(CDC13) 53.9 (Me), 110.9 (C-5), 126.7 (CH, ArC), 
127.7 (2xCH, ArC), 127.8 (2xCH, ArC), 128.3 (CH, ArC), 129.4 (2xCH, 
ArC), 131.2 (2xCH, ArC), 134.4 (C, ArC), 138.6 (C, ArC), 161.3 (C), 165.2 
(C) and 168.5 (C). 
2-Amino-5-(2,4-dichlorophenyl)-4-methoxy-6-phenylpyrimidine 
136. Prepared according to the method for the preparation of 135, with 2- 
amino-5-bromo-4-methoxy-6-phenylpyrimidine (134) (0.210 g, 0.75 mmol), 
2,4-dichloro-benzeneboronic acid (0.158 g, 0.83 mmol), tetrakis(triphenyl- 
phosphine)palladium(0) (0.030 g, 0.026 mmol) and sodium carbonate (0.203 
g, 1.92 mmol) in toluene (2 ml), ethanol (2 ml) and water (1 ml), and the 
mixture heated to reflux for 24 h. Three sequential silica gel column 
purifications of the residue with chloroform / diethyl ether (85: 15) as eluent 
gave a white solid (0.093 g) that by 1H NMR contained the title compound 
136 and starting pyrimidine 134 in approximately equal amounts. 
Crystallisation of this mixture from acetone (1 ml) gave a sample 90% pure in 
136 (0.021 g) which gave the following data: (m/z (ES+), 346,348,350. 
C17H13C12N30 requires M+1,346,348,350); vmax(KBr)/cm 1 3408,3183, 
1645,1568,1368,1051,814 and 698; SH(CDC13) 3.89 (3H, s, Me), 5.23 (2H, 
br s, NH2), 6.92 (1H, d, J 8,6'-H (5-Ar)), 7.09 (1H, dd, J8 and 2,5'-H (5- 
Ar)), 7.17-7.31 (5H, m, Ph) and 7.40 (1H, d, J 2,3'-H (5-Ar)); Sc(CDC13) 54.0 
(Me), 107.5 (C-5), 126.9 (CH, ArC), 127.9 (2xCH, ArC), 128.6 (2xCH, ArC), 
128.7 (CH, ArC), 129.1 (CH, ArC), 132.8 (C, ArC), 133.6 (CH, ArC), 133.7 
(C, ArC), 136.1 (C, ArC), 138.1 (C, ArC), 162.1(C), 165.7 (C) and 168.4 (C). 
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2-Amino-4-methoxy-6-phenyl-5-(3-thienyl)pyrimidine 137. 
Palladium acetate (5.1 mg, 0.023 mmol) and 1,1'-(diphenylphosphino)- 
ferrocene (dppf) (16.6 mg, 0.03 mmol) were heated in degassed 1,2- 
dimethoxyethane (DME) (3 ml) for 15 min, under nitrogen. After cooling of 
this mixture 2-amino-5-bromo-4-methoxy-6-phenylpyrimidine (134) (0.210 g, 
0.75 mmol), thiophene-3-boronic acid (0.106 g, 0.83 mmol) and potassium 
phosphate tribasic (0.318 g, 1.5 mmol) were added, along with DME (3 ml) 
and water (1 ml), and the mixture was heated under gentle reflux for 22 h, 
under nitrogen. The reaction mixture was then cooled, diluted with water (10 
ml) and extracted with diethyl ether (3x25 ml). The combined ethereal extracts 
were washed with water (10 ml), saturated brine (10 ml), dried (MgSO4) and 
reduced in vacuo to leave a pale brown solid. Succesive crystallisations of the 
brown solid from hexane / ethyl acetate (5: 1), then acetone yielded the title 
compound 137 (0.055 g, 26%) as a crystalline white solid, and had mp 206- 
207°C (Found: C, 63.6; H, 4.55; N, 14.6%; m/z (ES+), 284. C15H13N30S 
requires C, 63.6; H, 4.6; N, 14.8%; M+1,284); vmax(KBr)/cnrt 3461,3144, 
1630,1549,1479,1452,1344 and 1198; 611(CDC13) 3.93 (3H, s, Me), 4.99 
(2H, br s, NH2), 6.82 (1H, dd, JI and 5,4'-H (thienyl)), 6.96 (1H, dd, J1 and 
3,2'-H (thienyl)), 7.18 (1H, dd, J3 and 5,5'-H (thienyl)) and 7.23-7.32 (511, 
m, Ph); 6c(CDC13) 53.9 (Me), 115.4 (C-5), 124.7 (CH, thienyl), 125.2 (CH, 
thienyl), 128.2 (2xCH, ArC), 129.0 (CH), 130.2 (2xCH, ArC), 131.2 (CH), 
135.3 (C), 140.4 (C), 162.9 (C), 166.2 (C) and 169.3 (C). 
2-Amino-4-methoxy-6-phenylpyrimidine 138.196 According to the 
literature method, 196 guanidine sulfate was added to a solution of sodium 
(0.699 g, 30.4 mmol) in anhydrous methanol (50 ml), immediately followed 
by 3,3-bis(methylthio)-1-phenyl-2-propen-l-one (140) (3.252 g, 14.5 mmol), 
and the mixture heated to reflux, protected from moisture with a calcium 
chloride guard tube, for 24 h. The reaction mixture was evaporated under 
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vacuum, and the residue triturated with water, to leave a pale orange solid. 
The crude solid was then recrystallised from methanol (30 ml) to provide a 
crop of the title compound 138 (1.13 g), as a white, crystalline solid. From the 
filtrate, a further crop of 138 (0.37 g) was isolated by recrystallisation from 
hexane (75 ml) (total yield of 1.50 g, 51 %). The product obtained had mp 151- 
152°C (lit., 196 152°C) ; 8H(CDC13) 3.94 (3H, s, Me), 5.02 (2H, brs, NH2), 6.51 
(1H, s, 5-H), 7.42-7.48 (3H, m, ArH) and 7.92-7.96 (2H, m, ArH). 
2-Amino-4-methoxy-5-(4-methoxyphenyl)-6-phenylpyrimidine 
139. Prepared according to the method for the preparation of 137, with 
palladium acetate (5.1 mg, 0.023 mmol), dppf (16.6 mg, 0.03 mmol) 2-amino- 
5-iodo-4-methoxy-6-phenylpyrimidine (141) (see below) (0.245 g, 0.75 
mmol), 4-methoxybenzeneboronic acid (0.126 g, 0.83 mmol) and potassium 
phosphate tribasic (0.318 g, 1.5 mmol), in DME (6 ml) and water (1 ml), with 
a reaction time of 24 h. The crude residue of the organic extract, after work up 
as before, was purified by silica gel chromatography, with chloroform / 
diethyl ether (4: 1) as eluent, to provide impure 139 (0.20 g). Crystallisation 
from acetone yielded the title compound 139 (0.165 g, 72%) as a white 
crystalline mass, and had mp 174°C (Found: C, 70.4; H, 5.5; N, 13.55%; nz/z 
(ES+), 308. C18H17N302 requires C, 70.3; H, 5.6; N, 13.7%; M+1,308); 
Vmax(KBr)/cm 13484,3140,1545,1371,1246,1042,831 and 696; 611(CDC13) 
3.78 (3H, s, Me), 3.90 (3H, s, Me), 5.05 (2H, br s, NH2), 6.76-6.80 (211, m, 
ArH), 7.00-7.04 (2H, m, ArH) and 7.19-7.31 (5H, m, Ph); Sc(CDC13) 54.0 
(Me), 55.1 (Me), 110.5 (C-5), 113.4 (2xCH, ArC), 126.4 (C, ArC), 127.8 
(2xCH, ArC), 128.2 (CH, ArC), 129.4 (2xCH, ArC), 132.2 (2xCH, ArC), 
138.8 (C, ArC), 158.3 (C), 161.1 (C), 165.1 (C) and 168.7 (C). 
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3,3-Bis(methylthio)-1-phenyl-2-propen-l-one 140.195 Acetophenone 
(2.821 g, 23.5 mmol) and carbon disulfide (1.787 g, 23.5 mmol) were added 
dropwise under argon, to a stirred suspension of potassium tert-butoxide 
(5.546 g, 46.9 mmol) in anhydrous diethyl ether (35 ml) in a cold water bath, 
forming an orange precipitate. After 45 min stirring, iodomethane (2.9 ml, 47 
mmol) was added via syringe and the mixture stirred for a further 45 min at 
room temperature. Anhydrous methanol (100 ml) was added, and the diethyl 
ether was distilled from the reaction. The resultant red solution was poured 
into ice-cold water (200 ml), and the red precipitate formed was collected, 
washed with water and dried in vacuo. Crystallisation of the solid from ethyl 
acetate yielded the title compound 140 (2.809 g, 53%) as a crystalline orange 
solid. To recover more 140, the aqueous filtrate was extracted with chloroform 
(3x25 ml) and the combined extracts dried (MgSO4) and concentrated in 
vacuo to give a red oil. The ethyl acetate mother liquor from the first 
crystallisation was added to the oil, concentrated to an oil once more and 
triturated with cold toluene to provide a second crop of 140 (0.455 g, 9%). 
The sample crystallised from ethyl acetate had mp 92-93°C (lit., 195 93'C) and 
the following 1H NMR spectrum: SH(CDC13) 2.54 (3H, s, Me), 2.63 (3H, s, 
Me), 6.78 (1H, s, 2-H), 7.41-7.51 (3H, m, ArH) and 7.91-7.95 (2H, m, ArH). 
2-Amino-5-iodo-4-methoxy-6-phenylpyrimidine 141.2-Amino-4- 
methoxy-6-phenylpyrimidine (138)196 (1.29 g, 6.41 mmol) was heated to 
reflux with N-iodosuccinimide (1.88 g, 8.33 mmol) in anhydrous chloroform 
(20 ml) for 2 h, under nitrogen. After cooling, the red solution was diluted to 
50 ml with more chloroform and washed with water (2x25 ml), 5% sodium 
metabisulfite solution (15 ml), water (10 ml), then dried (MgSO4) and 
concentrated to dryness in vacuo to provide the title compound 141 (2.07 g, 
99%) directly in good purity, as a pale yellow solid. A portion crystallised 
from hexane had mp 179-180°C (Found: C, 40.7; H, 3.0; N, 12.9%; m/z (AP+), 
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328. C11H10IN30 requires C, 40.3; H, 3.0; N, 12.8%; M+1,328); 
vmax(KBr)/cm 1 3476,3150,1628,1545,1362,1198,1005 and 696; 
SH(CDC13) 3.96 (3H, s, Me), 5.46 (2H, br s, NH2) and 7.42-7.54 (5H, m, Ph); 
6c(CDC13) 54.9 (Me), 64.9 (C-5), 127.9 (2xCH, ArC), 128.6 (2xCH, ArC), 
129.0 (CH, ArC), 140.5 (C, ArC), 162.2 (C), 168.7 (C) and 170.2 (C). 
2-Amino-5-(4-chlorophenyl)-4-methoxy-6-phenylpyrimidine 142. 
Prepared according to the method for the preparation of 137, with palladium 
acetate (5.1 mg, 0.023 mmol), dppf (16.6 mg, 0.03 mmol) 2-amino-5-iodo-4- 
methoxy-6-phenylpyrimidine (141) (0.245 g, 0.75 mmol), 4-chlorobenzene- 
boronic acid (0.130 g, 0.83 mmol) and potassium phosphate tribasic (0.318 g, 
1.5 mmol), in DME (6 ml) and water (1 ml), with a reaction time of 16 h. The 
crude reaction product was crystallised from hexane / acetone (approx. 2: 1) to 
provide the title compound 142 (0.182 g, 78%) as pale brown crystals, and had 
mp 196-198°C (Found: C, 65.6; H, 4.75; N, 13.4%; m/z (ES+), 311,313. 
C17H14C1N30 requires C, 65.5; H, 4.5; N, 13.5%; M+1,311,313); 
vma(KBr)/cm 1 3493,3140,1634,1566,1543,1370,833 and 694; 81I(CDC13) 
3.90 (3H, s, Me), 5.16 (2H, br s, NH2), 7.01-7.06 (2H, m, 2xArH) and 7.17- 
7.30 (7H, m, ArH); 6c(CDC13) 53.7 (Me), 107.5 (C-5), 127.7 (2xCH, ArC), 
127.9 (2xCH, ArC),. 128.4 (CH, ArC), 129.4 (2xCH, ArC), 131.2 (C, ArC), 
133.1 (2xCH, ArC), 134.0 (C, ArC), 138.8 (C, ArC), 162.2 (C), 164.9 (C) and 
167.8 (C). 
2-Amino-4-methoxy. 5. (3-nitrophenyl)-6-phenylpyrimidine 143. 
Prepared according to the method for the preparation of 137, with palladium 
acetate (5.1 mg, 0.023 mmol), dppf (16.6 mg, 0.03 mmol) 2-amino-5-iodo-4- 
methoxy-6-phenylpyrimidine (141) (0.245 g, 0.75 mmol), 3-nitrobenzene- 
boronic acid (0.139 g, 0.83 mmol) and potassium phosphate tribasic (0.318 g, 
1.5 mmol), in DME (6 ml) and water (1 ml), with a reaction time of 16 h. 
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Crystallisation of the crude reaction product from hexane / acetone (approx. 
5: 2) yielded the title compound 143 (0.197 g, 75%) as its 2: 1 solvate with 
acetone, and had mp 184-185°C (Found: C, 63.0; H, 4.8; N, 16.0%; m/z (ES+), 
323. C17H14N403.0.5 C3H60 requires C, 63.2; H, 4.9; N, 15.9%; M+1,323 
(for free molecule)); Vmax(KBr)/cm 1 3322,3198,1640,1545,1346,1200, 
1065 and 775; 6- (CDC13) 2.18 (3H, s, Me-acetone), 3.91 (3H, s, Me), 5.24 
(2H, br s, NH2), 7.16-7.31(5H, m, Ph), 7.32-7.39 (2H, m, ArH) and 8.00-8.09 
(2H, m, ArH); Sc(CDC13) 30.9 (Me-acetone), 54.1 (Me), 108.6 (C-5), 121.6 
(CH, ArC), 126.2 (CH, ArC), 128.2 (2xCH, ArC), 128.6 (CH, ArC), 128.8 
(CH, ArC), 129.4 (2xCH, ArC), 136.5 (C, ArC), 137.5 (CH, ArC), 137.8 (C, 
ArC), 147.9 (C, ArC), 161.7 (C), 165.9 (C), 168.2 (C) and 207 (C-acetone). 
2-Amino-5-(4-methoxyphenyl)-6-phenylpyrimidin-4(3I1j-one 144. 
2-Amino-4-methoxy-5-(4-methoxyphenyl)-6-phenylpyrimidine (139) (0.17 g, 
0.55 mmol) was heated to reflux in a mixture of methanol (5 ml) and 12 M 
hydrochloric acid (5 ml) for 2 h. After cooling the reaction mixture was 
diluted with water (10 ml), basified with solid sodium hydroxide (2.24 g) and 
re-acidified with acetic acid to pH 6. The suspension formed was stirred in ice, 
filtered, and washed with water followed by a small portion of acetone, to 
furnish the title compound 144 (0.16 g, 97%) as a white solid. Crystallisation 
from ethanol / ethyl acetate yielded fine white crystals, and had mp 322-326'C 
(Found: C, 69.1; H, 5.4; N, 14.1; H20,0.6%; m/z (AP+), 294. C17H15N3O2.0.1 
H2O requires C, 69.2; H, 5.2; N, 14.2; H2O, 0.6%; M+1,294); vmax(KBr)/cm-J 
3383,3108,1651,1582,1518,1242,993 and 704; 811([2H6]DMSO) 3.68 (3H, 
s, Me), 6.61 (2H, br s, NH2), 6.68-6.75 (2H, m, ArH), 6.89-6.95 (2H, m, Ar!! ), 
7.16-7.23 (5H, m, Ph) and 11.10 (1H, br s, NH); Sc([2H6]DMSO) 55.1 (Me), 
112.9 (C-5), 113.1 (2xCH, ArC), 127.5 (2xCH, ArC), 127.7 (C, ArC), 128.1 
(CH, ArC), 129.4 (2xCH, ArC), 132.5 (2xCH, ArC), 139.9 (C, ArC), 154.1 
(C), 157.6 (C), 161.7 (C) and 162.9 (C). 
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6-Amino-2-butyl-4-phenylfuro[2,3-d]pyrimidine 148. 
Triethylamine (8 ml) was added to a stirred suspension of 2-amino-5-iodo-6- 
phenylpyrimidin-4(3H) 
-one (21)69 (0.626 g, 2.00 mmol), bis(triphenyl- 
phosphine)palladium dichloride (0.028 g, 0.04 mmol), cuprous iodide (0.100 
g, 0.52 mmol) in DMF (8 ml), held under nitrogen, forming a deep green 
solution. 1-Hexyne (0.329 g, 4.00 mmol) was added and the mixture stirred at 
room temperature for 40 h. The reaction mixture was then heated to 50°C 
(internal temperature) for 4 h. Concentration of the reaction mixture in vacuo 
gave a brown solid, which was suspended in diethyl ether (50 ml) and washed 
with 1M sodium hydroxide (2x10 ml), water (10 ml), 1M hydrochloric acid 
(2x10 ml), water (10 ml) and finally saturated brine (10 ml). The remaining 
ethereal solution was dried (MgSO4) and reduced in vacuo to give a brown oil, 
which was purified by silica gel column chromatography with 10% diethyl 
ether / dichloromethane, to give a sample of the title compound 148 (0.021 g, 
4%). The fluorescent 148 thus obtained was not totally pure and was not 
subjected to elemental analysis, but yielded the following spectroscopic data: 
vmu(CDC13 film)/cm-1 3530,3422,2961,2934,1616,1460,1371 and 698; 
SH(CDC13) 0.95 (3H, t, J 7, Me), 1.43 (2H, quintet, J 7, CH2CH2CH2CH3), 
1.68-1.79 (2H, m, CH2CH2CH2CH3), 2.74 (2H, td, J7 and 1, 
CH2CH2CH2CH3)9 5.20 (2H, br s, NH2), 6.52 (1H, t, J 1,3-H), 7.47-7.56 
(3H, m, ArH) and 7.95-8.01 (2H, m, ArH); 8c(CDC13) 13.7 (Me), 22.1 
(CH2CH2CH2CH3), 27.9 (CH2CH2CH2CH3), 29.3 (CH2CH2CH2CH3), 100.1 
(C-3), 108.2 (C-3a), 128.3 (2xCH, ArC), 128.7 (2xCH, ArC), 130.1 (CII, 
ArC), 137.5 (C, ArC), 156.7 (C), 158.6 (C), 159.9 (C) and 169.4 (C). 
2-Amino-5-(1-hexyn-1-yl)-4-methoxy-6-phenylpyrimidine 151.1- 
Hexyne (0.14 ml, 1.2 mmol) was added to a mixture of 2-amino-5-iodo-4- 
methoxy-6-phenylpyrimidine (141) (0.327 g, 1.0 mmol), bis(triphenyl- 
phosphine)palladium dichloride (0.014 g, 0.02 mmol) and cuprous iodide 
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(0.050 g, 0.26 mmol) in degassed (argon) triethylamine (10 ml), and the 
reaction mixture was then heated to 50-60°C for 16 h. The reaction mixture 
was then concentrated to dryness in vacuo, suspended in water (50 ml), and 
the mixture extracted with dichloromethane (3x25 ml). The combined organic 
extracts were washed with water (10 ml), dried (MgSO4), and evaporated to 
leave an oily brown solid. Silica gel column purification of the crude product, 
with 10% diethyl ether / chloroform as eluent, was only able to isolate a 
mixture (Rf 0.36) of starting pyrimidine 141 and the title compound 151 
(67/33%), the total return (0.255 g) accounting for 82% of starting material. 
The 1H NMR spectrum of the weakly fluorescent 151 (at 254 nm) was 
determined: SH(CDCI3) 1.22 (3H, t, J 7, CH2CH2CH2CH3), 1.26-1.56 (4H, m, 
CH2CH2CH2CH3), 2.38 (2H, t, CH2CH2CH2CH3), 3.97 (3H, s, OMe), 5.57 
(2H, br s, NH2), 7.39-7.45 (3H, m, ArH) and 7.88-7.92 (2H, m, ArH). 
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